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Abstract
Annually, 6500 cancer patients receive their care in Rochester, NY. This region is
served by over 200 registered dietitians (RD's). Published data showing the number of
oncology patients being supported by medical nutrition therapy from an RD is unavailable;
anecdotal information indicates referral numbers are very small perhaps 1% or less. The
purpose ofthis study was to explore RD involvement in oncology care in Rochester, NY.
A survey ofnutritional beliefs and practices in oncology care was mailed to 250
RD's and registered dietetic technicians with certified dietitian-nutritionist (CDN)
credentials. Of the 250 questionnaires distributed, 137 (55%) surveys were filled out and
returned. Data was tabulated for 96 (70%) of those returned. Excluded from tabulation
were five surveys received after data entry had been completed, and 36 surveys which
were deemed unusable because respondents either: marked all questions "not applicable,"
left the questionnaire mostly unmarked, or indicated they did not provide cancer therapy.
Data was tabulated for frequency and valid percent using SPSS Student Version 8.0 for
Windows. Further analysis was performed for correlation purposes using Pearson's and
Kendall's tau-b analyses.
Patients referred in an already-compromised nutrition status was identified as the
top barrier to providing oncological therapy by 55.2 % ofRD's surveyed, followed by
44.8 % ofRD's indicating they were uncomfortable answering
patients'
questions about
alternative therapies. Literature suggests to increase physician referrals, services provided
by RD's must be perceived as value-added. Results from this study indicated low RD
involvement in value-added services: one-third reported being involved with legislative
initiatives and documenting outcomes for cancer patients, 4.1% offered group cooking
classes regarding food preparation during cancer therapy, 1 1.4% offered group education
classes about cancer topics other than cooking, 12.5% have investigated being part of the
oncology team at their facilities.
Oncology is presented here as a significant opportunity for dietitians in the
Rochester community to expand their roles and strengthen their position in the healthcare
system. Use ofthe PG-SGA is recommended for dietitians who counsel cancer patients. It
serves as an easy-to-use, cost-effective, and standardized assessment tool to proactively
address nutritional risk or deficit.
We conclude that using this study as a guide, RD's can look at their own practice
settings, identify barriers, and use strategies to improve patient care. Every RD in
Rochestermust participate in outcomes research and legislative initiatives, and take
advantage ofopportunities that exist in the community. Alliance with physicians,
professional visibility, and expanded roles and responsibilities such as knowledge in
alternative therapies will make it possible for RD's to provide valuable nutrition services
to oncology patients. The goal is to make medical nutrition therapy, provided by a
registered dietitian, a standard ofcare which positively affects the quality ofcancer
patients' lives.
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Chapter 1
Introduction and Scope of the Problem
Global incidence ofcancer is projected to rise from 10.3 million cases in 1996 to
14.7 million cases in 2020 (American Institute for Cancer Research, 1997). The costs of
cancer, both economically and on quality of life, are high. An estimated $104 billion is
spent in the treatment ofcancer each year (Ottery, 1997). Nonetheless, cancer remains
the second leading cause ofdeath in the United States, even as research progresses
(Laviano et ah, 1996). It is estimated that 3500 residents of Monroe County, which
includes Rochester, NY, are diagnosed each year with some type ofcancer (New York
State Department ofHealth, 1997). Additionally, non-residents receive cancer care in
Monroe County. In 1996, the five
hospitals1
ofthe University ofRochester Cancer Center
treated 6,51 1 cancer patients (University ofRochester Cancer Center, May 1998). This
same geographic area is served by over 200 registered dietitians (RD's). These figures
suggest there are both oncology patients to be served and RD's to provide nutrition
services. No data is available on the number ofoncology patients being supported by
MedicalNutrition Therapy (MNT) from a registered dietitian. Anecdotal information
indicates the number ofoncology patients receiving referrals from their physicians to see
an RD is very small.
This paper explores how nutrition as an adjuvant cancer therapy is being delivered
to cancer patients who receive their care inMonroe County. It establishes a relationship
1 The five hospitals include: Rochester General Hospital, Strong Memorial Hospital, The Genesee
Hospital, Highland Hospital, and St. Mary's Hospital.
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between the number ofcancer patients treated inMonroe county and the number of
patients referred to a registered dietitian for nutrition therapy and counseling.
The role ofthe RD in the delivery ofoncology care was explored, along with RD-
perceived barriers to the provision ofnutrition therapy in oncology. Participation in the
activities shown to increase physician alliance was assessed. Suggestions are made for
increased involvement and effectiveness ofRD's in oncology care.
Background
Montgomery and Kinseth (1996) describe care at Mercy Cancer Center in Des
Moines, Iowa, as patient-centered and holistic. Patients consistently report their top
priorities after diagnosis ofcancer to be: nutrition support, printed information and
resources, cancer prevention, emotional support, and one single place to go for their care.
The center has a registered dietitian, offers social services, pastoral care, occupational
therapy and volunteer services. Mercy offers many support groups for those recently
diagnosed with cancer. The Enrichment Program includes nutrition counseling, massage
therapy, art therapy, music therapy, relaxation and meditation, soft exercise, and post-
mastectomy occupational therapy and education. This holistic approach with all its
components is offered to thepatient at no cost. Mercy introduced new opportunities in
1995 with the opening oftheir resource library and counseling rooms. These additions
made meeting with patients along the entire continuum ofcare, from diagnosis to the
resolution of the cancer, a reality. This system is an example ofpatient-centered care.
Unfortunately this kind of service is the exception, not a standard in cancer treatment.
Nutrition services in Rochester, NY must be assessed with respect to oncology.
Why is medical nutrition therapy vital to the cancer care process? Most
importantly, it is imperative to patient care, support and satisfaction. Patients who have
cancer are often desperate to know how they can take an active role in the healing
process, and in preventing the recurrence ofdisease. Nutrition care increases
patients'
quality of life.
Despite the importance ofnutrition care during cancer therapy, this population
apparently is under-served. Registered dietitians are the trained and certified health
professionals equipped to provide nutrition counseling during cancer treatment. However,
reimbursement and referral rates for RD services are very low. Barriers in the way of
dietitians providing medical nutrition therapy for the oncology population must be
identified and overcome, asMercy Cancer Center has done. These barriers include health
care professionals who judge their own care is adequate, the failure to identify cancer
patients at high nutrition risk, and amarketplace ofunproven therapies.
Two examples illustrate the problem locally. At one Rochester hospital, the
medical and surgical oncology departments reported that six oncology patients were
referred to the dietitian in 1997. This represents less than 1% ofoncology patients treated
in the radiation and surgical oncology department in 1997. Most of those six were
diabetic patients. In spite ofthe low referral numbers, oncologists strongly agreed that
nutrition is important to oncology patient care. Physicians are appreciative ofthe cancer
patients getting early intervention by a registered dietitian. Reasons oncologists gave for
the low number ofreferrals included:
1) Insurance does not cover nutrition counseling.
2) RD'smust be readily available "on the spot" to be an asset.
3) Budget restrictions impede the hiring ofanRD.
The nursing staffencounters the patients who exhibit difficulty eating or weight
loss, but may not specifically refer those patients for diet teaching. The nursing staff
agrees that patients would benefit from anRD available full time. Nurses are responsible
for driving the idea ofa dietitian being on staff, as well as generating RD referrals from
physicians (C. Hutchins, personal communication, March, 1998).
At The University ofRochester Cancer Center, where approximately 6,500
patients per year receive treatment, an in-house "mini
analysis"
was completed in 1996 to
determine howmany patients required nutrition counseling. The analysis was carried out
by nursing. In total, 350-400 patients were identified as requiring nutrition counseling. Of
this group, approximately 200 had lung cancer, 125 had colo-rectal cancer, 35 had
pancreatic cancer and 35 had esophageal cancer. Determination that a patient required
nutrition counseling was based on comfort level ofthe patient and clinical judgement of
the nursing staff. Nurses provided most of the 350-400 patients with basic nutrition
teaching, including supplement use, and distribution of information from the cancer society
and other community resources. Nursing reported being comfortable with basic nutrition
information, and generally had sufficient time to spend with patients. When patient needs
became too complex, nursing referred patients to a clinical nutrition specialist. No
screening or assessment tool was used during the study, nor is one used presently.
Nursing reported that an assessment tool would make the referrals more standardized.
Following the "mini-analysis," the cancer center identified a need for a clinical nutrition
specialist at the center. Funding is the major issue in the way ofachieving this goal (nurse
manager, personal communication, April 1998).
Curiously, breast cancer patients were not mentioned at either site. The nursing
staffat UR Cancer Center reported that breast cancer patients do well with basic nutrition
counseling as provided by nursing. Conversely, Monnin and Schiller (1993) concluded
that breast cancer brings unique problems with nutritional ramifications. Whereas other
cancer populations need counseling to control nausea and vomiting, prevent weight loss,
and reverse under-nutrition, womenwith breast cancer focus on delaying or preventing
recurrence for themselves and familymembers. This high-risk group apparently views diet
as a key factor in cancer prevention and disease-free survival. Breast cancer patients are
prone to subscribing to poor nutrition practices because they are anxious about
recurrence. For this type ofcancer, basic nutrition advice does not meet patient needs.
These examples provide insight to the delivery ofnutrition services in Rochester;
the 6,500 plus cancer patients here are not receiving the optimal care that is provided at
centers such asMercy.
Problem Statement
Substantial supporting evidence exists that nutrition therapy and counseling during
cancer treatment enhance quality of life and keep patients well enough to receive the
course of specified medical treatment. Nevertheless, referral numbers to registered
dietitians appear low. Nutrition counseling is being provided by various sources inside
and outside the supervision ofappropriately trained health professionals. To what extent
is the Rochester RD involved in the care ofoncology patients? What are the obstacles to
overcome in the delivery ofservices to oncology patients? Is the apparent scarcity of
services due to lack ofthird party reimbursement, lack ofphysician backing, or the manner
in which dietitians interface with physicians and patients? Are dietitians actively seeking
opportunities that exist in the community to serve oncology patients? What action steps
can RD's take to improve the referral rate, physician backing and third party
reimbursement? This study may provide registered dietitians a foundation on which to
build better care for their cancer patients.
Assumptions
The study assumed that RD's were concerned with nutrition therapy as part of
quality ofoncology care, and were forthright in answering the questionnaire.
An ideological assumption was this study served as an initial exploration ofRD
involvement in cancer care in the Greater Rochester community. An existing paper
addressing this topic area was not found. Therefore, the study was completed as a
stepping stone for dietitians to use in future studies. The paper was written on the premise
that all oncology patients should have access to a registered dietitian at the time of
diagnosis; be routinely screened during care, and referred to an RD as necessary. Other
health professionals may disagree. This study was undertaken with the belief that the
healthcare environment is a dynamic one that is pliable and amendable to study
recommendations.
Purpose
The primary purpose ofthis studywas to explore RD involvement in oncology
care in the greater Rochester community. Secondly, the study identified perceived barriers
to delivering quality patient care.
Hypotheses
Findings anticipated in this study were:
1 . RD's practicing inMonroe County received referrals for approximately 1% of
oncology patients receiving their care in Monroe County (estimated annual number) in
a typical year.
2. RD's perceived the top barriers to nutrition in oncological therapy were:
Low utilization ofor inconsistent use ofan appropriate nutrition screening tool.
Lack ofphysician support.
Lack ofthird-party reimbursement.
3. Low RD involvement in the actions noted in the literature to increase patient referral
from physicians.
4. Nursing is responsible for nutrition counseling in facilities.
5. There a need for RD familiarizationwith alternative therapies.
Significance
This study will serve as a resource to dietitians already providing cancer therapy so
that patient care may be expanded and improved. To those dietitians not involved in
oncology care in the greater Rochester community, this study examines the need and
opportunity to do so. Strategies for heightened registered dietitian involvement in the
provision ofquality cancer therapy are explored.
Definition ofTerms
Alternative Therapies Treatments considered unproven, unconventional, or not based in
science. Examples include herbal remedies and supplements, aromatherapy, massage,
relaxation, and many others.
Cancer Cachexia The progressive nutritional deterioration related to actual presence of
cancer, or to treatment ofcancer. Characterized by anorexia, poor appetite, early satiety,
severe weight loss, anemia, edema, and inanition (Ottery, 1994).
Enteral Nutrition The delivery ofnutrients directly into the stomach, duodenum, or
jejunum, orally, or via tube.
Inanition Progressive deteriorationwith muscle wasting and change in body
composition, based on mechanical factors or treatment-induced toxicities (Ottery, 1994).
Malnutrition Clinical state ofprotein, energy, or nutrient deficit, varying in type and
severity.
Medical Nutrition Therapy (MNT) nutrition assessment and counseling provided by
dietetics professionals resulting in health benefits for the public and reduced health care
costs. Medical nutrition therapy is an essential component ofany system designed to
provide quality, cost-effective care throughout the life cycle. After nutrition screening
identifies those at risk, appropriatemedical nutrition therapy leads to improved health
outcomes resulting in economic benefits and improved quality of life (American Dietetics
Association, 1998).
Nutrition Assessment The use ofdietary, laboratory, anthropometric and clinical
measurements to identify individuals' nutrition status.
Parenteral Nutrition The delivery ofnutrients directly into the blood stream.
Patient-Centered Care Care directed at the needs ofpatients; serving patients well.
PG-SGA (Patient-Generated Subjective Global Assessment) A specific nutritional
assessment tool used to proactively address nutritional risk or deficit. Accepted as the
standard in clinical pathways for oncology patients by the American Dietetics Association
(Ottery, 1998).
Phytochemical Substances naturally produced by plants to protect the plant from viruses,
bacteria, and fungi. Examples are carotenoids, flavenoids, and isoflavones.
Phytochemicals play a role in health promotion, and can be obtained by eating a variety of
fruits, vegetables, legumes, and whole grains.
Referral Written recommendation from a physician encouraging a patient to see another
health professional. A referral allows for health care cost reimbursement.
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Registered Dietitian (RD) The letters "RD" after a person's name signify that he/she
has completed academic and experience requirements established by the Commission on
Dietetic Registration, the credentialing agency for ADA including a minimum ofa
bachelor's degree granted by aU.S. regionally accredited college/university, or equivalent,
and an approved preprofessional experience program. RD's demonstrate their knowledge
of food and nutrition by successfully passing a national credentialing exam and by
completing ongoing continuing professional development (American Dietetics
Association, 1998).
Third-party reimbursement Payment for health services by an insurance company.
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Chapter 2
Review of the Literature
Cancer andMalnutrition
Cancer patients are physiologically under great stress from the disease process and
treatment. Rapid loss ofbody weight is associated with decreased effectiveness of
treatment and increased mortality. Malnutrition as a secondary diagnosis is common (The
American Dietetics Association, 1992).
As outlined by Ottery (1994), central to quality of life is management ofthe
metabolic syndrome known as cancer cachexia the progressive nutritional deterioration
related to actual presence of cancer, or to treatment ofcancer. Cachexia is characterized
by anorexia, poor appetite, early satiety, severe weight loss, anemia, edema, and inanition.
Weight loss ofmore than 10% ofpre-illness weight may occur in 45% ofhospitalized
adult cancer patients. An estimated 66% ofpatients may have inanition develop during
the course ofdisease with 20% ofcancer patients dying of its effects. Ottery (1997)
discussed further thinking about weight loss beyond the 10% loss in a 6 month time
period. While a 10% weight loss over a 6 month time period is the most widely
recognized indicator of increased complications and death inmultiple populations, other
data suggest similar prognosis when there is a 7.5% loss ofweight in 3 months, 5% loss in
1 month, or 2% loss in one week. Weight loss and inanition are the potentially treatable
or preventable components ofcancer malnutrition.
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Shike (1996) suggests most patients have malnutrition secondary to general
calorie-protein deficits from which weight loss results; but some patients have nutrient
deficiencies that can be present and devastating in the absence ofweight loss. Mercadente
(1996), advises interventions be instituted to modify controllable factors on an individual
basis.
Nutrition assessment and care are necessary (Mercadente, 1996). The benefits of
nutrition intervention in cancer therapy to maintain strength for treatment, prevent
recurrence, and improve quality of life are confirmed. The malnourished patient is
susceptible to lowered tolerance to chemotherapy. A reduced tolerance to subsequent
chemotherapy may limit the dose and efficacy oftreatment. Survival depends on
treatment; the course determined by weight loss and other factors.
Shike (1996) suggests diet therapy taken bymouth can improve nutritional status
in patients who are able to eat, but require special diets due to gastrointestinal dysfunction.
Appropriate Medical Nutrition Therapy (MNT) can save the cost ofmore complex and
costly feeding methods. Inadequate food consumption can also be corrected byMNT.
Ireton-Jones et al. (1995) completed an observational study to assess the impact of
the RD in improving nutrition status in cancer patients. Results showed the timely
intervention by an RD may allow the patient to avoid or correct malnutrition and therefore
prevent the need for more costly tube feedings or parenteral nutrition. Fifty-four percent
ofpatients who received intervention by the RD improved or maintained original
nutritional assessment parameters, while only 29% of the group not followed by the RD
improved or maintained parameters. While deterioration ofnutritional status occurred in
13
46% ofpatients followed by the RD, 71% ofthe patients not followed by the RD showed
deterioration.
In a study to determine the relationship between nutritional status, length ofstay in
a hospital discharge placement, readmission rates, and hospital costs and charges, Chima
et al. (1997), determined patients at risk formalnutrition had significantly longer length of
stay, and higher hospitalization cost per patient. Nutritionally at risk patients were more
likely to be discharged in need ofhome care services than those not at risk. Ninety-one
percent ofthe at-risk patients received nutrition care while hospitalized.
However, it must be noted that nutrition therapy has also shown in some studies to
be ineffective, of limited benefit, or controversial in nature (Shike, 1996; Ovesen, 1993).
Nutritional therapy has been successful in patients who need long-term provision of
nutrients with severely impaired gastrointestinal functionwho would not survive
otherwise; but unsuccessful as an adjuvant treatment during anticancer therapy. Noted is
the use ofparenteral nutrition, which must be individually evaluated as adjuvant therapy.
Enteral therapy as adjuvant therapy has not been fully evaluated (Shike, 1996). Ovesen et
al. (1993) examined the effect of frequent nutritional counseling by a dietitian on oral
intake, body weight, response rate, survival and quality of life with lung, ovary, or breast
cancer, undergoing cyclic chemotherapy. No clinical benefit was demonstrated despite
long-term and continuous improved food intake in cancer patients with solid tumors.
Quality of life increased by the same amount for both the control group (which received
no nutritional counseling) and the counseled group.
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On the contrary, Ollenschlager et al. (1993) found that nutritional counseling was
effective in increasing the body weight in the intervention group (receiving nutrition care
by a dietitian) earlier and more often than in the control group. Life-threatening
malnutrition was prevented in all patients during anti-tumor therapy. This study's
conclusion stated that intensive oral nutrition therapy with continuous dietetic counseling
and motivation is an effective adjuvant therapywith respect to nutritional status and
patients'
quality of life.
Unquestionably, nutrition care and cancer treatment consistently advance and
evolve. Much is unknown about the interrelationship. Still many sources sustain the
common message that malnutrition can be avoided, and that every patient should have
early assessment ofnutrition status with appropriate care and follow up. It is problematic
that cancer patients are not often assessed early. Although many patients with cancer in
various stages present severe malnutrition, nutritional status is not frequently assessed
(Mercadente, 1996). Early diagnosis ofcancer malnutrition is often missed because of
lack ofattention by the oncology team (Ottery, 1994). Without standardized assessment
and intervention, an estimated 60-80% ofoncology patients suffer detrimental weight loss
and decline in nutritional status during cancer treatment (Ottery, 1997).
The team approach is proposed by many authors as the optimal choice in
muhidisciphnary care. The multidisciplinary nutrition team is best comprised ofa dietitian,
clinical nurse specialist, and physician. Referrals are made to support staff (social work,
speech, physical therapists) as needed (Ottery, 1 994). Dietitians can be invaluable in the
initial assessment ofnutritional status and needs, and adequate communication with
15
patients and caregivers. RD's should be part of the cancer care teamwhen possible
(Tchekmedyian et al, 1992).
Role ofNutrition in Prevention and Management ofCancer
Prevention ofcancer is a global priority according to The American Institute of
Cancer Research (1997).2 Cancer presents a growing public health burden. Projections
into the twenty-first century show that populations with developing economies will not
have the resources to screen and treat cancer. The resources do not exist now, and will
not then. Public health policies aimed at primordial prevention (preserving appropriate
food patterns), and primary prevention (encouraging a population to change eating
behavior before disease occurs) are the proposed solution. These programs will be
complementary to policies and programs designed to combat other chronic diseases.
The worldwide panel of the American Institute for Cancer Research (1997) arrived
at a scientific consensus that cancers are largely preventable, and that the most effective
means of reducing risk are avoidance oftobacco use, consumption ofappropriate diets,
and limiting exposure to occupational and other environmental carcinogens. The panel
estimated that 30% to 40% ofcancer cases worldwide are preventable by dietarymeans,
representing approximately 3-4 million cases as of 1996. Over time, the single
recommendation to consume 400 grams ofvaried fruits and vegetables per day could
2 The American Institute for Cancer Research (non-profit organization) and theWorld Cancer Research
Fund (a registered charity) are affiliate organizations. Their mission is to increase scientific knowledge
about the role ofnutrition in the prevention of cancer, and raise awareness that the risk of cancer can be
reduced through proper nutrition. The expert panel is comprised ofhealth professionals, scientists,
members of the United Nations and organizations from throughout the world.
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decrease overall cancer incidence by 20%. The panel notes that different types ofcancer
will take varying amounts of time to decrease, perhaps more than one generation.
Laviano et al. (1996) stated there is scientific agreement about three priority goals
for the year 2000:
Increase fruit and vegetable consumption to 5 ormore servings per day.
Increase breads, cereals, and legumes to 6 or more servings daily.
Decrease fat intake to no more than 30% oftotal daily calories.
Ifachieved, this plan was estimated to yield 3 1 5,000 fewer new cases ofcancer
annually in the U.S., and save $25 billion dollars in health care costs. In summary, the
American Institute ofCancer Research Panel (1997) made fourteen dietary recommenda
tions, which emphasize a plant-based diet, physical activity, and safe food handling and
processing. These recommendations position dietitians as educators and clinicians in
cancer prevention
Diet and Breast Cancer
Nixon (1996) summarized that being overweight at diagnosis and weight gain on
adjuvant treatments have both been found to be adverse prognostic indicators. It was
suggested that weight control in overweight subjects might improve treatment and
survivaL Amount and type ofdietary fat may affect the growth or spread ofbreast cancer
during the preclinical phase. Excess energy intake leads to increased fat stores that may
contribute to changes in estrogen levels in the body and may stimulate tumor growth.
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Calorie reduction and increased exercise could benefit women with breast cancer. It is
proposed that emphasis be placed on dietary patterns, not single nutrients.
Nicholson (1996) summarized from ecological and case-controlled studies that
there is as association between low-fat, plant-based diets and a decreased risk for breast
cancer. A vegetarian diet with no added vegetable oil maximizes the amounts of
protective nutrients while minimizing the amounts ofcarcinogenic nutrients, and therefore
may be the most effective diet for both preventing breast cancer and improving the
prognosis for those with the disease.
In a large cohort study referred to as The IowaWomen's Health Study, findings
supported the hypothesis that a high fat intake is associated with reduced survival ofpost
menopausal women with breast cancer. Although clinical trials are needed, it was
suggested that women with breast cancer consider limiting intake of fat (Zhang et al.,
1995).
Physicians. Nutrition Therapy, and the Registered Dietitian
Locally, only a handful ofRD's could be identified as delivering oncology nutrition
and be contacted for comment. The common reasons cited for low involvement in cancer
care included: no payment for time and services; lack ofphysician alliance; patients
referred only when it's "too
late;" lack of insurance backing; and the assertion that many
health professionals involved in oncology case management social workers, nursing, and
various therapists provide nutrition counseling to their patients, but do not refer to the
dietitian (Anonymous Rochester dietitian, personal communication, March 31, 1998).
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In a survey ofmore than 3,400 primary care physicians, more than 75% agreed
that diet has an important role in disease prevention ofhypertension, osteoporosis, and
heart disease. Only 22% said they prescribe sessions with a registered dietitian (Tufts
UniversityHealth & Nutrition Letter, 1997). Kushner (1995) found that a wide gap exists
between the public's need for accurate and sensible dietary information and the availability
ofsuch advice from physicians. Over two-thirds ofphysicians surveyed provided dietary
counseling to 40% or less ofpatients and spent less than 5 minutes discussing dietary
changes. However, almost 75% of the physicians felt dietary counseling was important
and the responsibility ofthe physician. Ofthose 40% or less ofpatients who did receive
nutrition counseling, 87% ofthe physicians provided it directly. Ifnot provided by the
physician, 51% referred to a dietitian outside the practice, 34% referred to an office nurse,
and 27% referred to an office dietitian. Seventy-five ofthe physicians felt they should
utilize dietitians more often Healthy People 2000 objectives include increasing the
proportion ofprimary care providers who provide nutrition assessment and counseling
and/or referral to qualified nutritionists or dietitians to at least 75% .
Physicians ranked six potential barriers to the delivery ofnutrition counseling
(Kushner, 1995):
1. Lack of time (75%)
2. Lack ofpatient compliance (71%)
3. Inadequate teaching materials (69%)
4. Lack oftraining in nutrition counseling (67%)
5. Lack ofknowledge (62%)
19
6. Lack ofadequate reimbursement (6 1%)
Another study by Hiddink et al. (1995) found general practitioners in the
Netherlands regarded top barriers to delivering nutrition counseling to patients to be lack
ofnutrition training (65%), unfavorable conditions or lack oftime (47%), and lack of
patient motivation (43%).
Primary care physicians surveyed in Missouri were found to not be achieving their
full potential in cancer control especially in primary prevention. Reasons for lack ofa
preventive approach included having a disease orientation, protocol confusion, lack of
financial awards, and lack of immediate results. Respondents considered diet to be a
relatively unimportant factor in cancer causation as compared to sun exposure, genetics,
and radiation exposure (Brownson et al, 1993).
The family physician is in a unique position to assess patient health risks and
intervene in lifestyle behaviors which increase the risk ofcancer (Sohesz et al., 1995).
Because of the long term relationship between family physicians and patients, physicians
must be involved with dietary management ofcancer risk. Fifty-five percent of
respondents agreed that ifphysicians fail to address the dietary behavior oftheir clients in
a periodic health exam, the patient is likely to think dietary behavior is not important to
health. In this study, only 12% ofphysicians referred patients to an RD for help with diet
and cancer 70-100% of the time; 74% referred to the RD 0%-30% of the time.
Whatever the barriers may be, Rochester dietitians often report the provision of
cancer therapy for patients even when the client cannot pay, and the RD cannot be
reimbursed through insurance (personal communication, 1998).
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Physician-Dietitian Interface
Little is known about physicians' perceptions and expectations related to nutrition
services available from dietitians in ambulatory and clinical care. Splett et al. (1994)
explored
physicians'
expectations about RD's working in prenatal care. Physicians
expected dietitians to have expertise, and skillfully work with patients to achieve
compliance. To be judged excellent, dietitiansmust produce desired outcomes in patients.
If the outcome is not positive, the physicians judge nutrition service as falling short. Good
communication and feedback, documentation, visibility, and availability were important.
Financial issues were not ofconcern to this group of respondents. Physicians have service
needs and expectations that affect decisions to refer to a dietitian Respondents indicated it
was important to them that the dietitian be versatile in responding to staff and patients,
and that the dietitian be pleasant and cooperative. The dietitian is also expected to
establish rapport with a wide range ofpatients. The importance ofdietitiansmaking the
physician a customer was emphasized.
Dietitians could have a greater effect on nutrition care by discussing
recommendations with physicians (Skipper et al, 1994). The practice ofdiscussing
recommendations with the physicians before entry into the medical record resulted in the
physician implementing recommendations 65% ofthe time. The study was designed to
assess how often RD recommendations were implemented. Unfortunately, the RD's in the
study were reluctant to discuss their recommendations, and so the positive result of this
practice was less than hypothesized. In summary, the study found that physicians are
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receptive to RD recommendations particularly when solicited by the physician. Discussion
ofrecommendations is a powerful but inadequately used tool by RD's.
Strategies to Increase Referrals to the Registered Dietitian
Value-added services provided by RD's that overcome barriers to physician
referral were explored by Sowinski et al, (1994). The RD services physicians most
strongly agreed would increase referrals to an outpatient nutrition clinic were:
1 . Help patients receive reimbursement from third-party payers through proper use of
diagnostic and service codes (92.1%).
2. Provide a free initialmeeting with the patient (82.4%).
3 . Offer group cooking classes for various modified diets (8 1 .3%).
4. Charge on a sliding scale (80.5%).
5. Send follow-up reports to the physician's office after each patient visit so compliance
can be compared with changes in lab values and medications. Provide anthropometric
measurements showing change due to dietary intervention.
A value-added service is one that exceeds the minimal expectations ofthe
physician. Dietitians interested in providing this kind of service must successfully compete
with other sources ofnutrition information. One strategy is to make physicians aware of
services and availability of the RD; be visible. RD's have the unique skill and knowledge
to show patients and physicians that modified diets can be appetizing. Dietitians should
capitalize on reimbursement strategies, food demonstrations and cooking classes, and
saving time for the physician (Sowinski et al., 1994).
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RD services ofhighest value, as ranked by home care administrators, were patient
education and counseling, MNT for special cases, development ofnutrition care plans,
staff in-service training, and nutrition assessments. Most administrators expected RD
hours, services and staff to increase during the next 5 years. The home care environment is
an opportunity for RD's to capture. RD's can position themselves by proving cost-
effective, quality care through outcomes documentation; enhance consulting skills,
training, nutrition support, and outcomes research. Building relationships with home care
administrators, and advocating forMedicare coverage for MNT were recommended
(Schiller et al., 1998).
Patient-Focused Care
Patient-focused care centers on patients' needs and perspective. As health care
organizations attempt shifting from fragmented service to managed care, emphasis on
patient comfort and convenience increases. The concept involves the decentralization of
services, cross training ofpersonnel and streamlining of services and employees to better
serve patients (Schiller & Miller, 1996). Fear and insecurity has surrounded RD's during
the period oftransition in health care. Many suggestions have been made for RD's to
position themselves strategically for patient-centered organizations. First, networking and
finding internal and external liaisons is strongly encouraged. Taking part in all discussions
regarding the following topics is vital: inclusion ofnutrition services in critical care
pathways; charting by exception; and automated medical records. Other proactive
involvement includes pursuing legislative initiatives; working closely with case managers;
being visible to key decision makers; expanding the scope ofpractice; sharpening
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management skills; focusing on quality care; identifying criteria for and generating
nutrition referrals; and marketing.
The patient-centered organization welcomes the idea of interdisciplinary teams. It
is each employee's responsibility to carry out the nutrition care plan. Hospital
administrators are learning that the patient is the primary customer and that every
employee must meet patient needs. This includes discharge planning, specifically,
scheduling appointments with the RD to be convenient with other treatments
(Montgomery & Kinseth, 1996).
At an inner-city Rochester hospital a nurse manager reported only four patients
being formally referred for nutrition counseling with a dietitian in a one year period (nurse
manager, personal communication, May 1998). Because nurses, dietitians, and physicians
recognized the demand for nutrition care during cancer treatment, and were patient-
focused, one dietitian was made available four hours per week to patients receiving care in
the infusion center. The dietitian was well-received by cancer patients and health
professionals alike. Individual counseling, abundant literature and community resources,
and group counseling were delivered. Careful documentation was kept. It was
determined the dietitian was effective in enhancing
patients'
quality of life, and that
patients found her medical nutrition therapy helpfiil. The dietitian could be utilized full-
time ifbudgets allowed. The dietitian reported that the most visible, tangible service she
offered was group instruction with abundant supporting materials and teaching aids (i.e.,
props such as food models). Physicians were able to see the value of the dietitian's talents
with cancer patients when they observed the group sessions. A successful physician-
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dietitian alliance was formed, and grew from that point forward. The dietitian reported
physicians asking her advise more often and showing trust in her recommendations
(Rochester RD, personal communication, May 1998).
Documentation
While the professional organization ofdietitians, the American Dietetics
Association, pursues efforts to increase reimbursement through legislation and insurance
companies, it is recommended that outpatient nutrition clinics submit insurance claims for
clients; include letters ofmedical necessitywith claims; and request reimbursement be
mailed directly to clients (Bolonda et al., 1994).
Case managers may be apt to authorize additional visits with an RD ifeconomic
benefits are demonstrated forMNT. Documenting outcomes will increase referrals and
revenue and increase credibility ofthe RD. Clients will demand a service that has
beneficial results. Informing physicians ofnutrition counseling results withmonthly and
annual reports that demonstrate effectiveness ofMNT will help generate referrals.
Classifying and documenting malnutrition cases may increase compensation for patients in
managed health care (Harrity & Johnson, 1996).
Dietitians need to document outcomes in terms ofbenefit ofmedical nutrition
therapy in every setting. Recognition of the benefit ofMNT will determine its future
availabitity in standard preventive andmedical care, and help build demand forMNT. It
will also demonstrate the necessity (Harrity & Johnson, 1996).
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Essential Features in Oncology Care
In cancer care, several factors have been identified by Ottery (1994) that determine
the success ofnutrition intervention:
WhileRD's are often asked to see patients in a treatment setting (infusion room,
radiation department), it is beneficial to the patient to conduct nutrition therapy in a
counseling (clinic) setting.
Timing ofthe nutrition visit must be coordinated with other visits, but timing is
best determined by the patient.
The medical teammust be multidisciplinary in approach.
The physician must validate the importance ofnutritional therapy in the eyes ofthe
patient and caregiver.
Comprehensive evaluation must be done ofnutrition status.
Follow up and reassessment are imperative.
Interventionmust be early.
The Patient-Generated Subjective Global Assessment (PG-SGA) ofNutrition
Status is an one-page nutrition assessment tool that proactively addresses nutrition
risk or deficit in cancer patients (Appendix C). The American Dietetics
Association has accepted the PG-SGA as a standard in clinical pathways for
oncology patients, and it is widely used bymembers ofthe Oncology Nursing
Society (Ottery, 1 998). The PG-SGA is available in several languages.
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Screening and care initiatives in oncology care
At Fox Chase Cancer Center in Philadelphia, PA, 186 consecutive patients were
studied to document effectiveness ofa customized oral nutritional intervention consisting
offood and/or supplements. Results showed average weight loss for patients at the time
oftheir referral to the nutrition clinic was 16.8%. Patients were managed orally. Fifty
percent were able to gain or maintain weight, and improve visceral protein status. Success
increased to 80% ofpatients showing improvement when patients with limited life
expectancy of6 weeks or less were excluded. A triage system using the PG-SGA is being
validated in a multi-institutional study (Ottery, 1998).
The PG-SGA is utilized at Albany Medical Center, a 600-bed teaching hospital in
Albany, NY. A full service cancer center is under development. Currently, all newly
diagnosed cancer patients are referred to the resource center, where an RN performs an
assessment along with the PG-SGA. Ifa patient's score indicates a necessary referral, one
is made to the registered dietitian immediately. An appointment with the RD is made at a
convenient time for the patient. The dietitian performs a full assessment or aids in crisis
management as needed. RD services at the resource center are free ofcharge. Future
plans include using the PG-SGA in the radiation oncology department on a weekly basis
and in the medical oncology and hematology department at each visit. High risk patients
will be referred to the dietitian, likely with a charge to the
patients'insurance company (J.
Bagyl personal communication, June 1, 1998).
At Erie Cancer Center in Erie, PA a patient screening questionnaire was initiated
by the RD. The tool is filled out on the first visit to the center, and triggers a referral if
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appropriate. Since it is a free standing clinic, patients who are identified in the screen can
be seen by the RD automatically, without a physician referral. Outcomes measurement
has been critical in demonstrating the benefit ofhaving an RD on staff. Once physicians
realized the value ofthe RD, an alliance formed. When there are breaks in the schedule,
the RD creates a demand for services so that productivity cannot be argued. A list is
made ofpotential patients who can benefit from care, and the RD goes to find them,
instead ofwaiting for a physician request. "The opportunities are there ...seek patients out
...get physician backing it's very important." (S. Lutbringer, personal communication,
April 1998).
Alternative Therapies and Cancer
In 1989, Cassileth suggested American societywas aggressive and optimistic when
it came to illness, and the approach to cancer (i.e., "the war on cancer" ) differed greatly
from that ofother cultures. Americans wanted attention to emotional needs as well as to
disease; taking an active role in healing was common The use ofunproven therapies was a
natural extension ofbeliefs reflecting social emphasis on responsibility for oneself. As
beliefs change, so will alternative therapies. When a cure for cancer is found, it will no
longer be a concern.
McGinnis (1990) stated the longer a patient survives with cancer, the likelihood of
pursuing alternative or unproven cancer treatment increases. Use increased with increased
socioeconomic status, education, and income. White, foreign-born persons in the 30-50
year age group were the most likely to use alternative therapies. Studies indicated 60% of
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cancer patients are familiar with alternative therapies, with knowledge gained byword of
mouth and the media. Only 12% had to leave their residential area for access, with only
2% traveling to a foreign country. The decision to use alternative therapies was often
supported by familymembers and personal physicians. Thirty-five percent ofpatients
stated that alternative methods were used without informing their physician, and 50%
continued with conventional treatment while pursuing alternative therapies. Health
professionals must be concerned because patients who pursue potentially harmful
therapies impose economic harm through loss ofresources and by avoiding conventional
therapies while pursuing alternative ones. Potential direct harm can be done to patients
health including toxicity, viral and bacterial disease, ruptured colons and metabolic
disturbances. The societal impact of large groups advocating mistrust ofestablished
institutions and medical treatments is potentially harmful.
Gray et al. (1997), reported the results ofa pilot study investigating the physician
perspective on alternative therapies. The physicians were involved with cancer care. Pilot
work found that women with breast cancer were interested in unconventional therapies,
but discussions did not occur with the physician. Seventy two percent ofpeople using
alternative therapies did not inform their physician. Patients are seeking information about
unconventional therapies, and want help. Many times, patients were described as being
full ofignorance and driven by desperation The attraction ofunconventional therapies is
the practitioners, who spend time with the patient and promise the treatment will work.
Cancer survivors often express dissatisfaction about health
professionals'lack of
communication about unconventional therapies, and perceive the medical profession as a
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barrier to alternative therapies. Physicians perceived that patients have reluctance in
considering their own contribution to the communication problem. The study suggested
that health professionals increase attention to unconventional therapies, and learn how to
communicate the subject area with their patients.
People faced with the pain and debilitation ofcancer and its treatments are drawn
to alternative therapies that are touted to be more gentle and effective. More than 80
unconventionalmedical treatments from acupressure to macrobiotic Zen have been
documented (Aulas, 1996). Health professionals should realize that unconventional
treatments and diagnoses are different. No alternative diagnostic tool has a scientific,
rational basis. Cancer is a highly variable disease with some forms being curable. For
those cancers that have a cure, it is especially important that patients not trade alternative
methods for conventional ones that save lives.
Dietetics Involvement
The popularity ofherbal medications as adjunctive therapy has grown significantly.
In 1996, US herb sales amounted to approximately $12 billion. The growth is due to an
escalating distrust oftraditionalmedicine, poor medical insurance coverage, growing
populations ofpeople who traditionally used herbs in their cultures, AIDS, a "natural"
theme in the marketplace, and in light ofphytochemical research. In the near future, herbs
may be helpful in the prevention and treatment ofcancer. It is becoming the responsibility
ofthe health professional to determine which plant sources have promise, demonstrated in
science; and which are harmful (Spaulding-Albright, 1997).
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RD's can benefit patients by asking patients ifthey are pursuing alternative
therapies, maintaining information on therapies, and serving as a liaison between patient
and interested physicians. Skepticism is healthy, but an open mind in this arena is smart.
RD's can help reduce the chance ofpatients being harmed or caught up in health fraud by
keeping communication open, and closing the gap between traditional and unconventional
therapies. Being aware ofpotentially harmful situations involving oncology care and
alternative therapies is wise, as a large percentage ofcancer patients will experiment.
Chemotherapy combined with large amounts ofsome herbs may introduce risk for the
patient. A concern exists that patients will seek out an herbalist, bypass seeing a
physician, and compromise the chance of successful treatment. The herbal industry is
highly unregulated, and this poses other potential threats (Spaulding-Albreight, 1997).
Evaluation and monitoring ofdietary supplement use in the breast cancer population is
especially important (Newman et al., 1997).
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Chapter 3
Methodology
This study was conducted to determine the nature ofRD involvement in oncology
care in the greater Rochester, NY area. A survey regarding nutritional beliefs and
practices in oncology care was mailed to 250 registered dietitians and registered dietetic
technicians. A response rate of60 to 75 percent was expected (Dillman, 1978).
Participants
Respondents included members of the Genesee Dietetics Association (GDA) listed
in the 1996-1997 and 1997-1998 directories as RD, orDTR (Dietetic Technician,
Registered) with CDN (Certified Dietitian-Nutritionist) certification. Respondents were
excluded from the mailing ifstatus was listed as student, supporting colleague, retired, or
DTRwithout CDN. Respondents were also excluded ifboth home and work addresses
listed were not located inMonroe county. A cover letter signed by the thesis advisor and
author, and a self-addressed stamped envelope were included in the mailing.
This census-oriented study represented dietitians practicing in innumerable
facilities and environments in the greater Rochester, NY community.
Survey
The survey (Appendix A) consisted of two types ofquestions. Questions 1 to 3b
asked respondents to estimate how many cancer patients for whom they providedMNT,
their primary practice setting, and leading source ofreferrals. Questions 4 to 45 asked
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respondents to respond to each question on a 5-point Likert scale. Not Applicable (NA)
was also a response. Question content was compiled from the literature reviewed.
Questions were intended to measure the nature ofRD involvement in oncology care from
the RD's perspective. Respondents were given the choice of including name and contact
information or remaining anonymous.
Focus Group
The survey was reviewed by a focus group ofthree RD's for readability and
content. Modifications inwording and inclusion ofquestions was modified accordingly.
Statistical Analysis
SPSS Student Version 8.0 forWindows desktop statistical software was used to
analyze data. Data was tabulated for frequency and valid percent.
Further analysis of the datawas performed for correlation purposes. First, the
Pearson correlation coefficient was performed. The data included many "not
applicable"
responses throughout. To correct foT this occurrence, all
"NA"
responses for questions 4
to 45 were programmed as missing responses. For question la, concerning the number of
patients seen by the dietitian per month, the
"NA"
response was set to the 0-5 category.
Pairs ofquestions showing a positive linear relationship, and pairs ofquestions showing a
negative linear relationship at the .01 level were noted.
No single measure ofassociation is best for all situations. Pearson's is most
commonly used to discuss continuous data (Norusis, 1997); data in this study is ordinal.
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Therefore, Kendall's tau-b, another commonly used measure ofassociation (Norusis,
1997), was performed. Kendall's tau-b is customized for ordinal data found in this study.
Correlation at the .01 level was considered significant and noted.
To increase certainty that relationships existed, significant results noted at the .01
level for both Pearson's and Kendall tau-b were compared. Comments on correlations
were made only when correlations were significant for both Pearson's and Kendall's tau-b
at the .01 level (J. Halavin, personal communication, June, 1998).
34
Chapter 4
Results and Discussion
Of the 250 questionnaires distributed, 137 (55%) surveys were filled out and
returned. Data was tabulated for 96 (70%) ofthose returned. Excluded from tabulation
were five surveys received after data entry had been completed, and 36 surveys which
were deemed unusable because respondents either:
1 ) returned the survey unmarked.
2) marked all questions "not applicable."
3) indicated they did not provide cancer therapy.
Conclusions cannot be drawn about the 45% who did not return the survey. It can
only be speculated that it was due to non-involvement in cancer care in greater Rochester.
Many ofthe 36 unusable surveys included reasons for non-involvement (see Appendix B).
Results are presented for all data in Tables 1 through 4. Findings for hypotheses
are presented and discussed (Tables 5 & 6; Figures 1 & 2). Subsequent topics were
selected for discussion following further data analysis.
Table 1 shows 62.1 % ofRD's provide nutrition counseling to 0-5 cancer patients
per month, with an additional 9.5% indicating no participation in cancer therapy. Thirty-
six surveys not used in tabulation also indicated no participation in cancer therapy. Eight
RD's replied they provide cancer therapy to 25 or more patients per month. Anecdotal
information suggests 1% ofcancer patients or less (approximately 65 patients) inMonroe
County are referred to an RD.
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Table 1
Number ofcancer patients seen per month by RD
(Qla) In my best estimate, I provide nutrition therapy for cancer patients per month:
Number ofPatients Frequency (N) Valid % Responding
0-5 59 62
6-10 13 13.7
11-15 4 4.2
16-20 2 2.1
25 + 8 8.4
N.A. 9 9.5
total valid responses
responses missing
95
1
100.0
Findings for Hypothesis 1
Data to support or refute the hypothesis that 1% or less ofcancer patients in
Monroe County receive medical nutrition therapy from a registered dietitianwas
unobtainable because access to unpublished datawas not available. New York State
Department ofHealth released its latest cancer incidence and mortality rate by county in
May 1997 for the years 1989-1993. The New York Cancer Registry is the only source of
population-based, state-wide cancer incidence data.
Data for number of referrals to dietitians does not exist in a published reference.
According to the Bureau ofChronic Disease Epidemiology and Surveillance, the New
York State Cancer Registry is collecting information on the first course of treatment as of
1996. Nutrition therapy is not included because it is classified as supportive care.
Claims-
36
based systems such as the Medicaid Managed Care Encounter Data Set include only those
referrals that result in a claim, so are not adequate for assessing referral numbers. Health
care providers or insurance providers may collect this data but it is not accessible by the
bureau (C. McLaughlin, personal communication, January 15, 1998).
Preferred Care responded that the number ofphysician referrals to RD's is not
available because the visit may not result in a claim, or the costs of the RD services are
wrapped up in the cost ofanother service the patient received. It would take a medical
record review, done in-house, to determine referral numbers. This type ofreview was not
granted for this paper (P. Pulver, personal communication, March 11, 1998).
Anecdotal information on numbers of referrals was obtained through personal
communicationwith RD's and nurse managers who did in-house analyses for their own
purposes. Some ofthese did not wish to be identified by name. In the questionnaire,
respondents were asked to estimate the number ofoncology patients they counsel per
month (Qla). Results obtained in the questionnaire are unclear, as overlap ofdietitians
and patients, repeat visits, and follow-up assessments may be represented within the
dietitians'
estimates.
The leading practice settings in which dietitians indicated they provided cancer
patients withMNT (Q2) are shown in Table 2. First is in-patient hospital setting (34.7%),
followed by long term care (25%), out-patient hospital setting (19.4%), and community
clinics (8.3%). Building alliances with professionals in these leading settings is important
for maintaining and increasing referrals. RD's can focus on increasing visibility and
building alliances in settings where the provision ofcancer therapy by RD's is low.
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Table 2
Primary practice setting where RD's provide nutrition therapy for cancer patients
(Q2) My primary practice setting where I provide nutrition
is (please check one):
therapy for cancer patients
Practice Setting Frequency (N) Valid % Responding
In-patient, hospital 25 34.7
Long term care 18 25.0
Out-patient, hospital 14 19.4
Community clinic 6 8.3
Home health care 3 4.2
Private Practice 2 2.8
HMO 2 2.8
Physician's office 1 1.4
Office for the Aging 1 1.4
total valid responses 72 100.0
responses missing 24
Table 3 shows results for referral sources (Q3b). Thirty-one percent ofRD's
reported the leading sources ofreferrals to be Attending Physicians, 22.4% said Primary
Care Physicians were first, and 13.8% indicated Nursing.
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Table 3
Leading sources ofreferrals ofcancer patients to RD's
(Q3b) From 3a above, my leading source ofreferrals is
Referral Source Frequency (N) Valid % Responding
Attending Physician 18 31.0
Primary Care Physician 13 22.4
Nursing 8 13.8
Nurse Practitioner 4 6.9
Oncologist 4 6.9
Automatic by Policy 3 5.2
Case Manager 2 3.4
Home Health Care Agency 2 3.4
Medical Residents 2 3.4
SocialWorker 1 1.7
Cancer Action 1 1.7
total valid responses 58 100.0
responses missing 38
RD's can build professional relationships and offer value-added services to
increase referral rates in all practice settings. Home health care holds a promising future
for dietitians if they can position nutrition services as part ofcost-effective, quality care.
Building alliances with home health care leaders, advocating forMedicare coverage, and
skill building are requisite to RD success (Schiller, Arensberg and Kantor, 1998).
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Results from questions 4 - 45 are summarized in Table 4. Respondents answered
on a 5-point Likert scale, with an additional choice ofnot applicable.
Table 4
Response Summary for Questions 4 - 45.
For questions 4-45, respondents were asked to complete the questionnaire by circling the
response that best describes oncology practice in their practice setting.
SD = strongly disagree
D = disagree
N = neutral * ,* number ofresponses missingA = agree
SA = strongly agree
NA = not applicable
VALID % (N
# QUESTION SD D N A SA NA M*
4 Cancer patients seek me out on their own for nutrition
advice.
9.4
(9)
20.8
(20)
9.4
(9)
20.8
(20)
5.2
(5)
34.4
(33)
0
5 Individuals who are currently healthy seek me out for
nutrition advice about preventing cancer.
10.5
(10)
20.0
(19)
14.7
(14)
33.7
(32)
3.2
(3)
17.9
(17)
1
6 My cancer patients are pursuing alternative or
unproven cancer therapies (i.e., herbs, acupuncture,
meditation).
8.3
(8)
15.6
(15)
16.7
(16)
15.6
(15)
10.4
(10)
33.3
(32)
0
7 I am comfortable answering my
patients'
questions
regarding alternative or unproven cancer therapies.
9.4
(9)
35.4
(34)
18.8
(18)
18.8
(18)
1.0
0)
16.7
(16)
0
8 The cancer population in my practice setting is
adequately served by RD's.
14.6
(14)
12.5
(12)
9.4
(9)
27.1
(26)
13.5
(13)
22.9
(22)
0
9 I believe nutrition therapy during cancer treatment is
important to the patient's quality of life.
1.0
<1)
0 0 20.8
(20)
78.1
(75)
0 0
10 I am qualified to deliver oncology nutrition therapy. 0 3.2
(3)
22.1
(21)
50.5
(48)
18.9
(18)
5.3
(5)
1
11 When I counsel oncology patients, they indicate it was
helpful.
0 0 13.7
(13)
34.7
(33)
21.1
(20)
30.5
(29)
1
12 The breast cancer population requires nutrition therapy
that differs from other cancer populations.
2.1
(2)
24.2
(23)
30.5
(29)
30.5
(29)
6.3
(6)
6.3
(6)
1
13 Cancer patients are referred tome close to the time of
initial diagnosis.
10.4
(10)
31.3
(30)
10.4
(10)
8.3
(8)
3.1
(3)
36.5
(35)
0
14 Cancer patients are referred tome once the patient
demonstrates an already-compromised nutrition status
(i.e., malnutrition).
0 5.2
(5)
7.3
(7)
34.4
(33)
20.8
(20)
32.3
(31)
0
15 From reading documentation and charts, it is evident to
me that physicians often advise their patients about
nutrition during cancer.
9.4
(9)
24.0
(23)
26.0
(25)
15.6
(15)
3.1
(3)
21.9
(21)
0
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#16
a
QUESTION SD D N A SA NA M*
At my facility, determination ofwhich patients the RD
will see is based on admission diagnosis.
14.6
(14)
26.0
(25)
5.2
(5)
17.7
(17)
6.3
(6)
30.2
(29)
0
16
b
Admission diagnosis helps me to correctly identify
those cancer patients who need to be seen for nutrition
therapy.
6.4
(6)
9.6
(9)
7.4
(7)
30.9
(29)
3.4
(6)
39.4
(37)
2
16
c
I am satisfied with the systems in place that indicate to
me which cancer patients I need to see.
8.4
(8)
17.9
(17)
10.5
(10)
26.3
(25)
4.2
(4)
32.6
(31)
1
17 The nutrition screening tool or form in my facility is
being properly filled out on a consistent basis.
3.2
(3)
12.6
(12)
8.4
(8)
32.6
(31)
13.7
(13)
29.5
(28)
1
18 When performing assessments, I often find cancer
patients by chance who had an admitting diagnosis
other than cancer.
3.2
(3)
17.9
(17)
6.3
(6)
27.4
(26)
9.5
(9)
35.8
(34)
1
19 Patients want nutrition information about diet&
cancer, but cannot obtain an RD referral from their
physician.
4.2
(4)
19.8
(19)
20.8
(20)
16.7
(16)
5.2
(5)
33.3
(32)
0
20 I have had cancer patients cancel and/or not return for a
nutrition therapy appointment once they find out
insurance will not cover the visit.
2.1
(2)
7.3
(7)
13.5
(13)
7.3
(7)
5.2
(5)
64.6
(62)
0
21 I have experienced difficulty obtaining third party
reimbursement (insurance payments) for my services.
3.1
(3)
6.3
(6)
14.6
(14)
5.2
(5)
10.4
(10)
60.4
(58)
0
22 Lack oftime prevents me from seeing cancer patients
that could benefit from RD services.
6.3
(6)
28.1
(27)
7.3
(7)
17.7
(17)
6.3
(6)
34.4
(33)
0
23 Management supports me in providing nutrition
services to cancer patients as part ofmy existing work
load.
3.2
(3)
7.4
(7)
13.7
(13)
35.8
(34)
11.6
(H)
28.4
(27)
1
24 I have been approached by a medical professional at my
facility to offer oncology nutrition services.
6.3
(6)
25.0
(24)
10.4
(10)
14.6
(14)
5.2
(5)
38.5
(37)
0
25 I am recognized as part of the health care team and
included in oncology patient care decisions.
3.1
(3)
12.6
(12)
7.3
(7)
27.3
(26)
9.4
(9)
40.0
(38)
1
26 Scheduling a nutrition visit to coincide with other
scheduled treatment is done with ease at my facility.
0 10.5
(10)
10.5
(10)
17.9
(17)
11.6
(U)
49.5
(47)
1
27 I have success counseling cancer patients in a treatment
setting (i.e., infusion room or hallway).
4.2
(4)
8.3
(8)
12.5
(12)
9.4
(9)
4.2
(4)
61.5
(59)
0
28 High patient satisfaction is a goal of the organization. 1.0 1.0
0)
5.2
(5)
42.7
(41)
38.5
(37)
11.5
(H)
0
29 My approach to oncology nutrition care is patient-
focused.
1.0
(1)
1.0
(1)
0 47.9
(46)
27.1
(26)
22.9
(22)
0
30 Patients in my practice setting receive a majority of
their nutrition information from nursing.
9.4
(9)
30.2
(29)
14.6
(14)
16.7
(16)
9.4
(9)
19.8
(19)
0
31 Nursing is qualified to provide basic nutrition
information in my facility.
8.3
(8)
34.4
(33)
16.7
(16)
18.8
(18)
2.1
(2)
19.8
(19)
0
32 Nursing is qualified to provide nutrition information to
high risk cancer patients in my facility.
28.1
(27)
36.5
(35)
8.3
(8)
1.0
(J)
0 26.0
(25)
0
33 When 1 make nutrition-related recommendations for
cancer patients, the physician often implements them.
1.0
(1)
4.2
(4)
11.5
(H)
45.8
(44)
8.3
(8)
29.2
(28)
0
34 I seek out patients followingmastectomy. 7.3
(7)
16.7
(16)
12.5
(12)
5.2
(5)
0 58.3
(56)
0
35 I have investigated being part of the oncology team at
my facility.
6.3 10.4
(10)
8.3
(8)
9.4
(9)
3.1
(3)
62.5
(60)
0
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# QUESTION SD D N A SA NA M*
36 Inpatient Settings: When I receive a nutrition consult
(doctor's order) I am able to see the cancer patient
within 24 hours.
0 9.7
(9)
3.2
(3)
25.8
(24)
11.8
(H)
49.5
(46)
3
37 Outpatient Settings: When I receive a nutrition consult
(doctor's order), I am able to see the cancer patient
within one business week.
1.1
0)
3.2
(3)
6.4
(6)
19.1
(18)
10.6
(10)
59.6
(56)
2
38 I document outcomes for my nutrition services with
cancer patients.
6.3
(6)
12.5
(12)
10.4
(10)
25.0
(24)
8.3
(8)
37.5
(36)
0
39 I am involved with legislative initiatives for
reimbursement and medical nutrition therapy.
7.4
(7)
15.8
(15)
14.7
(14)
27.4
(26)
7.4
(7)
27.4
(26)
1
40 Submitting a form letter documenting nutrition care
with a claim form helps my patients attain payment
from insurance.
2.1
(2)
5.3
(5)
11.6
(H)
8.4
(8)
1.1
0)
71.6
(68)
1
41 I offer group cooking classes regarding food
preparation during cancer therapy.
9.4
(9)
17.7
(17)
4.2
(4)
3.1
(3)
1.0
(D
64.6
(62)
0
42 I offer group education classes about cancer topics other
than cooking.
8.3
(8)
17.7
(17)
3.1
(3)
10.4
(10)
1.0
(1)
59.4
(57)
0
43 I provide a free initial meeting to the patient/client. 7.3
(7)
13.5
(13)
6.3
(6)
4.2
(4)
2.1
(2)
66.7
(64)
0
44 I charge on a sliding scale. 5.2
(5)
12.5
(12)
8.3
(8)
1.0
d)
3.1
(3)
69.8
(67)
0
45 I see cancer patients when they request the service, even
if I cannot charge them for it or get reimbursed.
4.2
(4)
5.2
(5)
2.1
(2)
16.7
(16)
11.5
(H)
60.4
(58)
0
Total Cases = 96
Findings for Hypothesis 2
The second hypothesis addressed RD perceived barriers to the delivery of
oncological therapy. The top barriers were presupposed to be: lack ofor inconsistent use
ofan appropriate nutrition screening tool, lack ofphysician support, and lack of third
party reimbursement. Questions 6, 7, 10, 14, 16b, 17, 19, 20, 21, 22, 23, 25, 26, 27, 30,
and 33 included barriers to care. Results ofthe measured RD perception ofbarriers are
shown in Table 5.
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Table 5
Perceived Barriers a,b to the Delivery ofNutrition Therapy to Cancer Patients,
in descending order
POSSIBLE BARRIER TO NUTRITION
THERAPY DELIVERY
VALID % OF RD'S INDICATING
PERCEIVED BARRIER
Q14. Cancer patients are referred tome once the
patient demonstrates an already-compromised
nutrition status (i.e., malnutrition).
55.2%'
Q7. I am comfortable answering my
patients'
questions regarding alternative or unproven cancer
therapies.
44.8%'
Q22. Lack of time prevents me from seeing cancer
patients that could benefit from RD services.
24%
Q19. Patients want nutrition information about diet
& cancer, but cannot obtain an RD referral from
their physician.
21.9%
Q16b. Admission diagnosis helps me to correctly
identify those cancer patients who need to be seen
for nutrition therapy.
16%
Q17. The nutrition screening tool or form in my
facility is being properly filled out on a consistent
basis.
15.8%
Q21. 1 have experienced difficulty obtaining third
party reimbursement (insurance payments) for my
services.
15.6%,o/
Q25. 1 am recognized as part of the health care
team and included in oncology patient care
decisions.
15.6%
Q20. 1 have had cancer patients cancel and/or not
return for a nutrition therapy appointment once
they find out insurance will not cover the visit.
Q27. I have success counseling cancer patients in a
treatment setting (i.e., infusion room or hallway).
Q23. Management supportsme in providing
nutrition services to cancer patients as part ofmy
existing work load.
Q26. Scheduling a nutrition visit to coincide with
other scheduled treatment is donewith ease at my
facility.
Q33. When Imake nutrition-related
recommendations for cancer patients, the physician
often implements them.
Q10. I am qualified to deliver oncology nutrition
therapy.
a
barrier indicated by strongly agree and agree responses.
b barrier indicated by strongly disagree and disagree responses.
12.5%
12.5%
10.6%
10.5%
5.2% b
3.2%0/ b
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In summary, the top three RD-perceived barriers were:
Cancer patients are referred to RD once nutrition status is already compromised,
55.2% (Q14).
Discomfort answering
patients'
questions about alternative therapies, 44.8% (Q7).
Lack of time prevents 24% ofRD's from seeing cancer patients (Q22).
Questions 14, 16b and 17 show support for the hypothesis that there is lack ofor
inconsistent use ofan appropriate screening tool. The number one perceived barrier to
the delivery ofnutrition therapy was identified by 55% of respondents: cancer patients are
referred to RD's once the patient has already demonstrated a compromised nutrition
status. Sixteen percent said screening by admission diagnosis is a barrier to correctly
identifying cancer patients who need to be seen by the RD (Q16b). The correct utilization
ofa screening form was a barrier for 15.8% (Q17). Responses indirectly indicate that the
system ofdiagnosis, screening and referral ofpatients does not clearly and consistently
address the nutritional status ofthe patients, and reporting systems also do not separate
nutrition from other therapies.
Regarding RD satisfaction, 30% responded as being satisfied with the systems in
place to indicate which cancer patients need to be seen, while 26% were dissatisfied.
Another 43% gave a neutral or not applicable response (Q16c). Thirty-seven percent of
RD's agreed they often find cancer patients by chance who have an admitting diagnosis
other than cancer (Ql 8). These results suggest room for improvement in the type of
screening tools being used, and the effectiveness demonstrated. When proper systems are
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in place, dietitians may realize how many cancer patients are missed in the screening
process. Proper systems include means for early nutrition assessment and intervention
Nutrition screening and assessment must be conducted in a consistent and standardized
way, and address nutrition status as part of the overall assessment of the patient.
Results show evidence for the hypothesis that lack ofphysician support is a barrier.
Barriers are identified in questions 19, 25, and 33. Patients' ability to obtain an RD
referral from their physician is perceived as a barrier for 21 .9% ofRD's (Q19). Non-
recognition as part ofthe health care team is believed to be a barrier for 15.6% ofRD's
(Q25). Physician implementation ofRD recommendations is a perceived barrier for 5.2%
(Q33).
Results from questions 20 and 21 show support for the hypothesis that lack of
third party reimbursement is a barrier. Question 20, the RD experienced patient
cancellation due to non-coverage by insurance, was a barrier for 12.5% ofRD's.
Difficulty obtaining third party reimbursement (Q21) was experienced by 15.6% of
dietitians.
Unanticipated was the finding that 44.8% feel discomfort with answering
patients'
questions about alternative therapies (Q7). At 44.8%, this finding was the second highest
perceived barrier. Third on the list was lack of time, reported by 24% ofRD's.
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Findings for Hypothesis 3
Hypothesis 3 addresses RD involvement in actions noted to increase patient
referral from physicians. Questions 10, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, and 44
measured RD involvement in the provision ofvalue-added services. Results are shown in
Table 6.
Table 6
Results Summary for RD Participation in Value-
VALUE-ADDED SERMCES SHOWN
TO INCREASE PHYSICIAN
REFERRAL TO RD
VALID % OF RD'S INDICATING
PERCEIVED PARTICIPATION IN
VALUE-ADDED SERVICE a
Q10. I am qualified to deliver oncology nutrition
therapy.
69.4%
Q36. Inpatient Settings: When I receive a
nutrition consult (doctor's order) I am able to see
the cancer patient within 24 hours.
37.6%
Q39. I am involved with legislative initiatives for
reimbursement and medical nutrition therapy.
34.8%
Q38. I document outcomes for my nutrition
services with cancer patients.
33.3%
Q37. Outpatient Settings: When I receive a
nutrition consult (doctor's order), I am able to see
the cancer patient within one business week.
29.7%
Q35. I have investigated being part of the oncology
team at my facility.
12.5%
Q42. 1 offer group education classes about cancer
topics other than cooking.
11.4%
Q40. Submitting a form letter documenting
nutrition care with a claim form helpsmy patients
attain payment from insurance.
9.5%
Q43. 1 provide a free initial meeting to the
patient/client.
6.3%
Q34. I seek out patients following mastectomy. 5.2%
Q41. I offer group cooking classes regarding food
preparation during cancer therapy.
4.1%
Q44. I charge on a sliding scale. 4.1%
Participation indicated by a response ofstrongly agree or agree.
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Nearly 70% ofRD's in greater Rochester evaluated themselves as qualified to
deliver nutrition therapy to cancer patients (Q10). Approximately one-third ofRD's
working in both in-patient (Q36) and out-patient settings (Q37) are able to respond to
requests for nutrition consults within 24 hours and one week, respectively. One-third
reported being involved with legislative initiatives for reimbursement and medical nutrition
therapy, and documenting outcomes. Arguably, all dietitians should be involved in these
two activities. Participating in legislation and outcomes will secure a foothold for the
future ofdietetics. LowRochester RD involvement was reported for the following
value-added services:
12% have investigated involvement in the oncology team (Q35).
1 1 .4% offer group classes about topics other than cooking (Q42).
9.5% submit a form letter documenting nutrition care with a claim to patients
attain payment from insurance (Q40).
6.3% provide a free initialmeeting to the patient/client (Q43).
5% approach patients following mastectomy (Q34).
4.1% offer group cooking classes regarding food preparation during cancer
therapy (Q41).
4.1% charge on a sliding scale (Q44).
However, Rochester RD's are providing services to their patients, even when the
health system does not support their efforts. Twenty-seven percent reported seeing cancer
patients when the service is requested, even ifthe visit cannot be paid for by the patient, or
reimbursed through insurance (Q45).
47
Findings for Hypothesis 4
Results (Table 4) show 39.6% ofRD's do not believe the nursing staff is
responsible for providing nutrition education in their practice settings. Twenty-six percent
replied that nursing provides a majority ofnutrition counseling (Q30). Question 3 1 shows
twice as many RD's believe nursing is unqualified to deliver basic nutrition counseling, as
those who believe nursing is qualified (42.7% vs. 20.9%). When asked ifnursing is
qualified to provide nutrition counseling for high risk patients, the opinion that nursing is
unqualified increased to 64.6%. One RD agreed nursing was qualified to provide nutrition
care to high risk patients (Q32).
Findings for Hypothesis 5
Literature reviewed emphasized the need for RD involvement in and knowledge of
alternative therapies (Spaulding-Albright, 1997; Newman et al, 1997 ). While over two-
thirds ofRochester RD's (69.4%) felt qualified to provideMNT to cancer patients (Q10),
comfort level in answering
patients'
questions about alternative therapies was lower (See
Fig. 1). One-fifth (19.8%) indicated a positive comfort level answering
patients'
alternative therapy questions, 45% indicated discomfort, and 35.5% indicated it was a
non-issue (Q7).
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Figure 1
RD comfort level answering questions about alternative or unproven therapies
Q7) I am comfortable answering my patients'questions regarding alternative or
unproven cancer therapies.
Not Applicable
Strongly Disagree
Perception ofpatient involvement in alternative therapies had Rochester RD's
divided (Figure 2). Twenty-six percent indicated agreement that cancer patients were
pursuing these therapies; 23.9% disagreed, and about one-third rated alternative therapies
as a non-issue (Q6).
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Figure 2
RD perception ofpatients pursuing alternative or unproven therapies
Q6) My cancer patients are pursuing alternative or unproven cancer therapies
(i.e., herbs, acupuncture, meditation).
Strongly Die
Not Applicable
Whether or not RD's agree with the pursuit ofalternative therapies, or question
the ethics or effectiveness, alternative therapies are readily available in the market place
and ever-increasing in popularity. Cancer patients are especially interested, and at the
same time susceptible to alternative treatments (Aulas, 1996; Gray et al, 1997; Monnin &
Schiller, 1993; Newman^ al, 1998). Some alternative therapies hold promise ofbeing
successful adjuvant cancer therapies. However, alternative therapies present risks that
health professionals must be aware of so that optimal care can be provided for cancer
patients.
An impressive 20% ofRochester RD's participating in the survey indicated a
positive comfort level answering
patients'
questions about alternative therapies. However,
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the 36 respondents (not included in data analysis) that considered cancer therapy not
applicable to them, and the 40% ofRD's not responding to the survey represent a fair
number ofRD's in the Rochester community who are not associating cancer therapy with
alternative therapies. There remains a need for further Rochester RD familiarization with
alternative therapies.
RD perception of the nutritional needs ofbreast cancer patients
Patients at risk for breast cancer recurrence are likely to participate in alternative
therapies. Newman et al. (1998) found 80.9% ofwomen at risk for breast cancer
recurrence reported supplement use. Breast cancer patients are known to need nutrition
intervention that differs from other cancer populations (Monnin& Schiller, 1998;
Newman et al, 1993). Surprisingly, 26.3% ofdietitians disagreed with this philosophy
and an additional 36.8% had no opinion or viewed it as non applicable. Thirty-seven
percent appear to be practicing in step with current literature recommendations.
Approaching patients following amastectomy increases service to the breast cancer
patient and is a proactive method for RD's to be involved in nutrition care (Monnin &
Schiller, 1993). Interestingly, 5.2% ofRochester area RD's reported doing so, while
58.3% said this practice was not applicable (Q12).
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Further Analysis ofthe Data
Further analysis ofthe data included Pearson's and Kendall's tau-b statistical
analyses (Appendix D) to determine the strength ofthe linear association between pairs of
questions (variables). To increase certainty that relationships existed, significant results
noted at the .01 level for both Pearson's and Kendall tau-b were compared. When
correlations were significant for both Pearson's and Kendall's tau-b at the .01 level, the
correlation was explored (J. Halavin, personal communication, June, 1998).
Interesting findings surfaced regarding RD perception ofpatient-focused care,
strategies for increasing physician referral, outcomes and documentation, and increasing
professional visibility. Specific questions from the questionnaire are noted in parenthesis.
The questionnaire may be found in Appendix A.
RD perception ofpatient-focused care
RD's in Rochester appear to be taking their cue from patients when it comes to
assessing their own effectiveness. Ninety-nine percent ofrespondents believedMNT was
important to cancer patients'quality of life (Table 4, Q9). This beliefwas positively
associated with the event ofa patient indicating to the RD that nutrition therapy was
helpful (Ql 1). The event ofa patient indicating to the RD that nutrition therapy was
helpful (Qll) was associated the RD's perception that they were qualified to provide
MNT to cancer patients (Q10), and occurred when cancer patients were referred to the
dietitian once the patient demonstrated a compromised nutritional status (Q14) . Also tied
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to patients' indication the RD was helpful was the RD perception ofhaving a patient-
centered approach to care (Q29).
Forty percent ofRD's agreed that cancer patients in their facilities were adequately
served byRD's (Table 4, Q8). This perception was positively associated with the:
RD being satisfied with the systems in place that indicate which cancer patients need to
be seen (Q16c).
perception that the nutrition screening tool or form is being properly filled out on a
consistent basis (Q17).
support frommanagement to see cancer patients (Q23).
occurrence ofMD's implementing RD recommendations (Q33).
RD perception that cancer patients are adequately served by RD's (Q8) was
negatively associated with the perception that patients receive amajority ofnutrition
information from nursing (Q30).
Dietitians who provided a free initial meeting to the patient (Q43) were likely to
charge on a sliding scale (Q44) and see patients even ifthe visit could not be paid for or
reimbursed (Q45). These dietitians were also likely to seek out patients aftermastectomy
(Q34).
Outcomes & documentation
RD's were active with legislative efforts (Q39) ifthey had experienced difficulty
obtaining third party reimbursement (Q21). Being proactive in outcomes documentation
(Q38) was positively associated with the RD being involved with legislative efforts (Q39);
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offering cooking classes (Q41), and offering other group education classes (Q42).
Unfortunately, only 33.3% participate in outcomes documentation for cancer patients,
with 37.5% viewing it as not applicable to their job (Table 4, Q38).
Professional visibility
Healthy individuals were the most likely to seek out an RD for information on
preventing cancer (Q5) when the RD was involved in documenting outcomes (Q38),
offered cooking classes (Q41), and offered other group education (Q42).
Limitations
The results describe the experiences and viewpoints ofapproximately 40% ofRD's
practicing in the greater Rochester community who are members ofthe Genesee Dietetic
Association Recommendations may not apply to other communities that may have
differing dietetic philosophy and health care systems.
The questionnaire was developed from literature reviewed, as an existing model
was not found. Efforts to standardize the questionnaire are recommended.
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Chapter 5
Conclusions and Recommendations
Conclusions
Central to the issue ofRD involvement in cancer care is the capability to form
physician alliance. Physicians and insurance support are two keys to success for RD's in
oncology care, and the long-term viability ofthe profession. This study was completed
during a decade ofhealth care reform, and reorganization for cost containment.
Underlying doubt about the impact ofnutrition therapy in oncology remains a barrier to
physicians and insurance companies supporting medical nutrition therapy provided by
dietitians. This climate, paired with the newness ofpreventive and complementary
therapies in western culture, set the stage for controversy as well as the opportunity for
RD's to prove their value in oncology care.
All dietitians do not wish to participate in oncology care. However, oncology is
presented here as a significant opportunity within the community to provide nutrition
therapy to those in need. The need for nutrition services has been identified by several
Rochester area cancer centers. The turbulent health care environment and anxiety about
the role dietitians will play in the future are reasons for RD's to capture thismarket and
proactively strengthen their position in the healthcare system Opportunity clearly exists in
Rochester for dietitians' expanded role in the delivery ofnutrition care. Increased
participation in providing value-added services, being professionally visible and politically
active, and working strategically is necessary for Rochester dietitians to fulfill the need and
55
the opportunity. Ifdietitians fail to do so, other health professionals, qualified or not, will
fulfill the need. A small number ofdietitians in the community lead progressive efforts.
The work ofa few cannot compensate for the non-participation ofmany.
A case study reviewed for this paper clearly illustrates the problem ofmissed
opportunity in cancer care. A patient with breast cancer, receiving her care at the largest
cancer center in Rochester, approached her physicians and nurses repeatedly about the
role ofnutrition in her treatment and recovery. The patient felt strongly about
participating in the healing process and preventing recurrence through lifestyle change,
had insurance coverage, and disposable income. According to the patient, the physicians
and nurses were unable to answer nutrition questions, and seemed disinterested in doing
so. She attended a breast cancer forum at the hospital concerning wellness during
treatment, but a dietitianwas not present. In frustration, she obtained a referral from her
physician to see a dietitian. Sadly, the dietitian could not address the patients questions
about alternative treatments and organic food choices. The dietitian was only somewhat
effective; not current in the special needs ofthe breast cancer population. The patient did
not find the services to meet her needs until she consulted with a naturopath, with whom
she consults regularly for nutrition and wellness information. This scenario spells missed
opportunity for dietitians, and drives home the message that dietitians must be in touch
with the public's needs and desires, and current with research that serves the public well.
This unfortunate incident aside, cost containment and quality assurance endeavors,
along with quality nutrition care can be effectively provided by registered dietitians. Every
registered dietitian in Rochester must participate in outcomes research and legislative
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initiatives, and take advantage ofopportunities that exist in the community. Use of the
PG-SGA is recommended for dietitians who counsel cancer patients. It serves as an easy-
to-use, cost-effective, and standardized assessment tool to proactively address nutritional
risk or deficit. The PG-SGA is available in several languages (Ottery, 1997). Using this
study as a guide, RD's can look at their own practice settings, identify barriers, and use
strategies to improve patient care. Alliance with physicians, professional visibility, and
expanded roles and responsibilities such as knowledge in alternative therapies will
make it possible forRD's to provide valuable nutrition services to oncology patients. The
goal is to make medical nutrition therapy, provided by a registered dietitian, a standard of
care which positively affects the quality ofcancer
patients'lives.
Recommendations
Further refinement and redesign of the questionnaire would be beneficial.
Proposed changes include:
Question la. "Not
applicable"
removed as a response. A separate category
created for the response of
"0."
Question lb. Move to a more noticeable area, and ask
"yes"
or
"no."
Question 3a. For statistical summation, too many possible combinations exist with
the "check all that
apply"instruction Change to
"yes"
or
"no,"
or eliminate
question.
Questions 4 - 45. Remove "Not
Applicable"
as a response, as it proved
problematic. Removing
"NA"
will encourage the respondent to agree or disagree
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with the statement, thus providingmore definitive data Separate questions
regarding beliefs and those regarding actions, and adjust responses as necessary.
Suggestions for further study include making changes to the survey and
conducting a pilot study to assess the effectiveness ofthe design. Interest was generated
outside the Rochester area, as evidenced by calls and letters requesting results of the
study. Surveying dietitians by geographic area, and comparing beliefs and roles ofthe
dietitian in oncology, would be interesting and informative research.
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Appendix A
Cover Letter & Questionnaire
RIT Rochester Institute of Technology
School of Food, Hotel and
Travel Management
14 Lomb Memorial Drive
Rochester, NY 14623-5604
May 11, 1998
Dear GDA Dietitian:
Your participation is requested in the completion of a study designed to assess the role
of the registered dietitian in oncology care in Monroe County. Results will serve as a
resource to dietitians providing cancer therapy, and reveal strategies for increased
reimbursement and referral rates. Your responses are highly valued.
Thank you for taking 5-1 0 minutes to complete the questionnaire. After completion,
please use the enclosed stamped envelope to return the questionnaire by Monday, May 18.
All responses will remain confidential.
Results will be made available to interested respondents by late-summer. For inquiries,
please contact Natalie Gennett at (716) 624-731 1 or NRG1858@rit.edu.
Sincerely,
Natalie R. Gennett, BS Elizabeth A. Kmiecinski, MS, RD
Graduate Student Director, Coordinated Program In Dietetics
The RD & Oncology Care in Monroe County
Each item in the questionnaire relates to oncology patients in your practice
setting. This questionnaire will take only 5-10 minutes to complete.
Questions 1-3:
la) In my best estimate, I provide nutrition therapy for cancer patients per month.
? 0-5
D 6-10
D 11-15
D 16-20
D 25+
D NOT APPLICABLE
lb)
I I I practice inMonroe County
(mark if"YES")
2. My primary practice setting where I provide nutrition therapy for cancer patients is
(please check one):
? IN-PATIENT HOSPITAL SETTING
D OUT-PATIENT HOSPITAL SETTING
D FREE-STANDING CANCER CENTER
? PRIVATE PRACTICE
D LONG TERM CARE
? COMMUNITY CLINIC
D HOME HEALTH CARE
D PHYSICIAN'S OFFICE
D OTHER. PLEASE SPECIFY:
D NOT APPLICABLE
3a. The following professionals refer cancer patients to me for nutrition therapy
(please check all that apply):
? ATTENDING PHYSICIAN
D PRIMARY CARE PHYSICIAN
? NURSE PRACTITIONER
D ONCOLOGIST
DNURSING
D CASE MANAGER
? SOCIAL WORK
D HOME HEALTH CARE AGENCY
D OTHER RDs
D OTHER. PLEASE SPECIFY:
? NOT APPLICABLE
3b. From 3a above, my leading source of referrals is
Questionnaire: The RD & Oncology Care inMonroe County
MS Thesis/NatalieGennett/RITMay 1998.
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For questions 4-45, please complete the questionnaire by circling the
response that best describes oncology practice in your practice setting as
you see it:
SD = strongly disagree
D = disagree
N = neutral
A = agree
SA = strongly agree
NA = not applicable
(Circle Response)
4. Cancer patients seek me out on their own for nutrition advice. SD D N A SA NA
5. Individuals who are currently healthy seek me out for nutrition
advice about preventing cancer.
SD D N A SA NA
6. My cancer patients are pursuing alternative or unproven cancer
therapies (i.e., herbs, acupuncture, meditation).
SD D N A SA NA
7. I am comfortable answeringmy
patients'
questions regarding
alternative or unproven cancer therapies.
SD D N A SA NA
8. The cancer population in my practice setting is adequately
served by RDs.
SD D N A SA NA
9. I believe nutrition therapy during cancer treatment is important
to the patient's quality of life.
SD D N A SA NA
10. I am qualified to deliver oncology nutrition therapy. SD D N A SA NA
11. When I counsel oncology patients, they indicate it was helpful. SD D N A SA NA
12. The breast cancer population requires nutrition therapy that
differs from other cancer populations.
SD D N A SA NA
13. Cancer patients are referred to me close to the time of initial
diagnosis.
SD D N A SA NA
14. Cancer patients are referred to me once the patient
demonstrates an already-compromised nutrition status (i.e.,
malnutrition).
SD D N A SA NA
15. From reading documentation and charts, it is evident tome that
physicians often advise their patients about nutrition during
cancer.
SD D N A SA NA
16a At my facility, determination ofwhich patients the RD will see
is based on admission diagnosis.
SD D N A SA NA
16b Admission diagnosis helpsme to correctly identify those cancer
patients who need to be seen for nutrition therapy.
SD D N A SA NA
16c I am satisfied with the systems in place that indicate tome
which cancer patients I need to see.
SD D N A SA NA
17. The nutrition screening tool or form inmy facility is being
properly filled out on a consistent basis.
SD D N A SA NA
18. When performing assessments, I often find cancer patients by
chancewho had an admitting diagnosis other than cancer.
SD D N A SA NA
19. Patients want nutrition information about diet & cancer, but
cannot obtain an RD referral from their physician.
SD D N A SA NA
20. I have had cancer patients cancel and/or not return for a
nutrition therapy appointment once they find out insurance will
not cover the visit.
SD D N A SA NA
21. I have experienced difficulty obtaining third party
reimbursement (insurance payments) for my services.
SD D N A SA NA
Questionnaire: The RD & Oncology Care inMonroe County Page 2
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22. Lack oftime prevents me from seeing cancer patients that
could benefit from RD services.
SD D N A SA NA
23. Management supports me in providing nutrition services to
cancer patients as part ofmy existing work load.
SD D N A SA NA
24. I have been approached by a medical professional atmy facility
to offer oncology nutrition services.
SD D N A SA NA
25. I am recognized as part of the health care team and included in
oncology patient care decisions.
SD D N A SA NA
26. Scheduling a nutrition visit to coincide with other scheduled
treatment is done with ease at my facility.
SD D N A SA NA
27. I have success counseling cancer patients in a treatment setting
(i.e., infusion room or hallway).
SD D N A SA NA
28. High patient satisfaction is a goal of the organization. SD D N A SA NA
29. My approach to oncology nutrition care is patient-focused SD D N A SA NA
30. Patients in my practice setting receive a majority of their
nutrition information from nursing.
SD D N A SA NA
31. Nursing is qualified to provide basic nutrition information in
my facility.
SD D N A SA NA
32. Nursing is qualified to provide nutrition information to high
risk cancer patients in my facility.
SD D N A SA NA
33. When I make nutrition-related recommendations for cancer
patients, the physician often implements them.
SD D N A SA NA
34. I seek out patients following mastectomy. SD D N A SA NA
35. I have investigated being part ofthe oncology team at my
facility.
SD D N A SA NA
36. Inpatient Settings: When I receive a nutrition consult (doctor's
order) I am able to see the cancer patient within 24 hours.
SD D N A SA NA
37. Outpatient Settings: When I receive a nutrition consult
(doctor's order), I am able to see the cancer patient within one
business week.
SD D N A SA NA
38. I document outcomes for my nutrition services with cancer
patients.
SD D N A SA NA
39. I am involved with legislative initiatives for reimbursement and
medical nutrition therapy.
SD D N A SA NA
40. Submitting a form letter documenting nutrition care with a
claim form helpsmy patients attain payment from insurance.
SD D N A SA NA
41. I offer group cooking classes regarding food preparation during
cancer therapy.
SD D N A SA NA
42. I offer group education classes about cancer topics other than
cooking.
SD D N A SA NA
43. I provide a free initial meeting to the patient/client. SD D N A SA NA
44. I charge on a sliding scale. SD D N A SA NA
45. I see cancer patients when they request the service, even if I
cannot charge them for it or get reimbursed.
SD D N A SA NA
Thank you for your invaluable time and responses. All responses will remain confidential. Ifyou wish
to receive the results of this study please check the box below and fill in your name and
address.*
D Name __
Address
Fax/Email
D I wish to remain an anonymous respondent, but may contact the researcher for results.*
* Study results anticipated by late-summer, 1998. See cover page for contact information.
Questionnaire: The RD & Oncology Care in Monroe County Page 3
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Appendix B
Surveys Excluded from Tabulation
Notes from Respondents
Notes from respondents who either returned the survey unmarked, marked all
questions "not applicable,"or indicated they did not provide cancer therapy, included the
following notes on their surveys. The 36 surveys fromwhich these notes were obtained
were not included in tabulation.
"I do not do any
counseling."
"I don't see oncology
patients."
"Don't practice inMonroe County."
"Unemployed."
"No longer work with oncology
patients."
"Have not practiced dietetics since
1985."
"In school forMaster's
degree."
"Retired."
"Not practicing clinical dietetics right
now."
"Great survey. Don't work directly with
patients."
"Full time
homemaker."
"Sorry, I do not see cancer patients at
all."
"I am in wellness education
primarily."
"I currently practice frill time in the neonatal ICU. The
entire survey is
NA."
"Sorry, I work in a public school not in a clinical
setting."
Appendix C
The Patient-Generated Subjective Global Assessment (PG-SGA)
Scored
PG-SGA
Patient Code:Institutional Code:
Setting: Inpt Outpt Clinic/Office Homecare Hospice
PatientName:
Medical Record # (optional):
Sex: Male Female Age:
| History
1. Weight See Table 1
In summary ofmy current and recent weight:
I currently weigh about pounds
tallI am about feet
Sixmonths ago I weighed about
.
Onemonth ago Iweighed about
.
pounds
.
pounds
During the past two weeks my weight has:
Q decreased <j) O not changed <t |^ increased m
2. Food Intake:
As compared to my normal, Iwould rate my food
intake during the pastmonth as either:
? unchanged to
? more than usual
? less than usual m
I am now taking:
? normal food but less than normal oj
? little solid food a
? only liquids o
0 only nutritional supplements ra
O very little of anything (
O only tube feedings or only nutrition by vein
3. Symptoms: I have had the following problems that
have keptme from eating enough during the past two
weeks (check all that apply):
0 no problems eating <v>
Q no appetite, just did not feel like eating ra
0 nausea a> G vomiting o>
0 constipation m ^ diarrhea pj
0 mouth sores a O drymouth m
? pain;where? o
0 things taste funny or have no taste
0 smells botherme
0 other** a,
0)
4. Functional Capacity:
Over the pastmonth, I would rate my activity as
generally:
O normal with no limitations <d>
CJ notmy normal self, but able to be up and
aboutwith fairly normal activities oi
? not feeling up tomost things, but in bed
less than half the day o
? able to do little activity and spend most of
the day in bed or chair m
CJ pretty much bedridden, rarely out of bed m
Patient Signature.
* depression, money, dental problems, etc
THE REMAINDER OF THIS FORMWILL BE COMPLETED BY YOUR DOCTOR, NURSE, OR THERAPIST. THANK YOU.
' Disease and Its Relation to Nutritional Requirements See Table 2
Primary diagnoses (specify)
Stage, if known . -
Metabolic demand: See Table 3 Q no stress J low stress CImoderate stress ? high stress
Physical
For each trait specify: 0*= normal + = mild ++- moderate ?++- severe See
Table 4
loss of subcutaneous muscle wasting
fat (triceps, chest) (quadriceps, deltoids)
ankle edema sacral edema ascites
^GAlUting
Select one
0 A= well nourished 0 B =moderately (or suspected of being)malnourished
Clinician Signature
PG-SGA.*Patient-GeneratedSubjectiveGlobal Assessment
RD RN PA MD DO Other
^ C = severelymalnourished
Date_
Ottery 1998
For more information about the PG-SGA, please contact:
Faith Ottery, MD, PhD, FACN
President, Ottery & Associates, Oncology Care Consultants
Pier 5, Suite 139
Philadelphia, PA 19106
Phone: (215)351-4050
Fax: (215)351-3990
Email: noatpres@pol.net
Appendix D
Further Analysis of the Data
Pearson's and Kendall's tau-b Correlations at the .01 Level
SPS \-^MX^ iJftz./hm**--)
| 2^ } Sb I
Tit S? >*/3<*
o
Correlations
f^({ sakIo^j
Correlations
Q1A Q4 Q5 Q6 Q7 Q8
Q1A Pearson Correlation 1.000 .227 -.027 .070 -.009 .201
Sig. (2-tailed) .081 .825 .588 .941 .092
N 86 60 71 62 74 71
Q4 Pearson Correlation .227 1.000 .119 .102 .184
Sig. (2-tailed) .081 . .039 .371 .436 .152
N 60 63 61 59 61 62
Q5 Pearson Correlation -.027 1.000 .120 .110 .214
Sig. (2-talled) .825 .039 .360 .354 .087
N 71 61 78 60 73 65
Q6 Pearson Correlation .070 .119 .120 1.000 .111 -.221
Sig. (2-tailed) .588 .371 .360 :391 .082
N 62 59 60 64 62 63
Q7 Pearson Correlation -.009 .102 .110 .111 1.000 .093
Sig. (2-tailed) .941 .436 .354 .391 .441
N 74 61 73 62 80 70
Q8 Pearson-Correlation .201 .184 .214 -.221 .093 1.000
Sig. (2-tailed) .092 .152 .087 .082 .441
N 71 62 65 63 70 74
Q9 Pearson Correlation -.021 .011 .188 -.010
Sig. (2-tailed) .847 .931 .100 .020 .038 .936
N 86 63 78 64 80 74
Q10 Pearson Correlation .124 -.122 .193 .021 .007
Sig. (2-tailed) .010 .338 .303 .130 .858 .952
N 81 62 73 63 75 72
Q11 Pearson Correlation .039 -.002 .062 -.052
Sig. (2-tailed) .7.63 .001 .988 .025 .623 .684
N 63 > 57 62 59 65 63
Q12 Pearson Correlation -.211 -.009 -.084 .205 .102 -.226
Sig. (2-tailed) .060 .943 .482 .114 .382 .058
N 80 60 73 61 75 71
Q13
Pearson'
Correlation -.064 .212 .245 .003 .001
Sig. (2-tailed) . .625 .117 .067 .983 .994 .023
N 60 56 57 57 59 61
Q14 Pearson Correlation .061 .078 -.156 .110 -.066 -.229
Sig. (2-tailed) .636 .562 .231 .411 .602 .069
N 63 57 61 58 64 64
Q15 Pearson Correlation .176 -.070 -.137 .077 .089 -.104
Sig. (2-tailed) .142 .597 .277 .553 .469 .400
N 71 59 65 62 69 68
Q16A Pearson Correlation -.116 -.176 -.025 -.004 .072 -.159
Sig. (2-tailed) .367 .216 .851 .976 .574 .217
N 63 51 59 53 63 62
Q16B Pearson Correlation -.184 -.242 .074 -.204 .134 .157
Sig. (2-tailed) .178 .106 .602 .164 .335 .261
N 55 46 52 48 54 53
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Q1A Q4 Q5 Q6 Q7 Q8
Q16C Pearson Correlation
.128 .044 .086 -.233
Sig. (2-tailed) .321 .752 .521 .081 .018 .000
N 62 54 58 57 61 61
Q17 Pearson Correlation
.194 .159 .198 .070 .229
Sig. (2-tailed) .127 .275 .135 .625 .078 .000
N 63 49 58 51 60 58
Q18 Pearson Correlation -.055 .039 .138 -.138 -.073
Sig. (2-tailed) .676 .021 .780 .321 .302 .586
N 59 51 55 54 58 58
Q19 Pearson Correlation -.023 -.054 .095 .188 -.039 -.237
Sig. (2-tailed) .863 .715 .469 .190 .765 .081
N 60 48 60 50 60 55
Q20 Pearson Correlation .315 .286 .300 -.108 -.122
Sig. (2-tailed) .069 .119 .025 .095 .551 .498
N 34 31 34 32 33 33
Q21 Pearson Correlation
.125 .297 -.167 -.221
Sig. (2-tailed) .047 .489 .078 .050 .338 .202
N 38 33 36 33 35 35
Q22 Pearson Correlation .166 -.106 .082 .114 -.101
Sig. (2-tailed) .197 .433 .543 .395 .442 .004
N 62 57 57 58 60 62
Q23 Pearson Correlation -.056 .141 .017 .190
Sig. (2-tailed) .660 .300 .034 .898 .129 .000
N 65 56 63 59 65 63
Q24 Pearson Correlation .185 .155 .033 -.018 .170
Sig. (2-tailed) .000 .194 .263 .812 .894 .210
N 57 51 54 53 56 56
Q25 Pearson Correlation -.025 -.178 .121 -.211 -.036 .095
Sig. (2-tailed) .851 .206 .385 .123 .794 .476
N 57 52 54 55 56 58
Q26 Pearson Correlation .221 .299 .179 .245 .160 .004
Sig. (2-tailed) .145 .069 .256 .117 .288 .979
N 45 38 42 42 46 44
Q27 Pearson Correlation -.092 .138 -.221 .181 .162 -.106
Sig. (2-tailed) .601 .445 .208 .299 .345 .545
N 35 33 34 35 36 35
Q28 Pearson Correlation .171 .041 .115 .023 .203
Sig. (2-tailed) .130 .756 .335 .022 .847 .089
N 80 59 72 62 74 71
Q29 Pearson Correlation .220 -.221 .245 -.085 -.058
Sig. (2-tailed) .065 .031 .074 .053 .482 .635
N 71 60 66 63 70 69
Q30 Pearson Correlation -.049 -.144 -.196 .112 -.178
Sig. (2-tailed) .681 .275 .111 .385 .137 .000
N 74 59 67 62 71 68
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Correlations
Q1A Q4 Q5 Q6 Q7 L Q8
Q31 Pearson Correlation
.023 .122 -.071 -.008 .205 .175
Sig. (2-tailed) .846 .359 .570 .953 .087 .154
N 72 59 67 60 71 68
Q32 Pearson Correlation
.021 .140 -.186 .054
Sig. (2-tailed) .028 .876 .264 .158 .664 .027
N 66 58 65 59 68 66
Q33 Pearson Correlation
.068 -.092 -.045 .115
Sig. (2-tailed) .585 .039 .471 .733 .359 .003
N 66 58 63 60 66 66
Q34 Pearson Correlation
.134 .112 -.279 .174
Sig. (2-tailed) .422 .520 .026 .105 .291 .029
N 38 35 37 35 39 38
Q35 Pearson Correlation -.095 .303 .196 .290 .169 -.050
Sig. (2-tailed) .587 .092 .273 .107 .324 .780
N 35 32 33 32 36 34
Q36 Pearson Correlation .150 .091 -.074 .046
Sig. (2-tailed) .007 .349 .567 .008 .630 .759
N 45 41 42 44 45 46
Q37 Pearson Correlation .324 .000 -.125 -.085 .067 .259
Sig. (2-tailed) .050 1.000 .454 .612 .698 .121
N 37 36 38 38 36 37
Q38 Pearson Correlation -.133 .223 -.053 .256
Sig. (2-tailed) .319 .108 .002 .698 .024 .052
N 58 53 56 55 59 58
Q39 Pearson Correlation .062 .141 .241 .124 .060 .117
Sig. (2-tailed) .631 .338 .071 .405 .644 .392
N 62 48 57 47 61 56
Q40 Pearson Correlation -.325 -.247 -.121 .221 .320 .009
Sig. (2-tailed) .098 .234 .563 .289 .103 .966
N 27 25 25 25 27 27
Q41 Pearson Correlation .220 .349 -.312 -.017 .228
Sig. (2-tailed) .226 .050 .005 .082 .926 .210
N 32 32 33 32 34 32
Q42 Pearson Correlation -.039 .239 .026 .154 .222
Sig. (2-tailed) .820 .161 .000 .877 .350 .194
N 37 36 38 37 39 36
Q43 Pearson Correlation .065 .202 -.311 .126 .107
Sig. (2-tailed) .726 .046 .276 .094 .498 .580
N 32 28 31 30 31 29
Q44 Pearson Correlation .325 .333 .170 -.335 -.175 .257
Sig. (2-tailed) .086 .104 .386 .095 .373 .204
N 29 25 28 26 28 26
Q45 Pearson Correlation .132 .197 -.070 -.207 .212
Sig. (2-tailed) .438 .006 .242 .684 .212 .215
N 37 34 37 36 38 36
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Q9 Q10 Q11 Q12 Q13 Q14
Q1A Pearson Correlation
Sig. (2-tailed)
N
-.021
.847
86
.010
81
.039
.763
63
-.211
.060
80
-.064
.625
60
.061
.636
63
Q4 Pearson Correlation
Sig. (2-tailed)
N
.011
.931
63
.124
.338
62
.001
57
-.009
.943
60
.212
.117
56
.078
.562
57
Q5 Pearson Correlation
Sig. (2-tailed)
N
.188
.100
78
-.122
.303
73
-.002
.988
62
-.084
.482
73
.245
.067
57
-.156
.231
61
Q6 Pearson Correlation
Sig. (2-tailed)
N
.020
64
.193
.130
63
.025
59
.205
.114
61
.003
.983
57
.110
.411
58
Q7 Pearson Correlation
Sig. (2-tailed)
N
.038
80
.021
.858
75
.062
.623
65
.102
.382
75
.001
.994
59
-.066
.602
64
Q8 Pearson Correlation
Sig. (2-tailed)
N
-.010
.936
74
.007
.952
72
-.052
.684
63
-.226
.058
71
.023
61
-.229
.069
64
Q9 Pearson Correlation
Sig. (2-tailed)
N
1.000
96
.175
.098
90
.005
66
.083
.441
89
.125
.335
61
.117
.355
65
Q10 Pearson Correlation
Sig. (2-tailed)
N
.175
.098
90
1.000
90
.000
66
-.023
.837
85
-.122
.353
60
.049
64
Q11 Pearson Correlation
Sig. (2-tailed)
N
.005
66
.000
66
1.000
66
-.153
.224
65
.084
.533
58
.007
61
Q12 Pearson Correlation
Sig. (2-tailed)
N
.083
.441
89
-.023
.837
85
-.153
.224
65
1.000
89
.162
.220
59
-.219
.088
62
Q13 Pearson Correlation
Sig. (2-tailed)
N
.125
.335
61
-.122
.353
60
.084
.533
58
.162
.220
59
1.000
61
.000
59
Q14 Pearson Correlation
Sig. (2-tailed)
N
.117
.355
65
.049
64
.007
61
-.219
.088
62
.000
59
1.000
65
Q15 Pearson Correlation
Sig. (2-tailed)
N
.106
.363
75
.001
.995
73
-.143
.259
64
.062
.613
70
.121
.355
60
-.074
.560
64
Q16A Pearson Correlation
Sig. (2-tailed)
N
.024
.847
67
.007
.956
63
-.112
.415
55
.009
.941
63
-.200
.151
53
.225
.092
57
Q16B Pearson Correlation
Sig. (2-tailed)
N
-.093
.493
57
-.017
.901
55
-.261
.067
50
-.041
.769
54
.126
.398
47
.053
.707
52
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Q9 Q10 Q11 Q12 Q13 Q14
Q16C Pearson Correlation -.152 -.100 -.237 -.031 .177 -.121
Sig. (2-tailed) .230 .437 .074 .814 .199 .366
N 64 63 58 60 54 58
Q17 Pearson Correlation -.093 -.113 .002 -.016 .199 -.122
Sig. (2-tailed) .453 .376 .989 .903 .162 .383
N 67 63 52 63 51 53
Q18 Pearson Correlation
.200 .070 .233 -.061 -.232
Sig. (2-tailed) .122 .590 .084 .652 .098 .005
N 61 61 56 58 52 55
Q19 Pearson Correlation
.177 .082 .095 .083 .037 .088
Sig. (2-tailed) .162 .527 .499 .527 .801 .531
N 64 62 53 61 49 53
Q20 Pearson Correlation
.065 .078 -.024 -.298
Sig. (2-tailed) .049 .719 .666 .895 .098 .048
N 34 33 33 34 32 32
Q21 Pearson Correlation -.038 .066 .222 .209 .251
Sig. (2-tailed) .027 .824 .717 .187 .243 .166
N 38 37 33 37 33 32
Q22 Pearson Correlation .057 -.033 -.096 -.006 -.232
Sig. (2-tailed) .659 .799 .476 .966 .082 .033
N 63 62 57 59 57 58
Q23 Pearson Correlation .157 .088 .101 .010 -.089
Sig. (2-tailed) .201 .479 .433 .937 .020 .494
N 68 67 62 66 58 61
Q24 Pearson Correlation -.029 .168 -.012 -.016 .087 -.074
Sig. (2-tailed) .827 .203 .929 .906 .544 .600
N 59 59 54 57 51 53
Q25 Pearson Correlation -.190 -.258 -.237 -.040 .170 -.161
Sig. (2-tailed) .153 .053 .082 .772 .220 .236
N 58 57 55 56 54 56
Q26 Pearson Correlation .170 .267 .151 .066 .148
Sig. (2-tailed) .035 .254 .087 .304 .682 .362
N 48 47 42 48 41 40
Q27 Pearson Correlation .123 -.066 .177 -.002 -.328
Sig. (2-tailed) .469 .699 .308 .991 .006 .058
N 37 37 35 37 33 34
Q28 Pearson Correlation .116 .009 .116 .168 -.149
Sig. (2-tailed) .000 .304 .945 .311 .199 .240
N 85 81 64 78 60 64
Q29 Pearson Correlation
.428**]
.054 -.005
Sig. (2-tailed) .000 .000 .023 .652 .967 .040
N 74 72 65 71 61 64
Q30 Pearson Correlation .137 .216 -.048 .158 -.251 .048
Sig. (2-tailed) .233 .063 .709 .184 .055 .710
N 77 75 63 72 59 63
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Correlations
Q9 Q10 Q11 Q12 Q13 Q14
Q31 Pearson Correlation
Sig. (2-tailed)
N
.050
.664
77
.146
.219
73
.012
62
-.176
.143
71
-.080
.547
59
-.040
.757
63
Q32 Pearson Correlation
Sig. (2-tailed)
N
-.192
.110
71
-.019
.876
68
-.017
.897
61
-.158
.204
66
.039
.773
58
.035
62
Q33 Pearson Correlation
Sig. (2-tailed)
N
-.041
.738
68
.229
.065
66
.003
62
-.055
.662
65
.219
.095
59
.026
.840
64
Q34 Pearson Correlation
Sig. (2-tailed)
N
-.079
.628
40
-.209
.197
40
-.046
.789
37
.010
.952
40
.038
36
-.209
.202
39
Q35 Pearson Correlation
Sig. (2-tailed)
N
.189
.271
36
-.135
.439
35
.184
.306
33
.132
.449
35
.226
.198
34
-.152
.392
34
Q36 Pearson Correlation
Sig. (2-tailed)
N
.167
.263
47
.088
.560
46
.108
.491
43
.114
.461
44
.005
.973
43
.053
.729
45
Q37 Pearson Correlation
Sig. (2-tailed)
N
-.019
.908
38
.094
.574
38
-.042
.807
37
.071
.674
38
-.196
.253
36
.063
.723
34
Q38 Pearson Correlation
Sig. (2-tailed)
N
.016
.906
60
-.097
.459
60
.152
.258
57
.030
59
.210
.132
53
-.092
.506
55
Q39 Pearson Correlation
Sig. (2-tailed)
N
.117
.336
69
.108
.382
67
.147
.293
53
-.125
.320
65
-.004
.980
50
-.114
.422
52
Q40 Pearson Correlation
Sig. (2-tailed)
N
.111
.583
27
.050
.805
27
.142
.509
24
-.110
.584
27
.171
.415
25
-.214
.294
26
Q41 Pearson Correlation
Sig. (2-tailed)
N
.145
.412
34
.036
34
.072
.693
32
.033
32
.128
.484
32
.031
.862
33
Q42 Pearson Correlation
Sig. (2-tailed)
N
.251
.123
39
-.142
.387
39
.175
.300
37
-.308
.060
38
.019
36
-.099
.567
36
Q43 Pearson Correlation
Sig. (2-tailed)
N
-.082
.656
32
.009
32
-.261
.172
29
-.011
.952
32
.002
.991
29
.196
.319
28
Q44 Pearson Correlation
Sig. (2-tailed)
N
-.146
.451
29
-.069
.728
28
-.183
.381
25
-.108
.576
29
.066
.750
26
-.062
.770
25
Q45 Pearson Correlation
Sig. (2-tailed)
N
.112
.503
38
-.070
.674
38
-.065
.712
35
-.011
.948
38
-.153
.380
35
.020
.907
35
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Q15 Q16A Q16B Q16C Q17 Q18
Q1A Pearson Correlation
Sig. (2-tailed)
N
.176
.142
71
-.116
.367
63
-.184
.178
55
.128
.321
62
.194
.127
63
-.055
.676
59
Q4 Pearson Correlation
Sig. (2-tailed)
N
-.070
.597
59
-.176
.216
51
-.242
.106
46
.044
.752
54
.159
.275
49
.021
51
Q5 Pearson Correlation
Sig. (2-tailed)
N
-.137
.277
65
-.025
.851
59
.074
.602
52
.086
.521
58
.198
.135
58
.039
.780
55
Q6 Pearson Con-elation
Sig. (2-tailed)
N
.077
.553
62
-.004
.976
53
-.204
.164
48
-.233
.081
57
.070
.625
51
.138
.321
54
Q7 Pearson Correlation
Sig. (2-tailed)
N
.089
.469
69
.072
.574
63
.134
.335
54
.018
61
.229
.078
60
-.138
.302
58
Q8 Pearson Correlation
Sig. (2-tailed)
N
-.104
.400
68
-.159
.217
62
.157
.261
53
.000
61
.000
58
-.073
.586
58
Q9 Pearson Correlation
Sig. (2-tailed)
N
.106
.363
75
.024
.847
67
-.093
.493
57
-.152
.230
64
-.093
.453
67
.200
.122
61
Q10 Pearson Correlation
Sig. (2-tailed)
N
.001
.995
73
.007
.956
63
-.017
.901
55
-.100
.437
63
-.113
.376
63
.070
.590
61
Q11 Pearson Correlation
Sig. (2-tailed)
N
-.143
.259
64
-.112
.415
55
-.261
.067
50
-.237
.074
58
.002
.989
52
.233
.084
56
Q12 Pearson Correlation
Sig. (2-tailed)
N
.062
.613
70
.009
.941
63
-.041
.769
54
-.031
.814
60
-.016
.903
63
-.061
.652
58
Q13 Pearson Correlation
Sig. (2-tailed)
N
.121
.355
60
-.200
.151
53
.126
.398
47
.177
.199
54
.199
.162
51
-.232
.098
52
Q14 Pearson Correlation
Sig. (2-tailed)
N
-.074
.560
64
.225
.092
57
.053
.707
52
-.121
.366
58
-.122
.383
53
.005
55
Q15 Pearson Correlation
Sig. (2-tailed)
N
1.000
75
.009
.944
61
-.013
.928
54
-.022
.865
63
-.100
.455
58
-.139
.291
60
Q16A Pearson Correlation
Sig. (2-tailed)
N
.009
.944
61
1.000
67
.037
55
.011
.935
55
.014
58
.073
.599
54
Q16B Pearson Correlation
Sig. (2-tailed)
N
-.013
.928
54
.037
55
1.000
57
.256
.066
52
.078
.586
51
-.060
.671
52
Page 7
Correlations
Q15 Q16A Q16B Q16C Q17 Q18
Q16C Pearson Correlation -.022 .011 .256 1.000
Sig. (2-tailed) .865 .935 .066 .001 .020
N 63 55 52 64 54 58
Q17 Pearson Correlation -.100 .078 1.000 -.122
Sig. (2-tailed) .455 .014 .586 .001 . .376
N 58 58 51 54J 67 55
Q18 Pearson Correlation -.139 .073 -.060 -.122 1.000
Sig. (2-tailed) .291 .599 .671 .020 .376 .
N 60 54 52 58 55 61
Q19 Pearson Correlation -.002 -.057 -.184 .272
Sig. (2-tailed) .986 .004 .717 .002 .206 .062
N 56 48 43 49 49 48
Q20 Pearson Correlation .173 .518*1 -.053 -.036 .013 .204
Sig. (2-tailed) .344 .006 .820 .849 .950 .317
N 32 27 21 30 25 26
Q21 Pearson Correlation .046 .058 -.179 .230
Sig. (2-tailed) .799 .040 .793 .345 .239 .016
N 33 29 23 30 28 27
Q22 Pearson Correlation .169 -.007 -.223 .105
Sig. (2-tailed) .184 .013 .962 .096 .016 .447
N 63 53 47 57 52 55
Q23 Pearson Correlation -.242 .008
Sig. (2-tailed) .052 .043 .037 .000 .002 .951
N 65 57 52 60 56 58
Q24 Pearson Correlation .212 -.106 .024 .134 .015 -.251
Sig. (2-tailed) .111 .462 .876 .339 .918 .072
N 58 50 44 53 50 52
Q25 Pearson Correlation .062 .066 .000 .084 .004 -.169
Sig. (2-tailed) .647 .635 .999 .553 .978 .235
N 57 54 49 L 52 49 51
Q26 Pearson Correlation -.086 -.166 -.057 .116 .184
Sig. (2-tailed) .576 .313 .754 .481 .000 .268
N 45 39 33 39 38 38
Q27 Pearson Correlation .066 -.256 .041 .125 .168 -.255
Sig. (2-tailed) .699 .151 .822 .482 .359 .139
N 37 33 32 L_ 34 32 35
Q28 Pearson Correlation -.055 .109 .168 .205 -.107
Sig. (2-tailed) .644 .388 .216 .007 .102 .414
N 72 65 56 63 65 60
Q29 Pearson Correlation .069 -.009 .028 .047 .230 .164
Sig. (2-tailed) .570 .944 .842 .714 .082 .216
N 70 61 54 62 58 59
Q30 Pearson Correlation .139 -.217 -.228 -.035
Sig. (2-tailed) .043 .286 .115 .020 .077 .790
N 70 61 54 62 61 60
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Correlations
Q15 Q16A Q16B Q16C Q17 Q18
Q31 Pearson Correlation
Sig. (2-tailed)
N
-.109
.371
69
-.038
.768
63
.032
.820
54
.104
.425
61
-.084
.523
60
-.040
.762
59
Q32 Pearson Correlation
Sig. (2-tailed)
N
.042
66
-.048
.709
62
.196
.157
54
.183
.166
59
-.014
.917
57
-.197
.143
57
Q33 Pearson Correlation
Sig. (2-tailed)
N
-.241
.051
66
-.163
.216
59
.098
.486
53
.142
.280
60
.177
.200
54
-.118
.383
57
Q34 Pearson Correlation
Sig. (2-tailed)
N
-.301
.063
39
-.239
.154
37
.056
.762
32
.211
.216
36
.244
.157
35
.036
.837
35
Q35 Pearson Correlation
Sig. (2-tailed)
N
.030
34
.040
33
-.168
.376
30
-.129
.490
31
.164
.362
33
.044
.814
31
Q36 Pearson Correlation
Sig. (2-tailed)
N
.032
46
-.088
.561
46
-.184
.226
45
.058
.705
45
.236
.118
45
.170
.259
46
Q37 Pearson Correlation
Sig. (2-tailed)
N
.212
.209
37
.027
.889
29
.044
.839
24
.282
.106
34
.108
.578
29
.011
.953
31
Q38 Pearson Correlation
Sig. (2-tailed)
N
.104
.435
59
.069
.633
51
.186
.215
46
.177
.201
54
.265
.066
49
.228
.104
52
Q39 Pearson Correlation
Sig. (2-tailed)
N
-.256
.055
57
.099
.492
50
-.073
.657
39
-.048
.745
49
.032
.828
49
.135
.365
47
Q40 Pearson Correlation
Sig. (2-tailed)
N
.043
.837
25
-.253
.244
23
.015
.950
20
.005
.982
23
.024
.917
22
-.063
.780
22
Q41 Pearson Correlation
Sig. (2-tailed)
N
-.006
.974
33
.048
.808
28
-.008
.971
25
-.145
.444
30
-.007
.971
26
.110
.583
27
Q42 Pearson Correlation
Sig. (2-tailed)
N
.169
.310
38
.026
.890
31
.085
.672
27
.000
1.000
34
-.014
.940
31
.160
.382
32
Q43 Pearson Correlation
Sig. (2-tailed)
N
.014
.942
30
.225
.290
24
.010
.969
19
.343
.086
26
-.096
.670
22
.338
.115
23
Q44 Pearson Correlation
Sig. (2-tailed)
N
-.261
.197
26
-.171
.436
23
-.214
.409
17
.226
.299
23
.117
.614
21
.176
.457
20
Q45 Pearson Correlation
Sig. (2-tailed)
N
-.206
.228
36
-.196
.300
30
.023
25
.266
.129
34
.105
.582
30
.305
.096
31
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Correlations
Q19 Q20 Q21 Q22 Q23 Q24
Q1A Pearson Correlation -.023 .315 .166 -.056
Sig. (2-tailed) .863 .069 .047 .197 .660 .000
N 60 34 38 62 65 57
Q4 Pearson Correlation -.054 .286 .125 -.106 .141 .185
Sig. (2-tailed) .715 .119 .489 .433 .300 .194
N 48 31 33 57 56 51
Q5 Pearson Correlation
.095 .297 .082 .155
Sig. (2-tailed) .469 .025 .078 .543 .034 .263
N 60 34 36 57 63 54
Q6 Pearson Correlation
.188 .300 .114 .017 .033
Sig. (2-tailed) .190 .095 .050 .395 .898 .812
N 50 32 33 58 59 53
Q7 Pearson Correlation -.039 -.108 -.167 -.101 .190 -.018
Sig. (2-tailed) .765 .551 .338 .442 .129 .894
N 60 33 35 60 65 56
Q8 Pearson Correlation -.237 -.122 -.221 .170
Sig. (2-tailed) .081 .498 .202 .004 .000 .210
N 55 33 35 62 63 56
Q9 Pearson Correlation .177 .057 .157 -.029
Sig. (2-tailed) .162 .049 .027 .659 .201 .827
N 64 34 38 63 68 59
Q10 Pearson Correlation .082 .065 -.038 -.033 .088 .168
Sig. (2-tailed) .527 .719 .824 .799 .479 .203
N 62 33 37 62 67 59
Q11 Pearson Correlation .095 .078 .066 -.096 .101 -.012
Sig. (2-tailed) .499 .666 .717 .476 .433 .929
N 53 33 33 57 62 54
Q12 Pearson Correlation .083 -.024 .222 -.006 .010 -.016
Sig. (2-tailed) .527 .895 .187 .966 .937 .906
N 61 34 37 59 66 57
Q13 Pearson Correlation .037 -.298 .209 -.232 .087
Sig. (2-tailed) .801 .098 .243 .082 .020 .544
N 49 32 33 57 58 51
Q14 Pearson Correlation .088 .251 -.089 -.074
Sig. (2-tailed) .531 .048 .166 .033 .494 .600
N 53 32 32 58 61 53
Q15 Pearson Correlation -.002 .173 .046 .169 -.242 .212
Sig. (2-tailed) .986 .344 .799 .184 .052 .111
N 56 32 33 63 65 58
Q16A Pearson Correlation -.106
Sig. (2-tailed) .004 .006 .040 .013 .043 .462
N 48 27 29 53 57 50
Q16B Pearson Correlation -.057 -.053 .058 -.007 .024
Sig. (2-tailed) .717 .820 .793 .962 .037 .876
N 43 21 23 47 52 44
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Correlations
Q19 Q20 Q21 Q22 Q23 Q24
Q16C Pearson Correlation -.036 -.179 -.223 .134
Sig. (2-tailed) .002 .849 .345 .096 .000 .339
N 49 30 30 57 60 53
Q17 Pearson Correlation -.184 .013 .230 .015
Sig. (2-tailed) .206 .950 .239 .016 .002 .918
N 49 25 28 52 56 50
Q18 Pearson Correlation .272 .204 .105 .008 -.251
Sig. (2-tailed) .062 .317 .016 .447 .951 .072
N 48 26 27 55 58 52
Q19 Pearson Correlation 1.000 .595*1 .155 -.205 -.060
Sig. (2-tailed) . .009 .000 292 .144 .682
N 64 33 34 48 52 49
Q20 Pearson Correlation .449*1 1.000 .209 -.032 .159
Sig. (2-tailed) .009 .000 .260 .861 .392
N 33 34 31 31 32 31
Q21 Pearson Correlation 1.000 .158 -.064 .141
Sig. (2-tailed) .000 .000 .389 .722 .434
N 34 31 38 32 33 33
Q22 Pearson Correlation .155 .209 .158 1.000 .129
Sig. (2-tailed) .292 .260 .389 . .003 .358
N 48 31 32 63 58 53
Q23 Pearson Correlation -.205 -.032 -.064 1.000 .020
Sig. (2-tailed) .144 .861 .722 .003 .879
N 52 32 33 58 68 58
Q24 Pearson Correlation -.060 .159 .141 .129 .020 1.000
Sig. (2-tailed) .682 .392 .434 .358 .879
N 49 31 33 53 58 59
Q25 Pearson Correlation .060 .012 -.002 .017 -.021 .154
Sig. (2-tailed) .697 .950 .991 .905 .878 .297
N 44 29 29 52 56 48
Q26 Pearson Correlation .130 .376 -.226 .291 .213
Sig. (2-tailed) .437 .064 .041 .166 .052 .192
N 38 25 27 39 45 39
Q27 Pearson Correlation -.247 -.318 -.170 -.209 .131 .258
Sig. (2-tailed) .181 .172 .450 .243 .446 .141
N 31 20 22 33 36 34
Q28 Pearson Correlation -.041 .119 .305 -.159 .242
Sig. (2-tailed) .760 .509 .067 .217 .016 .067
N 58 33 37 62 67 58
Q29 Pearson Correlation .076 .150 -.127 -.015 .180
Sig. (2-tailed) .573 .404 .045 .329 .907 .178
N 57 33 35 61 65 58
Q30 Pearson Correlation .092 .116 .181 .033
Sig. (2-tailed) .499 .010 .495 .164 .009 .807
N 56 33 37 61 65 57
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Correlations
Q19 Q20
_j
Q21 Q22 Q23 Q24
Q31 Pearson Correlation -.276 -.196 .102
Sig. (2-tailed) .002 .126 .001 .130 .034 .459
N 55 32 35 61 64 55
Q32 Pearson Correlation -.158 -.099 -.252 -.248 .060
Sig. (2-talled) .259 .594 .164 .059 .028 .671
N 53 31 32 59 62 53
Q33 Pearson Correlation -.060 -.300 -.018 .134
Sig. (2-tailed) .670 .101 .922 .015 .297 .002
N 53 31 32 60 62 54
Q34 Pearson Correlation .016 -.049 -.023 -.024 242 -.025
Sig. (2-tailed) .929 .830 .914 .886 .143 .886
N 32 22 24 37 38 35
Q35 Pearson Correlation -.331 .323 .026 -.121 .045 .326
Sig. (2-tailed) .079 .178 .902 .494 .800 .074
N 29 19 22 34 34 31
Q36 Pearson Correlation -.176 .221 .239 .070 -.008 .136
Sig. (2-tailed) .304 .378 .324 .657 .959 .411
N 36 18 19 43 43 39
Q37 Pearson Correlation .142 .032 -.234 .120 .080
Sig. (2-tailed) .027 .453 .867 .175 .480 .644
N 35 30 30 35 37 36
Q38 Pearson Correlation -.005 -.206 .149 -.022
Sig. (2-tailed) .976 .012 .014 .132 .269 .875
N 47 31 31 55 57 51
Q39 Pearson Correlation -.143 .071 -.066
Sig. (2-tailed) .035 .040 .008 .323 .610 .654
N 50 32 35 50 54 48
Q40 Pearson Correlation -.044 -.400 .080 .249 .110
Sig. (2-tailed) .834 .014 .053 .702 .231 .600
N 25 22 24 25 25 25
Q41 Pearson Correlation .231 .384 .134 -.125 .194
Sig. (2-tailed) .211 .039 .071 .473 .488 .297
N 31 22 23 31 33 31
Q42 Pearson Correlation .166 .189 .344 .181 .136 -.054
Sig. (2-taHed) .341 .387 .085 .298 .416 .756
N 35 23 26 35 38 36
Q43 Pearson Correlation -.241 .319 .120 .295 .023 .121
Sig. (2-tailed) .208 .120 .559 .120 .905 .541
N 29 25 26 29 29 28
Q44 Pearson Correlation -.049 .297 .238 .018 .249 .078
Sig. (2-tailed) .813 .158 .242 .932 .231 .711
N 26 24 26 26 25 25
Q45 Pearson Correlation .038 -.115 .237 -.116
Sig. (2-tailed) .038 .029 .844 .515 .158 .500
N 36 28 29 34 37 36
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Correlations
Q25 Q26 Q27 Q28 Q29 Q30
Q1A Pearson Correlation -.025 .221 -.092 .171 .220 -.049
Sig. (2-tailed) .851 .145 .601 .130 .065 .681
N 57 45 35 80 71 74
Q4 Pearson Correlation -.178 .299 .138 .041 279* -.144
Sig. (2-tailed) .206 .069 .445 .756 .031 275
N 52 38 33 59 60 59
Q5 Pearson Correlation
.121 .179 -.221 .115 -.221 -.196
Sig. (2-tailed) .385 .256 .208 .335 .074 .111
N 54 42 34 72 66 67
Q6 Pearson Correlation -211 .245 .181 291* 245 .112
Sig. (2-tailed) .123 .117 .299 .022 .053 .385
N 55 42 35 62 63 62
Q7 Pearson Correlation -.036 .160 .162 .023 -.085 -.178
Sig. (2-tailed) .794 .288 .345 .847 .482 .137
N 56 46 36 74 70 71
Q8 Pearson Correlation
.095 .004 -.106 203 -.058
Sig. (2-tailed) .476 .979 .545 .089 .635 .000
N 58 44 35 71 69 68
Q9 Pearson Correlation -.190 .123 .137
Sig. (2-tailed) .153 .035 .469 .000 .000 233
N 58 48 37 85 74 77
Q10 Pearson Correlation -.258 .170 -.066 .116 216
Sig. (2-tailed) .053 .254 .699 .304 .000 .063
N 57 47 37 81 72 75
Q11 Pearson Correlation -.237 .267 .177 .009 282* -.048
Sig. (2-tailed) .082 .087 .308 .945 .023 .709
N 55 42 35 64 65 63
Q12 Pearson Correlation -.040 .151 -.002 .116 .054 .158
Sig. (2-tailed) .772 .304 .991 .311 .652 .184
N 56 48 37 78 71 72
Q13 Pearson Correlation .170 .066
.464"]
.168 -.005 -251
Sig. (2-tailed) .220 .682 .006 .199 .967 .055
N 54 41 33 60 61 59
Q14 Pearson Correlation -.161 .148 -.328 -.149 258* .048
Sig. (2-tailed) .236 .362 .058 .240 .040 .710
N 56 40 34 64 64 63
Q15 Pearson Correlation .062 -.086 .066 -.055 .069 242*
Sig. (2-tailed) .647 .576 .699 .644 .570 .043
N 57 45 37 72 70 70
Q16A Pearson Correlation .066 -.166 -256 .109 -.009 .139
Sig. (2-tailed) .635 .313 .151 .388 .944 286
N 54 39 33 65 61 61
Q16B Pearson Correlation .000 -.057 .041 .168 .028 -.217
Sig. (2-tailed) .999 .754 .822 216 .842 .115
N 49 33 32 56 54 54
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Correlations
Q25 Q26 Q27 Q28 Q29 Q30
Q16C Pearson Correlation
Sig. (2-tailed)
N
.084
.553
52
.116
.481
39
.125
.482
34
.007
63
.047
.714
62
.020
62
Q17 Pearson Correlation
Sig. (2-tailed)
N
.004
.978
49
.000
38
.168
.359
32
.205
.102
65
230
.082
58
-.228
.077
61
Q18 Pearson Correlation
Sig. (2-tailed)
N
-.169
235
51
.184
.268
38
-255
.139
35
-.107
.414
60
.164
216
59
-.035
.790
60
Q19 Pearson Correlation
Sig. (2-tailed)
N
.060
.697
44
.130
.437
38
-247
.181
31
-.041
.760
58
.076
.573
57
.092
.499
56
Q20 Pearson Correlation
Sig. (2-tailed)
N
.012
.950
29
.376
.064
25
-.318
.172
20
.119
.509
33
.150
.404
33
.010
33
Q21 Pearson Correlation
Sig. (2-tailed)
N
-.002
.991
29
.041
27
-.170
.450
22
.305
.067
37
.045
35
.116
.495
37
Q22 Pearson Correlation
Sig. (2-tailed)
N
.017
.905
52
-.226
.166
39
-209
243
33
-.159
217
62
-.127
.329
61
.181
.164
61
Q23 Pearson Correlation
Sig. (2-tailed)
N
-.021
.878
56
291
.052
45
.131
.446
36
294*
.016
67
-.015
.907
65
.009
65
Q24 Pearson Correlation
Sig. (2-tailed)
N
.154
297
48
.213
.192
39
.258
.141
34
242
.067
58
.180
.178
58
.033
.807
57
(325 Pearson Correlation
Sig. (2-tailed)
N
1.000
58
-.041
.805
39
.017
.921
35
.024
.857
57
-.077
.564
58
-.004
.978
58
Q26 Pearson Correlation
Sig. (2-tailed)
N
-.041
.805
39
1.000
48
295
.107
31
.185
213
47
.002
46
-.036
.812
47
Q27 Pearson Correlation
Sig. (2-tailed)
N
.017
.921
35
.295
.107
31
1.000
37
.157
.360
36
.102
.549
37
-.083
.623
37
Q28 Pearson Correlation
Sig. (2-tailed)
N
.024
.857
57
.185
213
47
.157
.360
36
1.000
85
.000
71
-.060
.608
75
Q29 Pearson Correlation
Sig. (2-tailed)
N
-.077
.564
58
.002
46
.102
.549
37
.000
71
1.000
74
207
.086
70
Q30 Pearson Correlation
Sig. (2-tailed)
N
-.004
.978
58
-.036
.812
47
-.083
.623
37
-.060
.608
75
.207
.086
70
1.000
77 |
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Correlations
Q25 Q26 Q27 Q28 Q29 Q30
Q31 Pearson Correlation -.142 -.100 .175 -.056 .049
Sig. (2-tailed) 291 .513 .017 .136 .652 .682
N 57 45 36 74 68 72
Q32 Pearson Correlation .193 -.151 .175 -.010 .046
Sig. (2-talled) .150 .333 .307 .932 .036 .712
N 57 43 36 69 66 66
Q33 Pearson Correlation -.053 257 .320 265* .157
Sig. (2-talled) .696 .096 .057 .031 203 .000
N 57 43 36 66 67 65
Q34 Pearson Correlation
.154 -.193 -.144 -.195 -286 -269
Sig. (2-tailed) .365 .345 .502 .229 .077 .102
N 34 26 24 40 39 38
Q35 Pearson Correlation
.045 .191 -.091 .073 245
Sig. (2-tailed) .808 .382 .010 .598 .681 .169
N 31 23 23 36 34 33
Q36 Pearson Correlation -212 -.037 .190 -.073
Sig. (2-tailed) .173 .004 .855 .016 207 .628
N 43 29 27 46 46 46
Q37 Pearson Correlation
.052 -.038 230 .219 .036
Sig. (2-tailed) .042 .781 .859 .165 .187 .834
N 31 31 24 38 38 37
Q38 Pearson Correlation .049 .073 .038 .114 .051
Sig. (2-tailed) .738 .656 .830 .386 .699 .025
N 50 40 35 60 60 58
Q39 Pearson Correlation -.112 .147 -.318 295* -.165
Sig. (2-tailed) .470 .377 .087 .018 .030 .211
N 44 38 30 64 56 59
Q40 Pearson Correlation -.164 .000 -.014 -.313
Sig. (2-talled) .465 1.000 .001 .944 .024 .120
N 22 20 19 27 26 26
Q41 Pearson Correlation .060 -.149 -217 -.054 -.185 -.319
Sig. (2-tailed) .753 .449 288 .764 .304 .075
N 30 28 26 34 33 32
Q42 Pearson Correlation .018 -.141 -.108 -.129 -.195 -.174
Sig. (2-tailed) .924 .457 .586 .435 241 295
N 32 30 28 39 38 38
Q43 Pearson Correlation .155 -.067 .039 -.318 -214 .158
Sig. (2-tailed) .468 .754 .875 .076 257 .403
N 24 24 19 32 30 30
Q44 Pearson Correlation .112 .122 -.401 -.080 .034 .005
Sig. (2-tailed) .620 .597 .099 .687 .869 .978
N 22 21 18 28 26 27
Q45 Pearson Correlation -.134 240 -.141 -.078 .135 206
Sig. (2-tailed) .471 209 .513 .641 .425 .221
N 31 29 24 38 37 37
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Correlations
Q31 Q32 Q33 Q34 Q35 Q36
Q1A Pearson Correlation .023 .068 .134 -.095
Sig. (2-tailed) .846 .028 .585 .422 .587 .007
N 72 66 66 38 35 45
Q4 Pearson Correlation .122 .021 272* .112 .303 .150
Sig. (2-tailed) .359 .876 .039 .520 .092 .349
N 59 58 58 35 32 41
Q5 Pearson Correlation -.071 .140 -.092 .196 .091
Sig. (2-tailed) .570 .264 .471 .026 273 .567
N 67 65 63 37 33 42
06 Pearson Correlation -.008 -.186 -.045 -279 290
Sig. (2-tailed) .953 .158 .733 .105 .107 .008
N 60 59 60 35 32 44
Q7 Pearson Correlation 205 .054 .115 .174 .169 -.074
Sig. (2-tailed) .087 .664 .359 291 .324 .630
N 71 68 66 39 36 45
Q8 Pearson Correlation .175 273* -.050 .046
Sig. (2-tailed) .154 .027 .003 .029 .780 .759
N 68 66 66 38 34 46
Q9 Pearson Correlation .050 -.192 -.041 -.079 .189 .167
Sig. (2-tailed) .664 .110 .738 .628 271 .263
N 77 71 68 40 36 47
Q10 Pearson Correlation .146 -.019 229 -.209 -.135 .088
Sig. (2-tailed) 219 .876 .065 .197 .439 .560
N 73 68 66 40 35 46
Q11 Pearson Correlation -.017 -.046 .184 .108
Sig. (2-tailed) .012 .897 .003 .789 .306 .491
N 62 61 62 37 33 43
Q12 Pearson Correlation -.176 -.158 -.055 .010 .132 .114
Sig. (2-tailed) .143 204 .662 .952 .449 .461
N 71 66 65 40 35 44
Q13 Pearson Correlation -.080 .039 .219 .226 .005
Sig. (2-tailed) .547 .773 .095 .038 .198 .973
N 59 58 59 36 34 43
Q14 Pearson Correlation -.040 .026 -209 -.152 .053
Sig. (2-tailed) .757 .035 .840 202 .392 .729
N 63 62 64 39 34 45
Q15 Pearson Correlation -.109 -241 -.301
Sig. (2-tailed) .371 .042 .051 .063 .030 .032
N 69 66 66 39 34 46
Q16A Pearson Correlation -.038 -.048 -.163 -239 -.088
Sig. (2-tailed) .768 .709 216 .154 .040 .561
N 63 62 59 37 33 46
Q16B Pearson Correlation .032 .196 .098 .056 -.168 -.184
Sig. (2-tailed) .820 .157 .486 .762 .376 .226
N 54 54 53 32 30 45
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Correlations
Q31 Q32 Q33 Q34 Q35 Q36
Q16C Pearson Correlation .104 .183 .142 .211 -.129 .058
Sig. (2-tailed) .425 .166 280 216 .490 .705
N 61 59 60 36 31 45
Q17 Pearson Correlation -.084 -.014 .177 244 .164 236
Sig. (2-tailed) .523 .917 200 .157 .362 .118
N 60 57 54 35 33 45
Q18 Pearson Correlation -.040 -.197 -.118 .036 .044 .170
Sig. (2-tailed) .762 .143 .383 .837 .814 259
N 59 57 57 35 31 46
Q19 Pearson Correlation -.158 -.060 .016 -.331 -.176
Sig. (2-tailed) .002 259 .670 .929 .079 .304
N 55 53 53 32 29 36
Q20 Pearson Correlation -276 -.099 -.300 -.049 .323 221
Sig. (2-tailed) .126 .594 .101 .830 .178 .378
N 32 31 31 22 19 18
Q21 Pearson Correlation -.546*1 -252 -.018 -.023 .028 239
Sig. (2-tailed) .001 .164 .922 .914 .902 .324
N 35 32 32 24 22 19
Q22 Pearson Correlation -.196 -248 -.024 -.121 .070
Sig. (2-tailed) .130 .059 .015 .886 .494 .657
N 61 59 60 37 34 43
Q23 Pearson Correlation 265* 279*
.134 242 .045 -.008
Sig. (2-tailed) .034 .028 297 .143 .800 .959
N 64 62 62 38 34 43
Q24 Pearson Correlation .102 .060 -.025 .326 .136
Sig. (2-tailed) .459 .671 .002 .886 .074 .411
N 55 53 54 35 31 39
Q25 Pearson Correlation -.142 .193 -.053 .154 .045 -212
Sig. (2-tailed) 291 .150 .696 .385 .808 .173
N 57 57 57 34 31 43
026 Pearson Correlation -.100 -.151 257 -.193 .191
Sig. (2-tailed) .513 .333 .096 .345 .382 .004
N 45 43 43 26 23 29
Q27 Pearson Correlation .175 .320 -.144 -.037
Sig. (2-tailed) .017 .307 .057 .502 .010 .855
N 36 36 36 24 23 27
Q28 Pearson Correlation .175 -.010 265* -.195 -.091
Sig. (2-tailed) .136 .932 .031 .229 .598 .016
N 74 69 66 40 36 46
Q29 Pearson Correlation -.056 .157 -286 .073 .190
Sig. (2-tailed) .652 .036 203 .077 .681 207
N 68 66 67 39 34 46
Q30 Pearson Correlation .049 .046 -269 245 -.073
Sig. (2-tailed) .682 .712 .000 .102 .169 .628
N 72 66 65 38 33 46
Page 17
Correlations
Q31 Q32 Q33 Q34 Q35 Q36
Q31 Pearson Correlation 1.000 .141 -.194 .227 -.032
Sig. (2-tailed) .001 259 242 204 .832
N 77 71 66 38 33 46
Q32 Pearson Correlation 1.000 .070 -.027 .096
Sig. (2-tailed) .001 . .577 .874 .595 .000
N 71 71 65 38 33 46
Q33 Pearson Correlation .141 .070 1.000 -.026 .104 .050
Sig. (2-tailed) 259 .577 .875 .564 .741
N 66 65 68 39 33 47
Q34 Pearson Correlation -.194 -.027 -.026 1.000 .185 -.168
Sig. (2-tailed) .242 .874 .875 . .338 .374
N 38 38 39 40 29 30
Q35 Pearson Correlation .227 .096 .104 .185 1.000 -.109
Sig. (2-tailed) 204 .595 .564 .338 .603
N 33 33 33 29 36 25
Q36 Pearson Correlation -.032 -.506*1 .050 -.168 -.109 1.000
Sig. (2-tailed) .832 .000 .741 .374 .603
N 46 46 47 30 25 47
Q37 Pearson Correlation .100 -.022 .100 -.114 -.127
Sig. (2-tailed) .569 .902 .568 .597 .583 .037
N 35 34 35 24 21 20
Q38 Pearson Correlation -.014 .095 .163 279 .014
Sig. (2-tailed) .918 .482 226 .042 .115 .933
N 57 57 57 36 33 40
Q39 Pearson Correlation -.131 .136 .090 .129 -.151 .080
Sig. (2-tailed) .326 .327 .526 .460 .410 .655
N 58 54 52 35 32 34
Q40 Pearson Correlation .190 -.040 287 -.077 .323 .191
Sig. (2-tailed) .354 .850 .155 .749 .165 .463
N 26 25 26 20 20 17
Q41 Pearson Correlation -.314 -.140 .153 .129 -.118
Sig. (2-tailed) .076 .435 .403 .000 .566 .602
N 33 33 32 25 22 22
Q42 Pearson Correlation .093 203 -.107 246 .131 -281
Sig. (2-taited) .591 241 .539 215 .541 .183
N 36 35 35 27 24 24
Q43 Pearson Correlation -.080 .091 -.132 -.352
Sig. (2-tailed) .690 .660 .511 .005 .008 .181
N 27 26 27 22 20 16
Q44 Pearson Correlation -.561**] -.086 -.072 .006 .041
Sig. (2-tailed) .004 .688 .739 .000 .980 .884
N 25 24 24 21 22 15
Q45 Pearson Correlation -.140 .190 -.122 298 -.012
Sig. (2-tailed) .430 289 .491 .005 .157 .957
N 34 33 34 26 24 22
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Correlations
Q37 Q38 Q39 Q40 Q41 Q42
Q1A Pearson Correlation .324 -.133 .062 -.325 .220 -.039
Sig. (2-tailed) .050 .319 .631 .098 .226 .820
N 37 58 62 27 32 37
Q4 Pearson Correlation .000 223 .141 -.247 .349 239
Sig. (2-tailed) 1.000 .108 .338 234 .050 .161
N 36 53 48 25 32 36
Q5 Pearson Correlation -.125 241 -.121
Sig. (2-tailed) .454 .002 .071 .563 .005 .000
N 38 56 57 25 33 38
Q6 Pearson Correlation -.085 -.053 .124 .221 -.312 .026
Sig. (2-tailed) .612 .698 .405 289 .082 .877
N 38 55 47 25 32 37
Q7 Pearson Correlation .067 294* .060 .320 -.017 .154
Sig. (2-tailed) .698 .024 .644 .103 .926 .350
N 36 59 61 27 34 39
Q8 Pearson Correlation 259 256 .117 .009 .228 .222
Sig. (2-tailed) .121 .052 .392 .966 210 .194
N 37 58 56 27 32 36
Q9 Pearson Correlation -.019 .016 .117 .111 .145 251
Sig. (2-tailed) .908 .906 .336 .583 .412 .123
N 38 60 69 27 34 39
Q10 Pearson Correlation .094 -.097 .108 .050 -.142
Sig. (2-tailed) .574 .459 .382 .805 .036 .387
N 38 60 67 27 34 39
Q11 Pearson Correlation -.042 .152 .147 .142 .072 .175
Sig. (2-tailed) .807 258 293 .509 .693 .300
N 37 57 53 24 32 37
Q12 Pearson Correlation .071 -.125 -.110 -.308
Sig. (2-tailed) .674 .030 .320 .584 .033 .060
N 38 59 65 27 32 38
Q13 Pearson Correlation -.196 210 -.004 .171 .128
Sig. (2-tailed) 253 .132 .980 .415 .484 .019
N 36 53 50 25 32 36
Q14 Pearson Correlation .063 -.092 -.114 -.214 .031 -.099
Sig. (2-tailed) .723 .506 .422 294 .862 .567
N 34 55 52 26 33 36
Q15 Pearson Correlation 212 .104 -256 .043 -.006 .169
Sig. (2-tailed) 209 .435 .055 .837 .974 .310
N 37 59 57 25 33 38
Q16A Pearson Correlation .027 .069 .099 -253 .048 .026
Sig. (2-tailed) .889 .633 .492 244 .808 .890
N 29 51 50 23 28 31
Q16B Pearson Correlation .044 .186 -.073 .015 -.008 .085
Sig. (2-tailed) .839 215 .657 .950 .971 .672
N 24 46 39 20 25 27
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Correlations
Q37 Q38 Q39 Q40 Q41 Q42
Q16C Pearson Correlation 282 .177 -.048 .005 -.145 .000
Sig. (2-tailed) .106 201 .745 .982 .444 1.000
N 34 54 49 23 30 34
Q17 Pearson Con-elation .108 265 .032 .024 -.007 -.014
Sig. (2-tailed) .578 .066 .828 .917 .971 .940
N 29 49 49 22 26 31
Q18 Pearson Correlation .011 .228 .135 -.063 .110 .160
Sig. (2-tailed) .953 .104 .365 .780 .583 .382
N 31 52 47 22 27 32
Q19 Pearson Correlation -.005 299* -.044 231 .166
Sig. (2-tailed) .027 .976 .035 .834 211 .341
N L_ 35 47 50 25 31 35
Q20 Pearson Correlation .142 .189
Sig. (2-tailed) .453 .012 .040 .014 .039 .387
N 30 31 32 22 22 23
021 Pearson Correlation .032 -.400 .384 .344
Sig. (2-tailed) .867 .014 .008 .053 .071 .085
N 30 31 35 24 23 26
Q22 Pearson Correlation -234 -.206 -.143 .080 .134 .181
Sig. (2-tailed) .175 .132 .323 .702 .473 298
N 35 55 50 25 31 35
Q23 Pearson Correlation .120 .149 .071 249 -.125 .136
Sig. (2-tailed) .480 269 .610 231 .488 .416
N 37 57 54 25 33 38
Q24 Pearson Correlation .080 -.022 -.066 .110 .194 -.054
Sig. (2-tailed) .644 .875 .654 .600 .297 .756
N 36 51 48 L_ 25 31 36
Q25 Pearson Correlation .049 -.112 -.164 .060 .018
Sig. (2-tailed) .042 .738 .470 .465 .753 .924
N 31 50 44 22 30 32
Q26 Pearson Correlation .052 .073 .147 .000 -.149 -.141
Sig. (2-tailed) .781 .656 .377 1.000 .449 .457
N 31 40 38 20 28 l 30
027 Pearson Correlation -.038 .038 -.318 -217 -.108
Sig. (2-tailed) .859 .830 .087 .001 288 .586
N 24 35 30 19 26 28
Q28 Pearson Correlation .230 .114 295* -.014 -.054 -.129
Sig. (2-tailed) .165 .386 .018 .944 .764 .435
N 38 60 64 27 34 39
Q29 Pearson Correlation 219 .051 291* -.185 -.195
Sig. (2-tailed) .187 .699 .030 .024 .304 241
N 38 60 56 26 33 38
Q30 Pearson Correlation .036 -.165 -.313 -.319 -.174
Sig. (2-tailed) .834 .025 .211 .120 .075 295
N 37 58 59 26 32 38
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Correlations
Q37 Q38 Q39 Q40 Q41 Q42
Q31 Pearson Correlation .100 -.014 -.131 .190 -.314 .093
Sig. (2-tailed) .569 .918 .326 .354 .076 .591
N 35 57 58 26 33 36
Q32 Pearson Correlation -.022 .095 .136 -.040 -.140 203
Sig. (2-talled) .902 .482 .327 .850 .435 241
N 34 57 54 25 33 35
Q33 Pearson Correlation .100 .163 .090 287 .153 -.107
Sig. (2-tailed) .568 .226 .526 .155 .403 .539
N 35 57 52 26 32 35
Q34 Pearson Correlation -.114 .129 -.077 246
Sig. (2-tailed) .597 .042 .460 .749 .000 215
N 24 36 35 20 25 27
Q35 Pearson Correlation -.127 279 -.151 .323 .129 .131
Sig. (2-tailed) .583 .115 .410 .165 .566 .541
N 21 33 32 20 22 24
Q36 Pearson Correlation .014 .080 .191 -.118 -281
Sig. (2-tailed) .037 .933 .655 .463 .602 .183
N 20 40 34 17 22 24
Q37 Pearson Correlation 1.000 .030 .037 -.039 -206
Sig. (2-tailed) . .864 .836 .013 .855 292
N 38 36 33 20 25 28
Q38 Pearson Correlation .030 1.000 .010
Sig. (2-tailed) .864 .002 .961 .001 .001
N 36 60 50 26 33 37
Q39 Pearson Correlation .037 1.000 -.045 .351 .302
Sig. (2-tailed) .836 .002 . .825 .053 .078
N 33 50 69 27 31 35
Q40 Pearson Correlation .010 -.045 1.000 -211 -.100
Sig. (2-tailed) .013 .961 .825 .386 .684
N 20 26 27 27 19 19
Q41 Pearson Correlation -.039 .351 -.211 1.000
Sig. (2-tailed) .855 .001 .053 .386 . .003
N 25 33 31 19 34 33
Q42 Pearson Correlation -206 .302 -.100 1.000
Sig. (2-tailed) 292 .001 .078 .684 .003 .
N 28 37 35 19 33 39
Q43 Pearson Correlation .145 -.190 -.180 .303
Sig. (2-tailed) .479 .033 .325 .447 .031 .117
N 26 29 29 20 24 28
Q44 Pearson Correlation 249 .338 -.310 .025
Sig. (2-tailed) 251 .092 .013 .172 .003 .911
N 23 26 28 21 21 ,_ 23
Q45 Pearson Correlation .245 .136 -.391 276 .046
Sig. (2-tailed) .015 .151 .435 .059 .172 .807
N 30 36 35 24 26 31
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Correlations
Q43 Q44 Q45
Q1A Pearson Correlation .065 .325 .132
Sig. (2-tailed) .726 .086 .438
N 32 29 37
04 Pearson Correlation .333
Sig. (2-tailed) .046 .104 .006
N 28 25 34
05 Pearson Correlation 202 .170 .197
Sig. (2-tailed) 276 .388 242
N 31 28 37
06 Pearson Correlation -.311 -.335 -.070
Sig. (2-tailed) .094 .095 .684
N 30 26 36
07 Pearson Correlation .126 -.175 -207
Sig. (2-tailed) .498 .373 212
N 31 28 38
08 Pearson Correlation .107 257 212
Sig. (2-tailed) .580 204 215
N 29 26 36
Q9 Pearson Correlation -.082 -.146 .112
Sig. (2-tailed) .656 .451 .503
N 32 29 38
Q10 Pearson Correlation -.069 -.070
Sig. (2-tailed) .009 .728 .674
N 32 28 38
Q11 Pearson Correlation -.261 -.183 -.065
Sig. (2-tailed) .172 .381 .712
N 29 25 35
Q12 Pearson Correlation -.011 -.108 -.011
Sig. (2-tailed) .952 .576 .948
N 32 29 38
Q13 Pearson Correlation .002 .066 -.153
Sig. (2-tailed) .991 .750 .380
N 29 26 35
Q14 Pearson Correlation .196 -.062 .020
Sig. (2-tailed) .319 .770 .907
N 28 25 35
Q15 Pearson Correlation .014 -261 -206
Sig. (2-tailed) .942 .197 .228
N 30 26 36
Q16A Pearson Correlation .225 -.171 -.196
Sig. (2-tailed) .290 .436 .300
N 24 23 30
Q16B Pearson Correlation .010 -214
Sig. (2-tailed) .969 .409 .023
N 19 17 25
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Correlations
Q43 Q44 Q45
Q16C Pearson Correlation .343 .226 .266
Sig. (2-tailed) .086 299 .129
N 26 23 34
Q17 Pearson Correlation -.096 .117 .105
Sig. (2-tailed) .670 .614 .582
N 22 21 30
Q18 Pearson Correlation .338 .176 .305
Sig. (2-tailed) .115 .457 .096
N 23 20 31
Q19 Pearson Correlation -241 -.049
Sig. (2-tailed) .208 .813 .038
N 29 26 36
Q20 Pearson Correlation
.319 297
Sig. (2-tailed) .120 .158 .029
N 25 24 28
021 Pearson Correlation
.120 .238 .038
Sig. (2-tailed) .559 242 .844
N 26 26 29
022 Pearson Correlation 295 .018 -.115
Sig. (2-tailed) .120 .932 .515
N 29 26 34
Q23 Pearson Correlation
.023 .249 237
Sig. (2-tailed) .905 231 .158
N 29 25 37
Q24 Pearson Correlation .121 .078 -.116
Sig. (2-tailed) .541 .711 .500
N 28 25 36
025 Pearson Correlation .155 .112 -.134
Sig. (2-tailed) .468 .620 .471
N 24 22 31
Q26 Pearson Correlation -.067 .122 240
Sig. (2-tailed) .754 .597 209
N 24 21 29
027 Pearson Correlation .039 -.401 -.141
Sig. (2-tailed) .875 .099 .513
N 19 18 24
028 Pearson Correlation -.318 -.080 -.078
Sig. (2-tailed) .076 .687 .641
N 32 28 38
Q29 Pearson Correlation -214 .034 .135
Sig. (2-tailed) 257 .869 .425
N 30 26 37
Q30 Pearson Correlation .158 .005 206
Sig. (2-tailed) .403 .978 .221
N 30 27 37
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Correlations
Q43 Q44 Q45
Q31 Pearson Correlation -.080 -.140
Sig. (2-tailed) .690 .004 .430
N 27 25 34
Q32 Pearson Correlation .091 -.086 .190
Sig. (2-tailed) .660 .688 289
N 26 24 33
Q33 Pearson Correlation -.132 -.072 -.122
Sig. (2-tailed) .511 .739 .491
N 27 24 34
Q34 Pearson Correlation
Sig. (2-tailed) .005 .000 .005
N 22 21 26
Q35 Pearson Correlation .577*1 .006 298
Sig. (2-tailed) .008 .980 .157
N 20 22 24
Q36 Pearson Correlation -.352 .041 -.012
Sig. (2-tailed) .181 .884 .957
N 16 15 22
Q37 Pearson Correlation .145 249
Sig. (2-tailed) .479 251 .015
N 26 23 30
Q38 Pearson Correlation .338 245
Sig. (2-tailed) .033 .092 .151
N 29 26 36
Q39 Pearson Correlation -.190 .136
Sig. (2-tailed) .325 .013 .435
N 29 28 35
Q40 Pearson Correlation -.180 -.310 -.391
Sig. (2-tailed) .447 .172 .059
N 20 21 24
Q41 Pearson Correlation 276
Sig. (2-tailed) .031 .003 .172
N 24 21 26
Q42 Pearson Correlation .303 .025 .046
Sig. (2-tailed) .117 .911 .807
N 28 23 31
Q43 Pearson Correlation 1.000
Sig. (2-tailed) .007 .003
N 32 26 30
Q44 Pearson Correlation 1.000
Sig. (2-tailed) .007 .000
N 26 29 26
Q45 Pearson Correlation 1.000
Sig. (2-tailed) .003 .000 .
N 30 26 38
*. Correlation is significant at the 0.05 level (2-tailed).
". Correlation is significant at the 0.01 level (2-tailed).
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Correlations
Q1A Q4 Q5 Q6 Q7
Kendall's tau b Q1A Correlation Coefficient 1.000 .178 -.017 .113 .066
Sig. (2-tailed) .112 .869 297 .523
N 86 60 71 62 74
Q4 Correlation Coefficient .178 1.000 213* .108 .088
Sig. (2-tailed) .112 .046 .317 .415
N 60 63 61 59 61
Q5 Correlation Coefficient -.017 213* 1.000 .105 .078
Sig. (2-tailed) .869 .046 .324 .429
N 71 61 78 60 73
06 Correlation Coefficient .113 .108 .105 1.000 .087
Sig. (2-tailed) 297 .317 .324 . .413
N 62 59 60 64 62
Q7 Correlation Coefficient .066 .088 .078 .087 1.000
Sig. (2-tailed) .523 .415 .429 .413
N 74 61 73 62 80
Q8 Correlation Coefficient .161 .176 .174 -.163 .062
Sig. (2-tailed) .112 .095 .091 .115 .536
N 71 62 65 63 70
Q9 Correlation Coefficient -.098 .006 .181 262*
Sig. (2-tailed) .338 .958 .083 .021 .040
N 86 63 78 64 80
Q10 Correlation Coefficient .108 -.111 .165 .011
Sig. (2-tailed) .001 .330 278 .130 .916
N 81 62 73 63 75
Q11 Correlation Coefficient .037 .002 258* .044
Sig. (2-tailed) .745 .001 .983 .022 .686
N 63 57 62 59 65
Q12 Correlation Coefficient -.181 -.010 -.067 .143 .102
Sig. (2-tailed) .066 .929 .500 .181 .300
N 80 60 73 61 75
Q13 Correlation Coefficient -.100 .184 270* -.030 .042
Sig. (2-tailed) .376 .103 .016 .784 .704
N 60 56 57 57 59
Q14 Correlation Coefficient .210 .045 -.163 .094 -.091
Sig. (2-talled) .061 .692 .141 .399 .403
N 63 57 61 58 64
Q15 Correlation Coefficient .100 -.049 -.116 .062 .070
Sig. (2-tailed) .330 .652 .264 .552 .490
N 71 59 65 62 69
Q16A Correlation Coefficient -.008 -.160 -.036 -.037 .073
Sig. (2-tailed) .944 .170 .740 .744 .493
N 63 51 59 53 63
Q16B Correlation Coefficient -.046 -.165 .049 -.124 .098
Sig. (2-tailed) .693 .187 .677 299 .399
N 55 46 52 48 54
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Correlations
Q1A Q4 Q5 Q6 Q7
Kendall's tau_b Q16C Correlation Coefficient .144 .067 .051 -201 244*
Sig. (2-tailed) .191 .559 .642 .066 .026
N 62 54 58 57 61
Q17 Correlation Coefficient .161 .108 .179 .079 204
Sig. (2-tailed) .142 .369 .108 .498 .064
N 63 49 58 51 60
Q18 Correlation Coefficient .035 288* .027 .130 -.124
Sig. (2-tailed) .757 .015 .816 252 271
N 59 51 55 54 58
Q19 Correlation Coefficient -.013 -.051 .071 .162 -.021
Sig. (2-tailed) .908 .671 .516 .167 .851
N 60 48 60 50 60
Q20 Correlation Coefficient 230 247 257 -.112
Sig. (2-tailed) .033 .125 .088 .081 .452
N 34 31 34 32 33
02 1 Correlation Coefficient
.099 232 283 -.139
Sig. (2-tailed) .020 .494 .099 .051 .334
N 38 33 36 33 35
Q22 Correlation Coefficient 223* -.112 .091 .062 -.114
Sig. (2-tailed) .044 .316 .414 .572 .302
N 62 57 57 58 60
Q23 Correlation Coefficient .063 .195 204 .074 .171
Sig. (2-tailed) .563 .085 .058 .499 .109
N 65 56 63 59 65
Q24 Correlation Coefficient 282* .157 .147 .007 -.031
Sig. (2-tailed) .014 .183 200 .948 .784
N 57 51 54 53 56
Q25 Correlation Coefficient .120 .081 290* -.022 .069
Sig. (2-tailed) 295 .484 .011 .845 .545
N 57 52 54 55 56
Q26 Correlation Coefficient .165 268 .159 210 .128
Sig. (2-tailed) 208 .051 .226 .103 .307
N 45 38 42 42 46
Q27 Correlation Coefficient -.168 .135 -.167 .186 .157
Sig. (2-tailed) 252 .352 241 .184 263
N 35 33 34 35 36
Q28 Correlation Coefficient .112 .102 .110 241* -.029
Sig. (2-tailed) 279 .380 296 .031 .783
N 80 59 72 62 74
Q29 Correlation Coefficient 270* .220 -205 218 -.100
Sig. (2-tailed) .015 .061 .068 .055 .366
N 71 60 66 63 70
Q30 Correlation Coefficient -.022 -.130 -.180 .103 -.149
Sig. (2-tailed) .826 231 .078 .326 .137
N 74 59 67 62 71
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Correlations
Q1A Q4 Q5 Q6 Q7
Kendall's tau_b Q31 Correlation Coefficient -.019 .100 -.055 -.004 .196
Sig. (2-tailed) .852 .364 .595 .972 .053
N 72 59 67 60 71
Q32 Correlation Coefficient .029 .116 -.192 .089
Sig. (2-tailed) .015 .799 286 .091 .410
N 66 58 65 59 68
Q33 Correlation Coefficient .064 270* -.011 .027 .183
Sig. (2-tailed) .560 .019 .919 .808 .091
N 66 58 63 60 66
Q34 Correlation Coefficient .095 .079 -241 .136
Sig. (2-tailed) .504 .578 .026 .091 .323
N 38 35 37 35 39
Q35 Correlation Coefficient -.095 246 .226 .221 .109
Sig. (2-tailed) .512 .092 .118 .130 .434
N 35 32 33 32 36
Q36 Correlation Coefficient
.087 .068 -.091
Sig. (2-tailed) .011 .522 .609 .005 .488
N 45 41 42 44 45
Q37 Correlation Coefficient .264 .062 -.074 -.028 .046
Sig. (2-tailed) .076 .662 .595 .836 .751
N 37 36 38 38 36
Q38 Correlation Coefficient -.132 201 -.036 234*
Sig. (2-tailed) 249 .078 .003 .744 .033
N 58 53 56 55 59
Q39 Correlation Coefficient .045 .143 .207 .126 .052
Sig. (2-tailed) .687 .233 .062 .298 .628
N 62 48 57 47 61
Q40 Correlation Coefficient -250 -.120 -.063 .192 285
Sig. (2-tailed) .151 .479 .717 256 .084
N 27 25 25 25 27
04 1 Correlation Coefficient -.023 .229 -283 -.003
Sig. (2-tailed) .884 .131 .009 .062 .986
N 32 32 33 32 34
Q42 Correlation Coefficient -.019 200 -.020 .107
Sig. (2-tailed) .895 .157 .000 .886 .438
N 37 36 38 37 39
Q43 Correlation Coefficient .121 288 .123 -248 .106
Sig. (2-tailed) .445 .068 .419 .103 .488
N 32 28 31 30 31
Q44 Correlation Coefficient .191 261 .125 -264 -.095
Sig. (2-tailed) 254 .122 .440 .112 .556
N 29 25 28 26 28
Q45 Correlation Coefficient .107 .106 -.052 -.182
Sig. (2-tailed) .466 .004 .449 .710 .191
N 37 34 37 36 38
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Correlations
Q8 Q9 Q10 Q11 Q12
Kendall's tau b Q1A Correlation Coefficient .161 -.098 .037 -.181
Sig. (2-tailed) .112 .338 .001 .745 .066
N 71 86 81 63 80
Q4 Correlation Coefficient .176 .006 .108 -.010
Sig. (2-tailed) .095 .958 .330 .001 .929
N 62 63 62 57 60
Q5 Correlation Coefficient .174 .181 -.111 .002 -.067
Sig. (2-tailed) .091 .083 278 .983 .500
N i_ 65 78 73 62 73
06 Correlation Coefficient -.163 .165 258* .143
Sig. (2-tailed) .115 .021 .130 .022 .181
N 63 64 63 59 61
Q7 Correlation Coefficient .062 .011 .044 .102
Sig. (2-tailed) .536 .040 .916 .686 .300
N 70 80 75 65 75
Q8 Correlation Coefficient 1.000 .027 .031 -.025
Sig. (2-tailed) .797 .761 .815 .045
N 74 74 72 63 71
Q9 Correlation Coefficient .027 1.000 .141 .079
Sig. (2-tailed) .797 .155 .005 .423
N 74 96 90 66 89
Q10 Correlation Coefficient .031 .141 1.000 -.017
Sig. (2-tailed) .761 .155 . .000 .860
N 72 90 90 66 85
Q11 Correlation Coefficient -.025 1.000 -.132
Sig. (2-tailed) .815 .005 .000 .224
N 63 66 66 66 65
Q12 Correlation Coefficient .079 -.017 -.132 1.000
Sig. (2-tailed) .045 .423 .860 .224
N 71 89 85 65 89
Q13 Correlation Coefficient 294" .095 -.120 .049 .067
Sig. (2-tailed) .006 .422 297 .675 .543
N 61 61 60 58 59
Q14 Con-elation Coefficient -.196 .142 292* -.157
Sig. (2-tailed) .067 .229 .010 .003 .157
N 64 65 64 61 62
Q15 Correlation Coefficient -.056 .102 -.007 -.128 .045
Sig. (2-tailed) .577 .337 .947 241 .659
N 68 75 73 64 70
Q16A Correlation Coefficient -.161 .011 -.002 -.125 -.017
Sig. (2-tailed) .126 .922 .989 287 .872
t N 62 67 63 55 63
Q16B Correlation Coefficient .164 -.034 .022 -.194 -.033
Sig. (2-tailed) .154 .784 .857 .118 .780
N 53 57 55 50 54
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Correlations
Q8 Q9 Q10 Q11 Q12
Kendall's tau_b Q16C Correlation Coefficient -.126 -.091 -.191 -.002
Sig. (2-tailed) .000 274 .413 .097 .989
N 61 64 63 58 60
Q17 Correlation Coefficient -.070 -.075 .009 .008
Sig. (2-talled) .000 .534 .496 .941 .942
N 58 67 63 52 63
Q18 Correlation Coefficient -.049 .178 .088 234* -.038
Sig. (2-tailed) .657 .133 .437 .048 .738
N , 58 61 61 56 58
Q19 Correlation Coefficient -.208 .155 .070 .064 .050
Sig. (2-tailed) .063 .176 .530 .595 .645
N 55 64 62 53 61
Q20 Correlation Coefficient -.128 .309 .055 .062 -.019
Sig. (2-tailed) .378 .051 .722 .686 .897
N 33 34 33 33 34
Q21 Correlation Coefficient -.178 .264 -.064 .051 .176
Sig. (2-tailed) 205 .074 .654 .738 .205
N 35 38 37 33 37
Q22 Correlation Coefficient .047 -.020 -.125 .002
Sig. (2-tailed) .011 .688 .855 285 .983
N 62 63 62 57 59
Q23 Correlation Coefficient .180 .166 .198 .003
Sig. (2-tailed) .000 .110 .125 .081 .980
N 63 68 67 62 66
Q24 Correlation Coefficient .167 -.027 .103 -.009 -.049
Sig. (2-tailed) .132 .823 .365 .938 .663
N 56 59 59 54 57
Q25 Correlation Coefficient 290" .103 -.084 -.040 -.119
Sig. (2-tailed) .008 .397 .476 .736 292
N 58 58 57 55 56
Q26 Correlation Coefficient .001 288* .158 256 .122
Sig. (2-tailed) .991 .031 .220 .062 .320
N 44 48 47 42 48
Q27 Correlation Coefficient -.103 .129 -.031 .155 -.034
Sig. (2-tailed) .460 .391 .827 298 .808
N 35 37 37 35 37
Q28 Correlation Coefficient .136 .199 .123 .058 .092
Sig. (2-tailed) .193 .058 .228 .616 .366
N 71 85 81 l 6* 78
029 Correlation Coefficient -.074 .161 296* .032
Sig. (2-tailed) .496 .161 .000 .012 .766
N 69 74 72 65 71
Q30 Correlation Coefficient .123 .168 -.024 .128
Sig. (2-tailed) .000 234 .091 .827 .197
N 68 77 75 63 72
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Correlations
Q8 Q9 Q10 Q11 Q12
Kendall's tau_b Q31 Correlation Coefficient .141 .044 .135 279* -.131
Sig. (2-tailed) .163 .675 .189 .013 .193
N 68 77 73 62 71
Q32 Correlation Coefficient 230* -.076 -.065 -.135
Sig. (2-tailed) .032 .047 .500 .585 215
N 66 71 68 61 66
Q33 Correlation Coefficient -.002 215 -.011
Sig. (2-tailed) .002 .986 .057 .006 .922
N 66 68 66 62 65
Q34 Correlation Coefficient 280* -.083 -215 -.067 .017
Sig. (2-tailed) .041 .576 .130 .644 .898
N 38 40 40 37 40
Q35 Correlation Coefficient -.042 .164 -.129 .151 .109
Sig. (2-tailed) .765 282 .381 .319 .443
N 34 36 35 33 35
Q36 Correlation Coefficient .106 .192 .126 .093 .089
Sig. (2-tailed) .403 .164 .348 .499 .498
N 46 47 46 43 44
Q37 Correlation Coefficient .181 .003 .107 -.002 .138
Sig. (2-tailed) .197 .986 .464 .988 .325
N 37 38 38 37 38
Q38 Correlation Coefficient 216* .033 -.071 .137
Sig. (2-tailed) .047 .779 .532 235 .035
N 58 60 60 57 59
Q39 Correlation Coefficient .103 -.001 .140 .135 -.134
Sig. (2-tailed) .348 .994 .186 259 200
N 56 69 67 53 65
Q40 Correlation Coefficient .004 .142 .105 .195 -.071
Sig. (2-tailed) .982 .431 .539 284 .674
N 27 27 27 24 27
04 1 Correlation Coefficient .129 .081 -.018
Sig. (2-talled) .394 .619 .012 .908 .016
N 32 34 34 32 32
Q42 Correlation Coefficient .133 218 -.180 .118
Sig. (2-tailed) .344 .146 205 .422 .036
N 36 39 39 37 38
Q43 Correlation Coefficient .064 -.108 -271 -.013
Sig. (2-tailed) .683 .511 .008 .097 .930
N 29 32 32 29 32
Q44 Correlation Coefficient .193 -.178 -217 -254 -.107
Sig. (2-tailed) 247 .304 203 .157 .498
N 26 29 28 25 29
Q45 Correlation Coefficient .109 .143 -.009 .032 .026
Sig. (2-tailed) .438 .345 .953 .830 .847
N 36 38 38 35 38
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Correlations
Q13 Q14 Q15 Q16A Q16B
Kendall's tau_b Q1A Correlation Coefficient -.100 210 .100 -.008 -.046
Sig. (2-tailed) .376 .061 .330 .944 .693
N 60 63 71 63 55
04 Correlation Coefficient
.184 .045 -.049 -.160 -.165
Sig. (2-tailed) .103 .692 .652 .170 .187
N 56 57 59 51 46
05 Correlation Coefficient 270* -.163 -.116 -.036 .049
Sig. (2-tailed) .016 .141 264 .740 .677
N 57 61 65 59 52
Q6 Correlation Coefficient -.030 .094 .062 -.037 -.124
Sig. (2-tailed) .784 .399 .552 .744 299
N 57 58 62 53 48
Q7 Correlation Coefficient .042 -.091 .070 .073 .098
Sig. (2-tailed) .704 .403 .490 .493 .399
N 59 64 69 63 54
Q8 Correlation Coefficient 294" -.196 -.056 -.161 .164
Sig. (2-tailed) .006 .067 .577 .126 .154
N 61 64 68 62 53
Q9 Correlation Coefficient
.095 .142 .102 .011 -.034
Sig. (2-tailed) .422 .229 .337 .922 .784
N 61 65 75 67 57
Q10 Correlation Coefficient -.120 292* -.007 -.002 .022
Sig. (2-talled) 297 .010 .947 .989 .857
N 60 64 73 63 55
Q11 Correlation Coefficient
.049 -.128 -.125 -.194
Sig. (2-tailed) .675 .003 241 287 .118
N 58 61 64 55 50
Q12 Correlation Coefficient .067 -.157 .045 -.017 -.033
Sig. (2-tailed) .543 .157 .659 .872 .780
N 59 62 70 63 54
Q13 Correlation Coefficient 1.000 .070 .097
Sig. (2-tailed) .000 .523 .036 .440
N 61 59 60 53 47
Q14 Correlation Coefficient 1.000 -.093 .176 .040
Sig. (2-tailed) .000 . .391 .126 .739
N 59 65 64 57 52
Q15 Correlation Coefficient .070 -.093 1.000 .001 .040
Sig. (2-tailed) .523 .391 . .995 .731
N 60 64 75 61 54
016A Correlation Coefficient .176 .001 1.000 281*
Sig. (2-tailed) .036 .126 .995 .013
N 53 57 61 67 55
Q16B Correlation Coefficient .097 .040 .040 281* 1.000
Sig. (2-tailed) .440 .739 .731 .013 .
N 47 52 54 55 57
Page 7
Correlations
Q13 Q14 Q15 Q16A Q16B
Kendall's tau b Q16C Correlation Coefficient .189 -.104 .008 -.004
Sig. (2-tailed) .102 .359 .943 .968 .032
N 54 58 63 55 52
Q17 Correlation Coefficient .126 -.043 -.088 .072
Sig. (2-talled) 288 .716 .427 .008 .544
N 51 53 58 58 51
Q18 Correlation Coefficient -.170 -.086 .047 -.065
Sig. (2-tailed) .151 .004 .429 .686 .587
N 52 55 60 54 52
Q19 Correlation Coefficient -.012 .076 .026 -.021
Sig. (2-tailed) .923 .528 .817 .006 .869
N 49 53 56 48 43
Q20 Correlation Coefficient -208 294 .152 .006
Sig. (2-tailed) .177 .057 .313 .005 .973
N 32 32 32 27 21
021 Correlation Coefficient .106 .213 .042 .096
Sig. (2-tailed) .479 .170 .774 .041 .594
N 33 32 33 29 23
Q22 Correlation Coefficient -216 .137 287* .036
Sig. (2-tailed) .055 .048 .195 .013 .773
N 57 58 63 53 47
Q23 Correlation Coefficient -.039 -.117 213
Sig. (2-tailed) .006 .729 266 .005 .071
N 58 61 65 57 52
Q24 Correlation Coefficient .085 -.092 .148 -.106 .055
Sig. (2-tailed) .473 .439 .179 .373 .662
N 51 53 58 50 44
Q25 Correlation Coefficient -.090 .091 .071 .140
Sig. (2-tailed) .006 .435 .411 .537 249
N 54 56 57 54 49
Q26 Correlation Coefficient .033 .155 -.066 -.182 -.016
Sig. (2-tailed) .802 265 .602 .186 .915
N 41 40 45 39 33
Q27 Correlation Coefficient -288 .069 -.228 .049
Sig. (2-tailed) .007 .051 .614 .117 .745
N 33 34 37 33 32
Q28 Correlation Coefficient .120 -.065 -.039 .050 .144
Sig. (2-tailed) .303 .574 .712 .650 231
N 60 64 72 65 56
029 Correlation Coefficient -.075 .057 -.055 .072
Sig. (2-tailed) .525 .002 .605 .637 .566
N 61 64 70 61 54
Q30 Correlation Coefficient -211 .060 .188 .148 -203
Sig. (2-tailed) .054 .579 .059 .163 .077
N 59 63 70 61 54
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Correlations
Q13 Q14 Q15 Q16A Q16B
Kendall's tau_b Q31 Correlation Coefficient -.014 -.052 -.055 -.017 .020
Sig. (2-tailed) .899 .639 .586 .871 .865
N 59 63 69 63 54
Q32 Correlation Coefficient .117 -.199 -.040 .152
Sig. (2-tailed) .315 .005 .067 .720 208
N 58 62 66 62 54
Q33 Correlation Coefficient .151 .039 -207 -.128 .152
Sig. (2-tailed) .189 .728 .055 .260 211
N 59 64 66 59 53
Q34 Correlation Coefficient -.224 -.224 -.196 .003
Sig. (2-tailed) .004 .118 .104 .160 .986
N 36 39 39 37 32
Q35 Correlation Coefficient .211 -.182 -.146
Sig. (2-tailed) .145 215 .034 .047 .341
N 34 34 34 33 30
Q36 Correlation Coefficient .016 -.002 258* -.095 -.116
Sig. (2-tailed) .903 .991 .044 .455 .377
N 43 45 46 46 45
Q37 Correlation Coefficient -.090 .077 .160 -.021 .048
Sig. (2-tailed) .535 .616 260 .897 .792
N 36 34 37 29 24
Q38 Correlation Coefficient 200 -.090 .114 .057 .152
Sig. (2-tailed) .084 .437 292 .629 223
N 53 55 59 51 46
Q39 Correlation Coefficient .001 -.044 .061 -.055
Sig. (2-tailed) .992 .717 .049 .605 .687
N 50 52 57 50 39
Q40 Correlation Coefficient .119 -.155 -.013 -233 .035
Sig. (2-tailed) .502 .374 .939 .195 .856
N 25 26 25 23 20
Q41 Correlation Coefficient .174 -.064 .005 .093 -.115
Sig. (2-tailed) 259 .684 .972 .574 .515
N 32 33 33 28 25
Q42 Correlation Coefficient -.092 .143 .032 .016
Sig. (2-tailed) .009 .535 299 .837 .924
N 36 L. 36 38 31 27
Q43 Correlation Coefficient .068 .108 .078 207 .015
Sig. (2-tailed) .668 .514 .615 236 .938
N 29 28 30 24 19
Q44 Correlation Coefficient .084 -.023 -.118 -.088 -.224
Sig. (2-tailed) .619 .895 .483 .622 290
N 26 25 26 23 17
Q45 Correlation Coefficient -.116 .083 -.134 -.135
Sig. (2-tailed) .426 .579 .345 .388 .046
N 35 35 36 30 25
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Correlations
Q16C Q17 J Q18 Q19 Q20
Kendall's tau b Q1A Correlation Coefficient .144 .161 .035 -.013
Sig. (2-tailed) .191 .142 .757 .908 .033
N 62 63 59 60 34
Q4 Correlation Coefficient .067 .108 288* -.051 230
Sig. (2-tailed) .559 .369 .015 .671 .125
N 54 49 51 48 31
Q5 Correlation Coefficient .051 .179 .027 .071 247
Sig. (2-tailed) .642 .108 .816 .516 .088
N 58 58 55 60 34
Q6 Correlation Coefficient -201 .079 .130 .162 257
Sig. (2-tailed) .066 .498 252 .167 .081
N 57 51 54 50 32
Q7 Correlation Coefficient 244* 204 -.124 -.021 -.112
Sig. (2-tailed) .026 .064 271 .851 .452
N 61 60 58 60 33
Q8 Correlation Coefficient -.049 -208 -.128
Sig. (2-tailed) .000 .000 .657 .063 .378
N 61 58 58 55 33
Q9 Correlation Coefficient -.126 -.070 .178 .155 .309
Sig. (2-tailed) 274 .534 .133 .176 .051
N 64 67 61 64 34
Q10 Correlation Coefficient -.091 -.075 .088 .070 .055
Sig. (2-tailed) .413 .496 .437 .530 .722
N 63 63 61 62 33
Q11 Correlation Coefficient -.191 .009 234* .064 .062
Sig. (2-tailed) .097 .941 .048 .595 .686
N 58 52 L 56 53 33
Q12 Correlation Coefficient -.002 .008 -.038 .050 -.019
Sig. (2-tailed) .989 .942 .738 .645 .897
N 60 63 58 61 34
Q13 Correlation Coefficient .189 .126 -.170 -.012 -208
Sig. (2-tailed) .102 .288 .151 .923 .177
N 54 51 52 49 32
Q14 Correlation Coefficient -.104 -.043 .076 294
Sig. (2-tailed) .359 .716 .004 .528 .057
N 58 53 55 53 32
Q15 Correlation Coefficient .008 -.088 -.086 .026 .152
Sig. (2-tailed) .943 .427 .429 .817 .313
N 63 58 60 56 32
Q16A Correlation Coefficient -.004 .047
Sig. (2-tailed) .968 .008 .686 .006 .005
N 55 58 54 48 27
Q16B Correlation Coefficient 252* .072 -.065 -.021 .006
Sig. (2-tailed) .032 .544 .587 .869 .973
N 52 51 52 43 21
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Correlations
Q16C Q17 Q18 Q19 Q20
Kendall's tali b Q16C Correlation Coefficient 1.000 -.040
Sig. (2-tailed) .001 .021 .002 .798
N 64 54 58 49 30
Q17 Correlation Coefficient 1.000 -.056 -.168 .022
Sig. (2-tailed) .001 . .628 .168 .897
N 54 67 55 49 25
Q18 Correlation Coefficient -.056 1.000 231 .118
Sig. (2-tailed) .021 .628 , .061 .489
N 58 55 61 48 26
Q19 Correlation Coefficient -.168 231 1.000
Sig. (2-tailed) .002 .168 .061 . .011
N 49 49 48 64 33
Q20 Correlation Coefficient -.040 .022 .118 1.000
Sig. (2-tailed) .798 .897 .489 .011
N 30 25 26 33 34
Q21 Correlation Coefficient -.150 245
Sig. (2-tailed) .331 .130 .010 .000 .000
N 30 28 27 34 31
Q22 Correlation Coefficient -.179 .076 .167 .147
Sig. (2-tailed) .109 .019 .508 .174 .341
N 57 52 55 48 31
Q23 Correlation Coefficient .016 -.017
Sig. (2-tailed) .000 .001 .884 .040 .912
N 60 56 58 52 32
Q24 Correlation Coefficient .117 .026 -.183 -.057 .085
Sig. (2-tailed) .306 .826 .120 .635 .576
N 53 50 52 49 31
Q25 Correlation Coefficient 267* .189 -.087 .043 .173
Sig. (2-tailed) .022 .116 .463 .733 267
N 52 49 51 44 29
Q26 Correlation Coefficient .108 .147 .075 .302
Sig. (2-tailed) .431 .000 .292 .584 .081
N 39 38 38 38 25
027 Correlation Coefficient .111 .136 -212 -.176 -215
Sig. (2-tailed) .439 .363 .135 243 .269
N 34 32 35 31 20
Q28 Correlation Coefficient 260* .192 -.057 -.045 .114
Sig. (2-tailed) .020 .083 .623 .703 .475
N 63 65 60 58 33
Q29 Correlation Coefficient .032 204 .150 .019 .126
Sig. (2-tailed) .783 .091 210 .878 .435
N 62 58 59 57 33
Q30 Correlation Coefficient -.035 .099
Sig. (2-tailed) .018 .034 .748 .371 .004
N 62 61 60 56 33
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Correlations
Q16C Q17 Q18 Q19 Q20
Kendall's tau_b 03 1 Correlation Coefficient .079 -.061 -.058 -.240
Sig. (2-tailed) .466 .584 .601 .003 .114
N 61 60 59 55 32
Q32 Correlation Coefficient .175 -.036 -.174 -.083
Sig. (2-tailed) .128 .763 .045 .151 .600
N 59 57 57 53 31
Q33 Correlation Coefficient 215 235* -.053 -.105 -232
Sig. (2-tailed) .058 .049 .648 .379 .144
N 60 54 57 53 31
Q34 Con-elation Coefficient
.159 .178 .012 .057 -.125
Sig. (2-tailed) 266 .220 .936 .706 .509
N 36 35 35 32 22
Q35 Correlation Coefficient -.104 .128 .011 234
Sig. (2-tailed) .495 .381 .941 .048 232
N 31 33 31 29 19
Q36 Correlation Coefficient
.073 .222 .168 -.176 .132
Sig. (2-tailed) .574 .087 .194 .226 .524
N 45 45 46 36 18
Q37 Correlation Coefficient .196 .169 .096 .119
Sig. (2-tailed) .188 296 .542 .048 .449
N 34 29 31 35 30
Q38 Correlation Coefficient .165 214 207 -.037
Sig. (2-tailed) .149 .075 .079 .764 .021
N 54 49 52 47 31
Q39 Correlation Coefficient -.024 .045 .123 246*
Sig. (2-tailed) .844 .710 .323 .036 .029
N 49 49 47 50 32
Q40 Correlation Coefficient -.059 .060 -.062 .027
Sig. (2-tailed) .744 .749 .742 .875 .017
N 23 22 22 25 22
041 Correlation Coefficient -.133 -.122 .123 .142 233
Sig. (2-tailed) .398 .468 .468 .358 217
N 30 26 27 31 22
Q42 Correlation Coefficient -.007 -.034 .154 .147 .194
Sig. (2-tailed) .961 .823 .315 .308 .287
N 34 31 32 35 23
Q43 Correlation Coefficient 271 -.101 259 -.166 290
Sig. (2-tailed) .101 .579 .150 290 .092
N 26 22 23 29 25
Q44 Correlation Coefficient 257 .060 .129 -.139 235
Sig. (2-tailed) .153 .756 .510 .409 .183
N 23 21 20 26 24
Q45 Correlation Coefficient .140 .134 240 -250
Sig. (2-tailed) .340 .397 .127 .080 .020
N | 34 30 31 36 28
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Correlations
Q21 022 Q23 Q24 Q25
Kendall's tau_b Q1A Correlation Coefficient .063 .120
Sig. (2-tailed) .020 .044 .563 .014 295
N 38 62 65 57 57
Q4 Correlation Coefficient .099 -.112 .195 .157 .081
Sig. (2-tailed) .494 .316 .085 .183 .484
N 33 57 56 51 52
05 Correlation Coefficient 232 .091 204 .147
Sig. (2-tailed) .099 .414 .058 200 .011
N 36 57 63 54 54
06 Correlation Coefficient 283 .062 .074 .007 -.022
Sig. (2-tailed) .051 .572 .499 .948 .845
N 33 58 59 53 55
Q7 Correlation Coefficient -.139 -.114 .171 -.031 .069
Sig. (2-tailed) .334 .302 .109 .784 .545
N 35 60 65 56 56
Q8 Correlation Coefficient -.178 .167 290*
Sig (2-tailed) 205 .011 .000 .132 .008
N 35 62 63 56 58
Q9 Correlation Coefficient .264 .047 .180 -.027 .103
Sig. (2-tailed) .074 .688 .110 .823 .397
N 38 63 68 59 58
Q10 Correlation Coefficient -.064 -.020 .166 .103 -.084
Sig. (2-tailed) .654 .855 .125 .365 .476
N 37 62 67 59 57
Q11 Correlation Coefficient .051 -.125 .198 -.009 -.040
Sig. (2-tailed) .738 285 .081 .938 .736
N 33 57 62 54 55
Q12 Correlation Coefficient .176 .002 .003 -.049 -.119
Sig. (2-tailed) 205 .983 .980 .663 292
N 37 59 66 57 56
Q13 Correlation Coefficient .106 -216 .085
Sig. (2-tailed) .479 .055 .006 .473 .006
N 33 57 58 51 54
Q14 Correlation Coefficient 213 -.039 -.092 -.090
Sig. (2-tailed) .170 .048 .729 .439 .435
N 32 58 61 53 56
Q15 Correlation Coefficient .042 .137 -.117 .148 .091
Sig. (2-tailed) .774 .195 266 .179 .411
N 33 63 65 58 57
Q16A Correlation Coefficient 287* -.106 .071
Sig. (2-tailed) .041 .013 .005 .373 .537
N 29 53 57 50 54
Q16B Correlation Coefficient .096 .036 213 .055 .140
Sig. (2-tailed) .594 .773 .071 .662 249
N 23 47 52 44 49
Page 13
Correlations
Q21 Q22 Q23 Q24 Q25
Kendall's tau_b Q16C Correlation Coefficient -.150 -.179 .117 267*
Sig. (2-talled) .331 .109 .000 .306 .022
N 30 57 60 53 52
Q17 Correlation Coefficient 245 .026 .189
Sig. (2-tailed) .130 .019 .001 .826 .116
N 28 52 56 50 49
Q18 Correlation Coefficient
.076 .016 -.183 -.087
Sig. (2-tailed) .010 .508 .884 .120 .463
N 27 55 58 52 51
Q19 Correlation Coefficient
.167 -.057 .043
Sig. (2-tailed) .000 .174 .040 .635 .733
N 34 48 52 49 44
Q20 Correlation Coefficient .147 -.017 .085 .173
Sig. (2-tailed) .000 .341 .912 .576 267
N 31 31 32 31 29
Q21 Correlation Coefficient 1.000 .112 -.034 .120 202
Sig. (2-tailed) .466 .819 .421 .192
N 38 32 33 33 29
Q22 Correlation Coefficient .112 1.000 .118 .001
Sig. (2-tailed) .466 .001 .313 .993
N 32 63 58 53 52
Q23 Correlation Coefficient -.034 -.369*1 1.000 .082 .190
Sig. (2-tailed) .819 .001 .463 .095
N 33 58 68 58 56
Q24 Correlation Coefficient .120 .118 .082 1.000
Sig. (2-tailed) .421 .313 .463 .000
N 33 53 58 59 48
Q25 Correlation Coefficient 202 .001 .190 1.000
Sig. (2-tailed) .192 .993 .095 .000
N 29 52 56 48 58
Q26 Correlation Coefficient -214 .174 .135
Sig. (2-tailed) .036 .123 .010 204 .321
N 27 39 45 39 39
027 Correlation Coefficient -.041 -.117 .133 .239 .138
Sig. (2-tailed) .824 .433 .346 .097 .332
N 22 33 36 34 35
Q28 Correlation Coefficient .192 -.122 219 289*
Sig. (2-tailed) .194 283 .005 .062 .015
N 37 62 67 58 57
029 Correlation Coefficient 216 -.147 .128 .135 .037
Sig. (2-tailed) .160 212 265 .264 .757
N 35 61 65 58 58
Q30 Correlation Coefficient .128 .140 -.001
Sig. (2-tailed) .348 .192 .022 .994 .003
N 37 61 65 57 58
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Correlations
Q21 Q22 Q23 Q24 Q25
Kendall's tau_b Q31 Correlation Coefficient -.159 .071 -.150
Sig. (2-tailed) .002 .146 .034 .532 .182
N 35 61 64 55 57
Q32 Correlation Coefficient -272 -209 215 .085 -.064
Sig. (2-tailed) .081 .071 .057 .482 .585
N 32 59 62 53 57
Q33 Correlation Coefficient .081
Sig. (2-tailed) .606 .011 .018 .002 .002
N 32 60 62 54 57
Q34 Correlation Coefficient -.010 -.010 .155 .004 .171
Sig. (2-tailed) .955 .942 .262 .975 239
N 24 37 38 35 34
Q35 Correlation Coefficient
.041 -.083 .086 .134
Sig. (2-tailed) .825 .564 .547 .037 .367
N 22 34 34 31 31
Q36 Correlation Coefficient .187 .044 .079 .116 .172
Sig. (2-tailed) .352 .743 .552 .404 .196
N 19 43 43 39 43
Q37 Correlation Coefficient
.094 -278 252 .004 .114
Sig. (2-tailed) .547 .060 .080 .975 .460
N 30 35 37 36 31
Q38 Correlation Coefficient -.154 .165 .064 254*
Sig. (2-tailed) .029 .177 .140 .586 .032
N 31 55 57 51 50
Q39 Correlation Coefficient -.124 .074 -.033 .018
Sig. (2-tailed) .008 .295 .518 .785 .888
N 35 50 54 48 44
Q40 Correlation Coefficient .046 .185 .109 .055
Sig. (2-tailed) .045 .793 279 .523 .761
N 24 25 25 25 22
Q41 Correlation Coefficient .331 .151 -.191 .169 200
Sig. (2-tailed) .076 .336 208 276 200
N 23 31 33 31 30
Q42 Correlation Coefficient .315 201 .077 -.021 217
Sig. (2-tailed) .066 .172 .580 .880 .147
N 26 35 38 36 32
Q43 Correlation Coefficient .173 -.072 .175 .189
Sig. (2-tailed) .311 .040 .648 273 266
N 26 29 29 28 24
Q44 Correlation Coefficient 217 .123 .135 .166 .147
Sig. (2-tailed) 203 .469 .434 .330 .413
N 26 26 25 25 22
Q45 Correlation Coefficient .152 -.114 219 -.137 -.190
Sig. (2-tailed) .345 .442 .119 .330 .211
I N 29 34 37 36 31
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Correlations
Q26 Q27 Q28 Q29 Q30
Kendall's tau_b Q1A Correlation Coefficient .165 -.168 .112 270* -.022
Sig. (2-tailed) 208 252 279 .015 .626
N 45 35 80 71 74
04 Correlation Coefficient .268 .135 .102 .220 -.130
Sig. (2-tailed) .051 .352 .380 .061 231
N 38 33 59 60 59
05 Correlation Coefficient .159 -.167 .110 -205 -.180
Sig. (2-tailed) .226 241 296 .068 .078
N 42 34 72 66 67
06 Correlation Coefficient 210 .166 241* 218 .103
Sig. (2-tailed) .103 .184 .031 .055 .326
N 42 35 62 63 62
07 Correlation Coefficient
.128 .157 -.029 -.100 -.149
Sig. (2-tailed) .307 263 .783 .366 .137
N 46 36 74 70 71
08 Correlation Coefficient
.001 -.103 .136 -.074
Sig. (2-tailed) .991 .460 .193 .496 .000
N 44 35 71 69 68
09 Correlation Coefficient 288*
.129 .199 .161 .123
Sig. (2-tailed) .031 .391 .058 .161 234
N 48 37 85 74 77
Q10 Correlation Coefficient .158 -.031 .123 .168
Sig. (2-tailed) .220 .827 .228 .000 .091
N 47 37 81 72 75
Q11 Correlation Coefficient 256 .155 .058 -.024
Sig. (2-tailed) .062 298 .616 .012 .827
N 42 35 64 65 63
Q12 Correlation Coefficient .122 -.034 .092 .032 .128
Sig. (2-tailed) .320 .808 .366 .766 .197
N 48 37 78 71 72
Q13 Correlation Coefficient .033 .120 -.075 -211
Sig. (2-tailed) .802 .007 .303 .525 .054
N 41 33 60 61 59
Q14 Correlation Coefficient .155 -288 -.065 .060
Sig. (2-tailed) 265 .051 .574 .002 .579
N 40 34 64 64 63
Q15 Correlation Coefficient -.066 .069 -.039 .057 .188
Sig. (2-tailed) .602 .614 .712 .605 .059
N 45 37 72 70 70
Q16A Correlation Coefficient -.182 -.228 .050 -.055 .148
Sig. (2-tailed) .186 .117 .650 .637 .163
N 39 33 65 61 61
Q16B Correlation Coefficient -.016 .049 .144 .072 -203
Sig. (2-tailed) .915 .745 231 .566 .077
N 33 32 56 54 54
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Correlations
Q26 Q27 Q28 Q29 Q30
Kendall's tau_b Q16C Correlation Coefficient .108 .111 260* .032
Sig. (2-tailed) .431 .439 .020 .783 .018
N 39 34 63 62 62
Q17 Correlation Coefficient .136 .192 204
Sig. (2-tailed) .000 .363 .083 .091 .034
N 38 32 65 58 61
Q18 Correlation Coefficient .147 -212 -.057 .150 -.035
Sig. (2-tailed) 292 .135 .623 210 .748
N 38 35 60 59 60
Q19 Correlation Coefficient .075 -.176 -.045 .019 .099
Sig. (2-tailed) .584 243 .703 .878 .371
N 38 31 58 57 56
Q20 Correlation Coefficient .302 -215 .114 .126
Sig. (2-tailed) .081 .269 .475 .435 .004
N 25 20 33 33 33
021 Correlation Coefficient -.041 .192 .216 .128
Sig. (2-tailed) .036 .824 .194 .160 .348
N 27 22 37 35 37
Q22 Correlation Coefficient -214 -.117 -.122 -.147 .140
Sig. (2-tailed) .123 .433 283 212 .192
N 39 33 62 61 61
Q23 Correlation Coefficient .133 .128
Sig. (2-tailed) .010 .346 .005 .265 .022
N 45 36 67 65 65
Q24 Correlation Coefficient .174 239 219 .135 -.001
Sig. (2-tailed) 204 .097 .062 264 .994
N 39 34 58 58 57
025 Correlation Coefficient .135 .138 289* .037
Sig. (2-tailed) .321 .332 .015 .757 .003
N 39 35 57 58 58
Q26 Correlation Coefficient 1.000 214 -.043
Sig. (2-tailed) .046 .104 .000 .727
N 48 31 47 46 47
Q27 Correlation Coefficient 1.000 .174 .080 -.092
Sig. (2-tailed) .046 . 239 .591 .500
N 31 37 36 37 37
Q28 Correlation Coefficient 214 .174 1.000 -.085
Sig. (2-tailed) .104 239 .000 .403
N 47 36 85 71 75
029 Correlation Coefficient .080 1.000 .155
Sig. (2-tailed) .000 .591 .000 . .153
N 46 37 71 74 70
Q30 Correlation Coefficient -.043 -.092 -.085 .155 1.000
Sig. (2-tailed) .727 .500 .403 .153
N 47 37 75 70 77
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Correlations
Q26 Q27 Q28 Q29 Q30
Kendall's tau_b Q31 Correlation Coefficient -.094 .112 -.093 .054
Sig. (2-tailed) .456 .027 285 .407 .582
N 45 36 74 68 72
Q32 Correlation Coefficient -.152 .169 -.055 .022
Sig. (2-tailed) .261 246 .622 .019 .842
N 43 36 69 66 66
Q33 Correlation Coefficient 238 218
Sig. (2-tailed) .006 .102 .006 .060 .000
N 43 36 66 67 65
Q34 Correlation Coefficient -.191 -.111 -212 -265 -.220
Sig. (2-tailed) .261 .522 .140 .078 .111
N 26 24 40 39 38
Q35 Correlation Coefficient
.156 -.047 .059 .193
Sig. (2-tailed) .378 .006 .750 .706 .181
N 23 23 36 34 33
Q36 Correlation Coefficient -.063 212 -.064
Sig. (2-tailed) .003 .706 .007 .124 .613
N 29 27 46 46 46
Q37 Correlation Coefficient .128 -.024 269 -.048
Sig. (2-tailed) .409 .891 .071 .038 .729
N 31 24 38 38 37
Q38 Correlation Coefficient
.071 .067 .140 -.007
Sig. (2-tailed) .594 .634 .222 .950 .027
N 40 35 60 60 58
Q39 Correlation Coefficient
.149 -.164 213 -.148
Sig. (2-tailed) 276 279 .017 .076 .166
N 38 30 64 56 59
Q40 Correlation Coefficient .092 -.009
Sig. (2-tailed) .641 .003 .960 .045 .047
N 20 19 27 26 26
04 1 Correlation Coefficient -271 -.084 -.154 -216
Sig. (2-tailed) .102 .618 .324 .041 .159
N 28 26 34 33 32
Q42 Correlation Coefficient -.173 -.062 -.169 -269 -.156
Sig. (2-tailed) 274 .698 244 .073 257
N 30 28 39 38 38
Q43 Correlation Coefficient -.111 .007 -.209 .158
Sig. (2-tailed) .528 .970 .022 216 .304
N 24 19 32 30 30
044 Correlation Coefficient .025 -.227 -.166 -.050 .063
Sig. (2-tailed) .894 .270 .344 .785 .698
N 21 18 28 26 27
Q45 Correlation Coefficient 289 -.108 .018 232 205
Sig. (2-tailed) .071 .534 .904 .132 .138
N 29 24 38 37 37
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Correlations
Q31 Q32 Q33 Q34 Q35
Kendall's tau_b Q1A Correlation Coefficient -.019 .064 .095 -.095
Sig. (2-tailed) .852 .015 .560 .504 .512
N 72 66 66 38 35
04 Correlation Coefficient .100 .029 270* .079 246
Sig. (2-tailed) .364 .799 .019 .578 .092
N 59 58 58 35 32
05 Correlation Coefficient -.055 .116 -.011 .226
Sig. (2-tailed) .595 286 .919 .026 .118
N 67 65 63 37 33
06 Correlation Coefficient -.004 -.192 .027 -241 .221
Sig. (2-tailed) .972 .091 .808 .091 .130
N 60 59 60 35 32
07 Correlation Coefficient .196 .089 .183 .136 .109
Sig. (2-tailed) .053 .410 .091 .323 .434
N 71 68 66 39 36
08 Correlation Coefficient .141 230* 280* -.042
Sig. (2-tailed) .163 .032 .002 .041 .765
N 68 66 66 38 34
09 Correlation Coefficient .044 -.002 -.083 .164
Sig. (2-talled) .675 .047 .986 .576 282
N 77 71 68 40 36
Q10 Correlation Coefficient .135 -.076 215 -215 -.129
Sig. (2-tailed) .189 .500 .057 .130 .381
N 73 68 66 40 35
Q11 Correlation Coefficient 279* -.065 -.067 .151
Sig. (2-tailed) .013 .585 .006 .644 .319
N 62 61 62 37 33
Q12 Correlation Coefficient -.131 -.135 -.011 .017 .109
Sig. (2-tailed) .193 215 .922 .898 .443
N 71 66 65 40 35
Q13 Correlation Coefficient -.014 .117 .151 211
Sig. (2-tailed) .899 .315 .189 .004 .145
N 59 58 59 36 34
Q14 Correlation Coefficient -.052 .039 -.224 -.182
Sig. (2-tailed) .639 .005 .728 .118 215
N 63 62 64 39 34
Q15 Correlation Coefficient -.055 -.199 -207 -.224
Sig. (2-tailed) .586 .067 .055 .104 .034
N 69 66 66 39 34
Q16A Correlation Coefficient -.017 -.040 -.128 -.196
Sig. (2-tailed) .871 .720 260 .160 .047
N 63 62 59 37 33
Q16B Correlation Coefficient .020 .152 .152 .003 -.146
Sig. (2-tailed) .865 208 .211 .986 .341
N 54 54 53 32 30
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Correlations
Q31 Q32 Q33 Q34 Q35
Kendall's tau_b Q16C Correlation Coefficient .079 .175 215 .159 -.104
Sig. (2-tailed) .466 .128 .058 266 .495
N 61 59 60 36 31
Q17 Correlation Coefficient -.061 -.036 235* .178 .128
Sig. (2-tailed) .584 .763 .049 220 .381
N 60 57 54 35 33
Q18 Correlation Coefficient -.058 -.053 .012 .011
Sig. (2-tailed) .601 .045 .648 .936 .941
N 59 57 57 35 31
Q19 Correlation Coefficient -.174 -.105 .057
Sig. (2-tailed) .003 .151 .379 .706 .048
N 55 53 53 32 29
Q20 Correlation Coefficient -240 -.083 -232 -.125 234
Sig. (2-tailed) .114 .600 .144 .509 232
N 32 31 31 22 19
Q21 Correlation Coefficient -272 .081 -.010 .041
Sig. (2-tailed) .002 .081 .606 .955 .825
N 35 32 32 24 22
Q22 Correlation Coefficient -.159 -209 -.010 -.083
Sig. (2-tailed) .146 .071 .011 .942 .564
N 61 59 60 37 34
Q23 Correlation Coefficient 215 267* .155 .086
Sig. (2-tailed) .034 .057 .018 .262 .547
N 64 62 62 38 34
Q24 Correlation Coefficient .071 .085 .004
Sig. (2-tailed) .532 .482 .002 .975 .037
N 55 53 54 35 31
025 Correlation Coefficient -.150 -.064 .171 .134
Sig. (2-tailed) .182 .585 .002 239 .367
N 57 57 57 34 31
Q26 Correlation Coefficient -.094 -.152 -.191 .156
Sig. (2-tailed) .456 261 .006 .261 .378
N 45 43 43 26 23
Q27 Correlation Coefficient .169 238 -.111
Sig. (2-tailed) .027 246 .102 .522 .006
N 36 36 36 24 23
Q28 Correlation Coefficient .112 -.055 -212 -.047
Sig. (2-tailed) 285 .622 .006 .140 .750
N 74 69 66 40 36
Q29 Correlation Coefficient -.093 218 -265 .059
Sig. (2-tailed) .407 .019 .060 .078 .706
N 68 66 67 39 34
Q30 Correlation Coefficient .054 .022 -.220 .193
Sig. (2-talled) .582 .842 .000 .111 .181
N 72 66 65 38 33
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Correlations
Q31 Q32 Q33 Q34 Q35
Kendall's tau_b Q31 Correlation Coefficient 1.000 .091 -.169 .182
Sig. (2-tailed) . .002 .399 .224 .220
N 77 71 66 38 33
Q32 Correlation Coefficient 1.000 .034 -.004 .112
Sig. (2-tailed) .002 . .766 .976 .465
N 71 71 65 38 33
Q33 Correlation Coefficient .091 .034 1.000 -.059 .093
Sig. (2-talled) .399 .766 .679 .539
N 66 65 68 39 33
Q34 Correlation Coefficient -.169 -.004 -.059 1.000 204
Sig. (2-taited) 224 .976 .679 , .194
N 38 38 39 40 29
Q35 Correlation Coefficient .182 .112 .093 204 1.000
Sig. (2-tailed) .220 .465 .539 .194
N 33 33 33 29 36
Q36 Correlation Coefficient -.063 -.423*1 .183 -.144 -.113
Sig. (2-tailed) .625 .002 .163 .365 .513
N 46 46 47 30 25
Q37 Correlation Coefficient .044 -.069 251 -.113 -.111
Sig. (2-tailed) .762 .654 .100 .535 .554
N 35 34 35 24 21
Q38 Correlation Coefficient .007 .087 210 276 258
Sig. (2-tailed) .952 .452 .068 .051 .074
N 57 57 57 36 33
Q39 Correlation Coefficient -.115 .123 .089 .073 -.160
Sig. (2-tailed) 297 .303 .457 .611 277
N 58 54 52 35 32
Q40 Correlation Coefficient .164 -.010 .300 .022
Sig. (2-tailed) .338 .957 .084 .913 .047
N 26 25 26 20 20
04 1 Correlation Coefficient -207 -.012 -.023 .227
Sig. (2-tailed) .176 .940 .885 .000 215
N 33 33 32 25 22
Q42 Correlation Coefficient .049 .115 -.167 270 .147
Sig. (2-tailed) .733 .448 270 .105 .394
N 36 35 35 27 24
Q43 Correlation Coefficient -.107 .144 -.182
Sig. (2-tailed) .523 .409 283 .003 .010
N 27 26 27 22 20
Q44 Correlation Coefficient -.011 -.146 .088
Sig. (2-taHed) .004 .954 .428 .000 .626
N 25 24 24 21 22
Q45 Correlation Coefficient -.141 .044 -.016 .328 .179
Sig. (2-tailed) .337 .774 .915 .055 .298
N 34 33 34 26 24
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Correlations
Q36 Q37 Q38 Q39 Q40
Kendall's tau_b Q1A Correlation Coefficient 264 -.132 .045 -250
Sig. (2-tailed) .011 .076 249 .687 .151
N 45 37 58 62 27
Q4 Correlation Coefficient .087 .062 201 .143 -.120
Sig. (2-tailed) .522 .662 .078 233 .479
N 41 36 53 48 25
Q5 Correlation Coefficient .068 -.074 .335*1 207 -.063
Sig. (2-tailed) .609 .595 .003 .062 .717
N 42 38 56 57 25
Q6 Correlation Coefficient -.028 -.036 .126 .192
Sig. (2-tailed) .005 .836 .744 298 256
N 44 38 55 47 25
07 Correlation Coefficient -.091 .046 .052 285
Sig. (2-tailed) .488 .751 .033 .628 .084
N 45 36 59 61 27
08 Correlation Coefficient .106 .181 216* .103 .004
Sig. (2-tailed) .403 .197 .047 .348 .982
N 46 37 58 56 27
09 Correlation Coefficient .192 .003 .033 -.001 .142
Sig. (2-tailed) .164 .986 .779 .994 .431
N 47 38 60 69 27
Q10 Correlation Coefficient .126 .107 -.071 .140 .105
Sig. (2-tailed) .348 .464 .532 .186 .539
N 46 38 60 67 27
Q11 Correlation Coefficient .093 -.002 .137 .135 .195
Sig. (2-tailed) .499 .988 235 259 284
N 43 37 57 53 24
Q12 Correlation Coefficient .089 .138 -.134 -.071
Sig. (2-talled) .498 .325 .035 200 .674
N 44 38 59 65 27
Q13 Correlation Coefficient .016 -.090 200 .001 .119
Sig. (2-tailed) .903 .535 .084 .992 .502
N 43 36 53 50 25
Q14 Correlation Coefficient -.002 .077 -.090 -.044 -.155
Sig. (2-tailed) .991 .616 .437 .717 .374
N 45 34 55 52 26
Q15 Correlation Coefficient 258* .160 .114 -.013
Sig. (2-tailed) .044 260 292 .049 .939
N 46 37 59 57 25
Q16A Correlation Coefficient -.095 -.021 .057 .061 -233
Sig. (2-tailed) .455 .897 .629 .605 .195
N 46 29 51 50 23
Q16B Correlation Coefficient -.116 .048 .152 -.055 .035
Sig. (2-tailed) .377 .792 .223 .687 .856
N 45 24 46 39 20
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Correlations
Q36 Q37 Q38 Q39 Q40
Kendall's tau_b Q16C Correlation Coefficient .073 .196 .165 -.024 -.059
Sig. (2-tailed) .574 .188 .149 .844 .744
N 45 34 54 49 23
Q17 Correlation Coefficient .222 .169 .214 .045 .060
Sig. (2-tailed) .087 296 .075 .710 .749
N 45 29 49 49 22
Q18 Correlation Coefficient .168 .096 207 .123 -.062
Sig. (2-tailed) .194 .542 .079 .323 .742
N 46 31 52 47 22
Q19 Correlation Coefficient -.176 -.037 246* .027
Sig. (2-tailed) .226 .048 .764 .036 .875
N 36 35 47 50 25
Q20 Con-elation Coefficient .132 .119
Sig. (2-tailed) .524 .449 .021 .029 .017
N 18 30 31 32 22
021 Correlation Coefficient .187 .094
Sig. (2-tailed) .352 .547 .029 .008 .045
N 19 30 31 35 24
Q22 Correlation Coefficient .044 -278 -.154 -.124 .046
Sig. (2-tailed) .743 .060 .177 295 .793
N 43 35 55 50 25
Q23 Correlation Coefficient .079 252 .165 .074 .185
Sig. (2-tailed) .552 .080 .140 .518 279
N 43 37 57 54 25
Q24 Correlation Coefficient .116 .004 .064 -.033 .109
Sig. (2-tailed) .404 .975 .586 .785 .523
N 39 36 51 48 25
Q25 Correlation Coefficient .172 .114 254* .018 .055
Sig. (2-tailed) .196 .460 .032 .888 .761
N 43 31 50 44 22
Q26 Correlation Coefficient .128 .071 .149 .092
Sig. (2-tailed) .003 .409 .594 276 .641
N 29 31 40 38 20
Q27 Correlation Coefficient -.063 -.024 .067 -.164
Sig. (2-tailed) .706 .891 .634 279 .003
N 27 24 35 30 19
Q28 Correlation Coefficient .269 .140 -.009
Sig. (2-tailed) .007 .071 .222 .017 .960
N 46 38 60 64 27
029 Correlation Coefficient 212 -.007 213
Sig. (2-tailed) .124 .038 .950 .076 .045
N 46 38 60 56 26
Q30 Correlation Coefficient -.064 -.048 -.148
Sig. (2-tailed) .613 .729 .027 .166 .047
N 46 37 58 59 26
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Correlations
Q36 Q37 Q38 Q39 Q40
Kendall's tau_b Q31 Correlation Coefficient -.063 .044 .007 -.115 .164
Sig. (2-tailed) .625 .762 .952 297 .338
N 46 35 57 58 26
Q32 Correlation Coefficient -.069 .087 .123 -.010
Sig. (2-tailed) .002 .654 .452 .303 .957
N 46 34 57 54 25
Q33 Correlation Coefficient .183 251 210 .089 .300
Sig. (2-tailed) .163 .100 .068 .457 .084
N 47 35 57 52 26
Q34 Con-elation Coefficient -.144 -.113 276 .073 .022
Sig. (2-tailed) .365 .535 .051 .611 .913
N 30 24 36 35 20
Q35 Correlation Coefficient -.113 -.111 258 -.160
Sig. (2-tailed) .513 .554 .074 277 .047
N 25 21 33 32 20
Q36 Correlation Coefficient 1.000 .018 .072 .182
Sig. (2-tailed) .039 .896 .630 .389
N 47 20 40 34 17
Q37 Correlation Coefficient 1.000 .117 .067
Sig. (2-tailed) .039 .411 .648 .012
N 20 38 36 33 20
Q38 Correlation Coefficient .018 .117 1.000 -.027
Sig. (2-tailed) .896 .411 . .002 .876
N 40 36 60 50 26
Q39 Correlation Coefficient .072 .067 1.000 -.012
Sig. (2-tailed) .630 .648 .002 . .945
N 34 33 50 69 27
Q40 Correlation Coefficient .182 -.027 -.012 1.000
Sig. (2-tailed) .389 .876 .945
N 17 20 26 27 27
Q41 Correlation Coefficient -235 -.119 244 -.024
Sig. (2-tailed) 214 .501 .001 .115 .905
N 22 25 33 31 19
Q42 Correlation Coefficient -249 -.158 273 -.087
Sig. (2-tailed) .166 .336 .001 .057 .666
N 24 28 37 35 19
Q43 Correlation Coefficient -.309 .073 -.116 -.152
Sig. (2-tailed) .156 .661 .034 .462 .433
N 16 26 29 29 20
Q44 Correlation Coefficient -.013 .140 -221
Sig. (2-tailed) .955 .442 .047 .048 251
N 15 23 26 28 21
Q45 Correlation Coefficient .071 208 .076
Sig. (2-tailed) .705 .004 .143 .597 .018
N 22 30 36 35 24
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Correlations
Q41 Q42 Q43 Q44 Q45
Kendall's tau_b Q1A Correlation Coefficient -.023 -.019 .121 .191 .107
Sig. (2-tailed) .684 .895 .445 254 .466
N 32 37 32 29 37
04 Correlation Coefficient .229 200 288 .261
Sig. (2-tailed) .131 .157 .068 .122 .004
N 32 36 28 25 34
05 Correlation Coefficient
.123 .125 .106
Sig. (2-tailed) .009 .000 .419 .440 .449
N 33 38 31 28 37
06 Correlation Coefficient -283 -.020 -248 -.264 -.052
Sig. (2-taDed) .062 .886 .103 .112 .710
N 32 37 30 26 36
07 Correlation Coefficient -.003 .107 .106 -.095 -.182
Sig. (2-talled) .986 .438 .488 .556 .191
N 34 39 31 28 38
08 Correlation Coefficient .129 .133 .064 .193 .109
Sig. (2-tailed) .394 .344 .683 247 .438
N 32 36 29 26 36
09 Correlation Coefficient .081 218 -.108 -.178 .143
Sig. (2-tailed) .619 .146 .511 .304 .345
N 34 39 32 29 38
Q10 Correlation Coefficient -.180 -217 -.009
Sig. (2-tailed) .012 205 .008 203 .953
N 34 39 32 28 38
Q11 Correlation Coefficient -.018 .118 -271 -254 .032
Sig. (2-tailed) .908 .422 .097 .157 .830
N 32 37 29 25 35
Q12 Correlation Coefficient -.013 -.107 .026
Sig. (2-tailed) .016 .036 .930 .498 .847
N 32 38 32 29 38
Q13 Correlation Coefficient .174 .068 .084 -.116
Sig. (2-tailed) 259 .009 .668 .619 .426
N 32 36 29 26 35
Q14 Correlation Coefficient -.064 -.092 .108 -.023 .083
Sig. (2-tailed) .684 .535 .514 .895 .579
N 33 36 28 25 35
Q15 Correlation Coefficient .005 .143 .078 -.118 -.134
Sig. (2-tailed) .972 299 .615 .483 .345
N 33 38 30 26 36
Q16A Correlation Coefficient .093 .032 207 -.088 -.135
Sig. (2-tailed) .574 .837 236 .622 .388
N 28 31 24 23 30
Q16B Correlation Coefficient -.115 .016 .015 224
Sig. (2-tailed) .515 .924 .938 290 .046
N 25 27 19 17 25
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Correlations
Q41 Q42 Q43 Q44 Q45
Kendall's tau_b Q16C Correlation Coefficient -.133 -.007 271 257 .140
Sig. (2-tailed) .398 .961 .101 .153 .340
N 30 34 26 23 34
Q17 Correlation Coefficient -.122 -.034 -.101 .060 .134
Sig. (2-tailed) .468 .823 .579 .756 .397
N 26 31 22 21 30
Q18 Correlation Coefficient .123 .154 259 .129 240
Sig. (2-tailed) .468 .315 .150 .510 .127
N 27 32 23 20 31
Q19 Correlation Coefficient .142 .147 -.166 -.139 -250
Sig. (2-tailed) .358 .308 290 .409 .080
N 31 35 29 26 36
Q20 Correlation Coefficient 233 .194 290 235
Sig. (2-tailed) 217 287 .092 .183 .020
N 22 23 25 24 28
Q21 Correlation Coefficient .331 .315 .173 .217 .152
Sig. (2-tailed) .076 .066 .311 203 .345
N 23 26 26 26 29
Q22 Correlation Coefficient .151 201 .123 -.114
Sig. (2-tailed) .336 .172 .040 .469 .442
N 31 35 29 26 34
Q23 Correlation Coefficient -.191 .077 -.072 .135 219
Sig. (2-tailed) 208 .580 .648 .434 .119
N 33 38 29 25 37
Q24 Correlation Coefficient .169 -.021 .175 .166 -.137
Sig. (2-tailed) 276 .880 273 .330 .330
N 31 36 28 25 36
Q25 Correlation Coefficient 200 217 .189 .147 -.190
Sig. (2-tailed) 200 .147 .266 .413 .211
N 30 32 24 22 31
Q26 Correlation Coefficient -271 -.173 -.111 .025 289
Sig. (2-tailed) .102 274 .528 .894 .071
N 28 30 24 21 29
Q27 Correlation Coefficient -.084 -.062 .007 -.227 -.108
Sig. (2-tailed) .618 .698 .970 270 .534
N 26 28 19 18 24
Q28 Correlation Coefficient -.154 -.169 -.166 .018
Sig. (2-tailed) .324 244 .022 .344 .904
N 34 39 32 28 38
029 Correlation Coefficient -269 -209 -.050 232
Sig. (2-tailed) .041 .073 216 .785 .132
N 33 38 30 26 37
Q30 Correlation Coefficient -216 -.156 .158 .063 205
Sig. (2-tailed) .159 257 .304 .698 .138
N 32 38 30 27 37
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Correlations
Q41 Q42 Q43 Q44 Q45
Kendall's tau_b Q31 Correlation Coefficient -.207 .049 -.107 -.141
Sig. (2-tailed) .176 .733 .523 .004 .337
N 33 36 27 25 34
Q32 Correlation Coefficient -.012 .115 .144 -.011 .044
Sig. (2-tailed) .940 .448 .409 .954 .774
N 33 35 26 24 33
Q33 Con-elation Coefficient -.023 -.167 -.182 -.146 -.016
Sig. (2-tailed) .885 270 283 .428 .915
N 32 35 27 24 34
Q34 Correlation Coefficient 270 .328
Sig. (2-tailed) .000 .105 .003 .000 .055
N 25 27 22 21 26
Q35 Correlation Coefficient .227 .147 .088 .179
Sig. (2-tailed) 215 .394 .010 .626 298
N 22 24 20 22 24
Q36 Correlation Coefficient -235 -249 -.309 -.013 .071
Sig. (2-tailed) 214 .166 .156 .955 .705
N 22 24 16 15 22
Q37 Correlation Coefficient -.119 -.158 .073 .140
Sig. (2-tailed) .501 .336 .661 .442 .004
N 25 28 26 23 30
Q38 Correlation Coefficient 208
Sig. (2-tailed) .001 .001 .034 .047 .143
N 33 37 29 26 36
Q39 Correlation Coefficient 244 273 -.116 .076
Sig. (2-tailed) .115 .057 .462 .048 .597
N 31 35 29 28 35
Q40 Correlation Coefficient -.024 -.087 -.152 -.221
Sig. (2-tailed) .905 .666 .433 251 .018
N 19 19 20 21 24
041 Correlation Coefficient 1.000 .126
Sig. (2-tailed) .000 .003 .002 .465
N 34 33 24 21 26
Q42 Correlation Coefficient 1.000 .097 -.006
Sig. (2-taiied) .000 . .035 .585 .970
N 33 39 28 23 31
Q43 Correlation Coefficient 1.000
Sig. (2-tailed) .003 .035 .000 .005
N 24 28 32 26 30
Q44 Correlation Coefficient .097 1.000
Sig. (2-tailed) .002 .585 .000 . .000
N 21 23 26 29 26
Q45 Correlation Coefficient .126 -.006 1.000
Sig. (2-tailed) .465 .970 .005 .000 ,
N 26 31 30 26 38
-. Correlation is significant at the .01 level (2-tailed).
*. Correlation is significant at the .05 level (2-tailed).
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